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| ABSTRACT 
Sepsis is an overwhelming inflammatory response to infection that can progress to septic 
shock, characterised by refractory hypotension and insufficient organ perfusion. It is 
predominantly associated with nosocomial infections, and tends to occur in extremes of age, 
where it is associated with very high mortality rates. Sepsis and sepsis-associated multi-organ 
failure represent a tremendous healthcare burden and a significant cause of morbidity and 
mortality worldwide. Incidence has continued to increase over several decades, and septic 
shock is now the leading cause of death in intensive care units, claiming an estimated 20,000 
lives per day worldwide.  
Despite decades of endeavour, research has not produced any specific pharmacological 
treatments shown definitively to improve survival in septic patients. Cardiovascular collapse 
plays a key role in mortality, and correspondingly, pre-clinical and clinical assessment of the 
impact of interventions on disease progression has been based upon systemic haemodynamics 
and achieving target blood pressures. In recent years, however, it has become increasingly 
clear that systemic stabilisation does not necessarily prevent the onset of organ failure, and 
may actually be achieved at the expense of visceral perfusion. Sepsis is now increasingly 
understood to be a ‘disease of the microcirculation’, though pre-clinical models rarely assess 
this parameter, perhaps accounting for the lack of research translatability. There is thus a 
critical need to develop more clinically relevant pre-clinical models, which focus on clinically 
prognostic endpoints, in order to identify novel drug targets for the treatment of sepsis. 
This thesis will describe the development of a novel approach to monitoring cardiovascular 
dysfunction in two widely used pre-clinical models of sepsis: lipolysaccharide (LPS)-induced 
endotoxaemia, and cecal ligation and puncture (CLP). This approach comprises a multi-
parameter monitoring system in which all levels of the cardiovascular system – global 
haemodynamics, cardiac function, microcirculatory blood flow and haematological markers – 
can be evaluated in a single animal. Using a novel application of laser speckle contrast imaging 
technology, in combination with gold standard haemodynamic monitoring techniques, we 
demonstrate that mesenteric blood flow is severely and time-dependently decreased following 
the induction of sepsis, despite stabilisation of arterial pressure, heart rate and cardiac output. 
Decreased mesenteric perfusion is shown to correlate with the development of metabolic 
acidosis and organ dysfunction, suggesting that global haemodynamic indices are insufficiently 
predictive of syndrome progression. Mesenteric blood flow, on the other hand, appears to be 
a sensitive and clinically relevant prognostic marker of disease severity, correlating with 
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haematological markers of organ dysfunction, and sensitive to standard clinical interventions 
known to improve survival in patients.  
This thesis will go on to describe a mechanistic investigation of sepsis-induced microcirculatory 
flow impairment, using vasodilatory and anti-coagulant agents. Finally, it will describe the use 
of this model, in addition to in vitro models, for assessing the potential role of two ion 
channels – transient receptor potential vanilloid (TRPV) 1 and 4 – in modulating vascular 
dysfunction during sepsis.  
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CO cardiac output 
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HEK cell human embryonic kidney cell 
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HR heart rate 
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hTRPV1 human transient receptor potential vanilloid 1 




ICAM-1 intercellular adhesion molecule 1 
ICU intensive care unit 




iNOS inducible nitric oxide synthase 
IP3 inositol triphosphate 
IVC inferior vena cava 
IVM intravital microscopy 
kb kilobase 
KCa channel calcium-sensitive potassium channel 
kDa kilo Dalton 
KO knockout 
L-NAME Nω-nitro-L-arginine methyl ester 
L-NMMA NG-monomethyl-L-arginine 
LPS lipopolysaccharide 
LSCI laser speckle contrast imaging 
MAP mean arterial pressure 
MCSF macrophage colony-stimulating factor 
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min minute 
MLC myosin light chain 
MLCK myosin light chain kinase 
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MODS multiple organ dysfunction syndrome 
MRSA methicillin-resistant Staphylococcus aureus 
ms millisecond 
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NA noradrenaline 
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respectively) 
NGF nerve growth factor 
NIRS  near-infrared spectroscopy 
NK1 receptor neurokinin 1 receptor 
NO nitric oxide 
NSAIDs non-steroidal anti-inflammatory drugs 
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OPS imaging orthogonal polarisation spectral imaging 
PAF platelet aggregative factor 
PBS phosphate-buffered saline 
PCO2 partial pressure of carbon dioxide 
PCR polymerase chain reaction 
PCT procalcitonin 
PCV packed cell volume 
PGI2 prostacyclin 
pHi intestinal pH 
12  |  A B B R E V I A T I O N S  
PI3 kinase phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKA protein kinase A 
PKC protein kinase C 
PKG protein kinase G 
PLA2 phospholipase A2 
PO2  qRT-PCR 
Resus resuscitation 
RH-PAT reactive hyperaemia peripheral arterial tonometry 
RIPA radioimmunoprecipitation assay 
rpm revolutions per minute 
RR ruthenium red 




SAPS Simplified Acute Physiology Score 
SDF imaging sidestream dark field imaging 
SDS  sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
SIRS systemic inflammatory response syndrome 
SKCa channel small-conductance calcium-sensitive potassium channel 
SO2 oxygen saturation 
SOFA score Sequential Organ Failure Assessment score 
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SP substance P 
SSC Surviving Sepsis Campaign 
SVR systemic vascular resistance 
TBS tris-buffered saline 
TBS-T tris-buffered saline containing 1% Tween-20 
TCA cycle tricarboxylic acid cycle 
TCO2 total carbon dioxide 
TEA tetraethylammonium 
Temp temperature 
TLR4 toll-like receptor 4 
TNFα tumour necrosis factor α 
TRP transient receptor potential 
TRPA transient receptor potential ankyrin 
TRPC transient receptor potential canonical 
TRPM transient receptor potential melastatin 
TRPML transient receptor potential mucoliptin  
TRPP transient receptor potential polycystin 
TRPV transient receptor potential vanilloid 
UV ultraviolet 
Veh vehicle 
VGCC voltage-gated calcium channel 
VR-OAC vanilloid receptor-related osmotically activated channel 
VR1 vanilloid receptor 1 
VSMC vascular smooth muscle cell 
w/v weight/volume 
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CHAPTER 1 | GENERAL INTRODUCTION 
 Introduction to sepsis 1.1
Sepsis is an overwhelming inflammatory response to infection that can progress to septic 
shock, characterised by refractory hypotension and insufficient organ perfusion. It is 
predominantly associated with nosocomial infections, and tends to occur in extremes of age, 
where it is associated with very high mortality rates. Sepsis and sepsis-associated multi-organ 
failure represent a tremendous healthcare burden and a significant cause of morbidity and 
mortality worldwide. Incidence has continued to increase over several decades (Melamed and 
Sorvillo, 2009), and  septic shock is now the leading cause of death in intensive care units, 
accounting for an estimated 20,000 deaths per day worldwide (Daniels, 2011).  
 The global impact of sepsis 1.2
 Incidence and epidemiology 1.2.1
Sepsis is one of the few conditions that is said to ‘strike with equal ferocity’ in developed and 
developing areas (Reinhart et al., 2013).  Following a 1992 clinical consensus on the definition 
of sepsis (Bone et al., 1992b), comparable epidemiological studies have been carried out in 
almost all developed countries, and many developing countries. In developed nations, sepsis is 
thought to occur in 2% of all hospitalisations, and 6–30%  of all ICU patients, with marked 
heterogeneity across different ICUs (Vincent et al., 2006).  
A decade-long study of 343,860 admissions to 172 intensive care units in England, Wales and 
Northern Ireland between 1995 and 2005, found that 31,000 patients (9%) developed severe 
sepsis within 24 hours of admission; of these, 14,000 (45%) died in hospital (Harrison et al., 
2006). Similar patterns have emerged in the USA (Martin et al., 2003, Dombrovskiy et al., 
2007), Croatia (Degoricija et al., 2006), Australia and New Zealand (Finfer et al., 2004a).  
In the US and EU combined, more than 1.5 million hospitalised patients are diagnosed with 
sepsis every year; approximately 15% go on to develop severe sepsis and septic shock, as 
defined in Table 1 (Angus et al., 2001, Levy et al., 2010). Overall, mortality exceeds 40%, 
accounting for approximately 30% of all hospital-based deaths (Beale et al., 2009), making 
sepsis the leading cause of death in critically ill patients worldwide. This comprises estimated 
annual death figures of 36,800 in the UK (Daniels, 2011) and 215,000 in the USA, where sepsis 
is the 10th most common cause of death overall (Martin, 2012). Globally, sepsis claims 1000 
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lives every hour, or 24,000 deaths per day (Daniels, 2011). In developing countries, it accounts 
for 60–80% of childhood deaths, and affects 6 million infants every year (Reinhart et al., 2013). 
Alarmingly, incidence of sepsis is still rising. A 20-year study of hospitalisations in the USA 
reported an 8.7% increase in the number of cases every year (Martin et al., 2003), and 
numerous reports from around the world have confirmed that global patterns of rising 
incidence are in excess of population growth (Martin et al., 2003, Dombrovskiy et al., 2007, 
Sundararajan et al., 2005, Dombrovskiy et al., 2005). A national hospital discharge survey 
conducted in the USA reported that hospitalisations for sepsis more than doubled between 
2000 and 2008, though overall hospitalisations did not increase during this period (Hall et al., 
2011). 
There are several explanations for this rising incidence. Firstly, sepsis is a condition that tends 
to occur in extremes of age: as both life expectancy and the viability of pre-term babies grow, 
it is perhaps natural that global susceptibility to sepsis should increase in parallel. 
Demographic considerations are compounded by the escalating frequency of increasingly 
invasive clinical procedures, and, of course, the evolution of multi-drug-resistant pathogens 
(Ma et al., 2013b). The increasing prevalence of HIV infection may also contribute to greater 
susceptibility (Angus et al., 2001, Angus and Wax, 2001). In the developing world, poverty, 
malnutrition, limited access to vaccines and medical centres are all likely to play a significant 
role.  
 The economic burden of sepsis 1.2.2
In general, more than 70% of patients with severe sepsis will require intensive care - the most 
expensive form of hospital treatment. The overall yearly cost of sepsis treatment exceeds $3.5 
billion in the UK (Vincent et al., 2006) and $16.7 billion in the USA (Angus et al., 2001). 
Between 1997 and 2008, the inflation-adjusted aggregate costs for treating hospitalised sepsis 
patients increased by an average 11.9% annually (HCUP, 2008). In spite of this increasing 
expenditure, sepsis is often fatal, and those who survive are more likely to have permanent 
organ damage, cognitive impairment, and physical disabilities. 
 The Surviving Sepsis Campaign 1.2.3
International guidelines for the management of severe sepsis were published in 2004 by the 
Surviving Sepsis Campaign (Dellinger et al., 2004) and were subsequently updated in 2008 
(Dellinger et al., 2008). The guidelines contained specific Care Bundles created in collaboration 
with the Institute for Healthcare Improvement and designed to optimise and standardise 
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sepsis care around the world. In 2010, the SSC published results from its improvement 
programme. Data were reported for 15,022 patients from 165 centres across 30 countries; 
71.5% presented with septic shock. Although absolute mortality was reduced by 5.4% over a 2-
year period, in line with increasing compliance with SSC guidelines, reliability was not 
achieved, and compliance reached only 31% (Levy et al., 2010). 
Although limited by voluntary data reporting, these results demonstrate that a multi-faceted 
and co-ordinated approach can be successful in changing treatment strategies for sepsis; 
compliance with guidelines increased significantly over time. Peak compliance was still only 
31% at the end of the two-year period, however, and the SCC has further been subject to 
intense criticism over its links with industry during the second phase of implementation 
(Eichacker et al., 2006). This has largely centred on the inclusion of activation protein C 
(Xigris®; Eli Lilly and Co.) in the Management Care Bundle; Xigris® was subsequently withdrawn 
from the market in 2011, as discussed below. Debate surrounding the feasibility of complying 
with the more invasive aspects of care (especially the administration of early goal-directed 
therapy; EGDT) has also been fierce. Many tasks recommended by the Bundle are particularly 
invasive and require specialist skills and resources that are unavailable outside extremely well-
resourced units (Daniels, 2011) and are frequently inaccessible in the UK (Sivayoham, 2007).  
Nonetheless, SSC guidelines continue to be endorsed by the European Society of Intensive 
Care Medicine, the Intensive Care Society and the College of Emergency Medicine, among 
others.  
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 Clinical diagnosis and treatment of sepsis 1.3
 Signs and symptoms 1.3.1
Sepsis, or the systemic inflammatory response syndrome (SIRS) that occurs during infection 
(Bone et al., 1992a), is identified on the basis of numerous clinical symptoms in the presence 
of an established or presumed infection.  
Definitions, signs and symptoms pertaining to the clinical diagnosis of sepsis are outlined in 
Table 1.  
As described in Table 1, a clinical diagnosis of sepsis is made when a patient exhibits two or 
more SIRS criteria in the presence or suspected presence of microbial infection. Syndrome 
progression can result in severe sepsis, characterised by evidence of organ dysfunction, such as 
hypotension, oliguria, lactic acidosis or unexplained changes in mental state. Subsequent 
development of persistent hypotension that is refractory to fluid resuscitation is termed septic 
shock (King, 2007). In a meta-analysis of US hospital admissions, Martin et al. found that the 
primary sites of infection were the upper respiratory tract (40–44% of cases), genitourinary 
infections (9–18%) and intra-abdominal infections (9–14%) (Martin et al., 2003). 
Rough estimates for the mortality rates associated with each stage of the sepsis syndrome are 
as follows (Martin, 2012): 
- Sepsis: 10–20% 
- Severe sepsis: 20–50% 
- Septic shock: 40–80% 
Difficulties in diagnosis arise from the lack of specificity and sensitivity of symptoms: SIRS 
symptoms may also occur in patients with pancreatitis, severe burns or major tissue trauma, 
for example (Reinhart, 2001). Thus, identification of specific biomarkers is essential for 
accurate diagnosis, appropriate intervention, and assessment of prognosis. 
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Systemic inflammatory response syndrome (SIRS): presence of two or more of the following 
clinical signs: 
Core temperature >38°C or <36°C 
Heart rate > 90 beats/min 
Respiratory rate >20 breaths/min, or arterial partial pressure of CO2 (PaCO2) <32 mmHg 




, or >10% immature (band) forms 
 
Sepsis: SIRS with evidence or suspected evidence of infection   
 
Severe sepsis: sepsis with evidence of end-organ dysfunction: 
Decreased platelet count 
Hypotension or hypoperfusion 
Lactic acidosis 
Oliguria 
Acute changes in mental status 
Abdominal pain 
Mottled skin 
Cardiac dysfunction, measured by echocardiography  
 
 
Septic shock: Severe sepsis that is refractory to fluid resuscitation 
 
Multiple organ dysfunction syndrome (MODS): dysfunction of multiple organs requiring fluid, 
vasopressor therapy and positive inotropic support. 
 
Table 1. Definitions pertaining to the clinical diagnosis of sepsis. Adapted from Box 1 of Sepsis in 
Critical Care, J.E. King (2007) Critical Care Nursing Clinics of North America. (King, 2007) 
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 Identification of sepsis  1.3.2
 Microbial cultures 1.3.2.1
Following proliferation at the nidus of infection, microorganisms may invade the bloodstream 
directly, leading to a positive microbial culture from blood, urine, cerebrospinal or bronchial 
fluid – the most definitive method of diagnosis in sepsis. In some cases, however, locally 
proliferating microorganisms can release microbial products or toxins into the systemic 
circulation, triggering SIRS in the absence of a positive culture. A meta-review of diagnostic 
data found that a positive culture was confirmed in 8–73% of neonatal diagnoses, and in 8–
88% of adult diagnoses (Carrigan et al., 2004). In a large-scale epidemiological analysis of 
hospital records in the USA between 1979 and 2000 (in which pathogens were identified in 
51% of cases), Martin and colleagues found that 52.1% of cases were caused by gram-positive 
infection; 37.5% by gram-negative infection; 4.7% by polymicrobial infection; 4.6% by fungal 
infection; and 1.0% by anaerobic bacterial infection (Martin et al., 2003).  
Gram-positive infections increased at a rate of 26.3% per year over the study period. This was 
attributed to a rise in nosocomial infections acquired following catheterisation or 
immunosuppressive therapy, for example, and is particularly alarming when viewed in the 
context of the rising prevalence of multi-drug-resistant pathogens; methicillin-resistant 
Staphylococcus aureaus (MRSA) isolates range from 29–45%, with incidence rising 
continuously (Carrigan et al., 2004).  
 Clinical severity classification systems  1.3.2.2
Classification systems were devised to aid clinical diagnosis in the absence of a positive 
microbial culture. In addition to SIRS, the Acute Physiology Age and Chronic Health 
Examination (APACHE) and Simplified Acute Physiology Score (SAPS) have been used to stratify 
suspected sepsis cases based on various physiological indices (Carrigan et al., 2004). While 
such classification systems have been found to be useful in some studies (Oberholzer et al., 
2001, Wanner et al., 2000), neither APACHE II (Balc et al., 2003, Muller et al., 2000, 
Giamarellos-Bourboulis et al., 2002, Oberhoffer et al., 1999b, Tugrul et al., 2002) nor SAPS II 
(Harbarth et al., 2001, Suprin et al., 2000) has proved sufficiently sensitive to distinguish 
between SIRS and sepsis in the majority of clinical studies.  
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 Lactate 1.3.2.3
Under anaerobic conditions, pyruvate accumulates in the cytosol due to inhibition of the 
tricarboxylic acid (TCA) cycle. During anaerobic glycolysis, NAD+ is reduced to NADH, and in 
order to regenerate NAD+, electrons donated by NADH are used to convert pyruvate into 
lactate via the lactate dehydrogenase enzyme (Fink, 1997). Thus, lactate accumulation is a 
characteristic feature of anaerobic metabolism, and is frequently observed in patients with 
septic shock. While this increase in blood lactate levels was traditionally considered to reflect 
regional dysoxia and anaerobic cellular metabolism, direct sepsis-mediated production, and 
alterations in clearance mechanisms, can complicate clinical interpretation of lactate 
measurements (Bakker, 2001). 
Numerous clinical studies have indicated that lactate levels may have prognostic value in 
sepsis (Trzeciak et al., 2007a, Goyal et al., 2010), though they may be more useful when 
measured serially to guide response to therapeutic intervention (Nguyen et al., 2004). 
Nonetheless, there is considerable debate surrounding the validity of lactate measurements 
and their interpretation in this context. Hyperlactataemia is not always evident in septic 
patients (Hernandez et al., 2012a), and it was not considered in a 2010 SCC report to correlate 
with outcome (Levy et al., 2010). This is likely to reflect the low specificity of lactate for organ 
hypoperfusion secondary to severe sepsis.  
Interestingly, hyperlactataemia with normal blood pressure has been observed in up to 25% of 
septic patients (Daniels, 2011). These normotensive patients – termed ‘cryptic shock’ patients 
– exhibit no difference in mortality to those with overt shock (Puskarich et al., 2011), indicating 
that haemodynamic indices alone are not sufficiently indicative of regional hypoxia or indeed 
prognosis.  
 Procalcitonin 1.3.2.4
While a vast range of biomarkers (from C-reactive protein to circulating cytokines and 
adhesion molecules) have been trialled as prognostic markers in sepsis, procalcitonin (PCT) has 
emerged as perhaps the most specific marker of bacteraemia (the most common cause of 
sepsis), though its induction in fungal and viral infections is more variable (Beaune et al., 1998, 
Hammer et al., 1998, Dornbusch et al., 2005, Assicot et al., 1993).  
A propeptide of calcitonin, PCT is produced in parafollicular cells of the thyroid gland (Snider et 
al., 1997). Under physiological conditions, circulating levels of procalcitonin are extremely low 
(>0.1 ng/ml). In sepsis, however, PCT is produced in large quantities by extrathyroid tissues  – 
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predominantly leukocytes and to a lesser extent the liver (Oberhoffer et al., 1999a) – with 
plasma concentrations sometimes exceeding several hundred ng/ml (Brunkhorst et al., 1998). 
Its role in sepsis pathogenesis is not clear, though administration of PCT has been shown to 
increase mortality, and neutralisation to confer significant protection in a murine model of 
sepsis (Nylen et al., 1998). 
Use of PCT as a biomarker for sepsis diagnosis, prognosis and antibiotic efficacy confers 
numerous advantages over the use of other clinical biomarkers: in contrast to cytokines, its 
long half-life of 22–29h (Assumma et al., 2000), and its prolonged increase during sepsis 
(Dandona et al., 1994) are favourable for clinical measurement. It is detectable in plasma 
approximately 20 h earlier than C-reactive protein (Reinhart, 2001), and its stability at room 
temperature negates the need for cold storage of samples (Carrigan et al., 2004).  
Although PCT levels have been shown in numerous studies to correlate with infection severity 
and outcome, conferring greater sensitivity than alternative biomarkers (Assicot et al., 1993, 
Azevedo et al., 2012, Boeken et al., 1998, Reith et al., 1998, Bell et al., 2003, Matesanz et al., 
2003, Balc et al., 2003, Kocabas et al., 2007, Rau et al., 2007, Aikawa et al., 2005, Endo et al., 
2008, Meisner et al., 1999, Oberhoffer et al., 1999b), other studies have found no diagnostic 
advantage (Ruokonen et al., 2002, Zhao et al., 2013, Oliveira et al., 2013, Wanner et al., 2000, 
Giamarellos-Bourboulis et al., 2002, Tugrul et al., 2002, Ugarte et al., 1999, Hensler et al., 
2003). The usefulness of PCT as a sepsis biomarker is further confounded by evidence that its 
ability to differentiate between SIRS and sepsis is dependent on patient age (Carrigan et al., 
2004), and furthermore that it may be produced in some cases of non-infectious inflammation 
(Monneret et al., 1998). Additionally, the diagnostic and prognostic value of PCT measurement 
may be diminished in leukopaenic patients, who produce significantly lower concentrations of 
PCT, even during severe sepsis and septic shock (Svaldi et al., 2001).  
 microRNAs 1.3.2.5
Despite some evidence of the diagnostic and prognostic value of the biomarkers described 
above, incidence of sepsis-associated mortality is high and rising; it is clear there is an urgent 
unmet healthcare need for early, sensitive and specific biomarkers to aid rapid and accurate 
diagnosis. Furthermore, delays associated with conventional biomarker analysis, and issues of 
sensitivity and specificity often result in the use of broad-spectrum antibiotics and 
inappropriate deployment of expensive technology, without significant benefit to septic 
patients (Dellinger et al., 2004, Gaieski et al., 2010). Not only does this add considerably to the 
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economic burden of sepsis, it is also particularly worrying in the context of rising antibiotic 
resistance. 
 In recent years, microRNAs – or non-coding RNAs – have emerged as important post-
translational regulators of genes linked to inflammation and immunity, among myriad other 
cellular processes (Baltimore et al., 2008, O'Connell et al., 2010). Induction or suppression of 
specific microRNAs in pathological conditions has already led to the quantification of 
expression levels for diagnostic and prognostic purposes in numerous cancers (Ji et al., 2009, 
Calin and Croce, 2006). Recently, this approach has also been applied to the study of 
inflammation and sepsis, revealing altered expression of a limited set of specific microRNAs 
both in vitro (O'Connell et al., 2007, Tili et al., 2007) and in vivo (Vasilescu et al., 2009, Wang et 
al., 2010). 
In a ground-breaking study published in 2013, Ma and colleagues undertook massive parallel 
sequencing of the entire whole blood microRNAome of patients with SIRS, sepsis or no obvious 
pathology, from two independent cohorts. Two microRNAs – miR-150 and miR-4772-5p-iso – 
were found to discriminate between the three clinical conditions, with 90.5% specificity and 
81.8% sensitivity in distinguishing sepsis from SIRS. Overall, 86% diagnostic accuracy was 
established across both cohorts, and this was later validated in vitro; pharmacological 
activation of toll-like receptors in isolated peripheral blood monocytes was sufficient to 
upregulate miR-4772-5p-iso within 24 h. Measurement of these microRNAs in SIRS patients 
may help to facilitate rapid identification of sepsis patients and optimise antimicrobial 
intervention.  
 Current lines of treatment 1.3.3
There are currently no specific anti-sepsis drugs available for clinical use, following the 
withdrawal of Xigris® by Eli Lilly & Co. in 2011. The first-line of treatment for septic patients is 
rapid administration of antimicrobial agents and intensive goal-directed fluid resuscitation. In 
cases of septic shock, where patients exhibit profound hypotension in spite of fluid 
resuscitation, vasopressors (noradrenaline in the first instance) may be indicated, either alone 
or in combination with inotropic support, transfusion of blood products or steroid therapy 
(Fitch and Gossage, 2002).  
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 Antimicrobial therapy 1.3.3.1
Although a definitive source of infection is only identified in up to 80% of patients with severe 
sepsis (Wheeler and Bernard, 1999), administration of antibiotics is one of the only 
interventions known to reduce sepsis-associated mortality (Wheeler and Bernard, 1999, Fitch 
and Gossage, 2002). The choice of antibiotics is generally based on the patient’s history and 
hospital prevalence and susceptibility patterns, and broad-spectrum antibiotics are often used 
if specific pathogens have not been identified (Merx and Weber, 2007). Expeditious 
administration is critical: for every 1 h delay in the administration of antibiotics to patients 
with septic shock, chances of survival are decreased by almost 8% (Gaieski et al., 2010). A 2010 
report detailing the results of the SSC initiative, found that early administration of antibiotics 
and sampling for microbial culture prior to administration were each independently associated 
with survival over the first 24 h [odds ratios (OR) for mortality 0.86 and 0.76, respectively; 
upper 95% CI limits < 1.0, p  <  0.001, for each] (Levy et al., 2010). 
 Fluid resuscitation 1.3.3.2
In a seminal 2001 study, Rivers and colleagues demonstrated that early, aggressive, goal-
directed fluid resuscitation significantly improved survival in patients with severe sepsis or 
septic shock (Rivers et al., 2001). This intervention was found to optimise cardiac preload and 
afterload, and to improve cardiac contractility. Subsequently, fluid resuscitation has been 
shown to improve microcirculatory perfusion and survival in septic patients (Trzeciak et al., 
2008). Similar improvements in cardiovascular performance and survival have been 
demonstrated in murine models of resuscitated sepsis (Hollenberg et al., 2001, Miyaji et al., 
2003), as well as rats (Anning et al., 2004, Smith et al., 1993), pigs (Wu et al., 2013, Correa et 
al., 2012, Marx et al., 2004), dogs (Natanson et al., 1990) and sheep (Ertmer et al., 2011).  
Resuscitation with excessively high volumes of fluid, however, has also been associated with 
increased mortality in a porcine model of endotoxaemia (Brandt et al., 2009). Furthermore, 
although continuous infusion with lactated Ringer’s solution improved cardiac index and 
systemic oxygen delivery after 165 min in a canine model of bacteraemia, laser Doppler 
flowmetry and gut tonometry revealed no significant improvement in mesenteric oxygen 
delivery, oxygen extraction ratios or portal lactate at the end of the study (Lagoa et al., 2004).  
Nonetheless, early fluid resuscitation remains a cornerstone of sepsis treatment, and forms a 
critical component of the SSC guidelines (Levy et al., 2012). Much debate has surrounded the 
optimal nature of the resuscitation fluid, though evidence suggests that crystalloid fluids 
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achieve a similar outcome to the more expensive colloid agents, such as albumin or Hetastarch 
(Finfer et al., 2004b, Hollenberg et al., 2004). 
 Glycaemic control 1.3.3.3
In 2001, van den Berghe and colleagues demonstrated that maintenance of blood glucose at 
4.4–6.1 mmol per litre resulted in lower morbidity and mortality among critically ill patients 
than did conventional therapy that maintained blood glucose at 10–11.1 mmol per litre (van 
den Berghe et al., 2001). Patients with bacteraemia who were treated with intensive insulin 
therapy had lower mortality than those receiving standard therapy (12.5% v. 29.5%) regardless 
of their diabetic status. The molecular mechanisms underlying this protective effect have not 
been established, though the phagocytic function of neutrophils is known to be impaired in 
conditions of hyperglycaemia (Van Oss, 1971). Insulin is also thought to confer antiapoptotic 
and cardioprotective effects by stimulating nitric oxide production via PI3 kinase-Akt-mediated 
phosphorylation of endothelial nitric oxide synthase (eNOS) (Gao et al., 2002). SSC results 
showed that tight glycaemic control was independently associated with survival (Levy et al., 
2010); continuous monitoring of blood glucose is essential, however, to avoid complications of 
brain hypoglycaemia.  
 Pharmacological treatment 1.3.3.4
Myriad agents, including vasopressors, inotropes, anti-inflammatory agents and anti-
coagulants have been trialled in the treatment of sepsis. Where hypotension is refractory to 
fluid resuscitation, noradrenaline and dopamine are the initial vasopressors of choice, and may 
be administered alone or in combination with dobutamine (if cardiac output is depressed), 
transfusion of blood products or steroid therapy (Dellinger et al., 2008). The use of 
corticosteroids is controversial, however, as some studies indicate that they do not improve 
survival (Bone et al., 1987) and may worsen outcomes by increasing the frequency of 
secondary infections (Cronin et al., 1995). A 2001 study by Annane, on the other hand, 
indicated that patients with persistent shock requiring vasopressors and prolonged mechanical 
ventilation may benefit from low doses of corticosteroids (Annane, 2001), since such patients 
may have relative adrenal insufficiency (Shenker and Skatrud, 2001). Catecholamines increase 
arterial pressure through activation of vascular adrenergic receptors, which may be 
downregulated in sepsis; corticosteroids increase the expression of adrenergic receptors, 
however, which may explain their efficacy in patients with persistent shock (Shenker and 
Skatrud, 2001). 
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 An unmet clinical need 1.3.3.5
In spite of SSC treatment guidelines (Dellinger et al., 2008), death rates from sepsis remain 
stubbornly high, and it is clear that more specific and effective therapies are necessary to 
tackle this burgeoning healthcare problem. A greater understanding of the pathophysiological 
mechanisms underlying sepsis mortality, and the development of more relevant pre-clinical 
models in which to test novel interventions are of paramount importance.  
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 The cardiovascular pathogenesis of sepsis 1.4
The pathogenesis of sepsis has traditionally been ascribed to an inappropriate and 
overwhelming inflammatory response. This theory was popularised by Lewis Thomas, who in 
1972 wrote: 
‘The micro-organisms that seem to have it in for us in the worst way — the ones that really 
appear to wish us ill — turn out on close examination to be rather more like bystanders, strays, 
strangers in from the cold. They will invade and replicate if given the chance, and some of them 
will get into our deepest tissues and set forth in the blood, but it is our response to their 
presence that makes the disease. Our arsenals for fighting off bacteria are so powerful, and 
involve so many different defense mechanisms, that we are in more danger from them than 
from the invaders.’ 
(Thomas, 1972) 
Over the last few decades, however, this view has begun to be challenged and may be overly 
simplistic: clinical trials of anti-inflammatory and immunomodulatory drugs have largely failed, 
and while circulating cytokines undoubtedly have a role in pathogenesis, blocking them 
entirely actually increases mortality, both in pre-clinical models of sepsis (Eskandari et al., 
1992, Echtenacher et al., 2001) and in human patients (Fisher et al., 1996, Fisher et al., 1994). 
Interestingly, C3H/HeJ mice, which are resistant to endotoxin due to a mutation in the TLR4 
gene, have increased mortality in sepsis (Hagberg et al., 1985, Hotchkiss et al., 1999). Although 
TLR4 activation can undoubtedly produce deleterious effects, blocking it entirely may be 
detrimental, and trials of monoclonal anti-endotoxin antibodies have failed (Warren et al., 
1993). Furthermore, the fundamental differences between the immune systems of pre-clinical 
species and humans (Seok et al., 2013) limit meaningful pre-clinical identification of 
immunological targets.  
The essential and beneficial role of cytokines in mediating defence against infections is 
underscored by the observation that sepsis frequently develops in patients treated with 
antagonists of tumour necrosis factor alpha (TNFα) for rheumatoid arthritis (Keane et al., 
2001). As a consequence of this, research focus has begun to shift away from the immune 
response towards other physiological systems, most notably the cardiovascular system – often 
affected in sepsis and always compromised in septic shock. This intense research interest may 
have been fuelled by the observation that the presence of cardiovascular dysfunction in sepsis 
increases mortality rates from approximately 20% to 70–90% (Parrillo et al., 1990).  
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 A historical perspective 1.4.1
The first descriptive account of sepsis-associated cardiovascular dysfunction in humans was 
provided in 1951 by Burton Waisbren, who described two subpopulations of septic patients: 
the first exhibited hypotension with bounding pulses, fever, oliguria and flushing; the second, 
hypotension with pallor, clamminess and low-volume pulses (Waisbren, 1951).  These distinct 
subpopulations are now thought to represent varying degrees of volume resuscitation; 
aggressive fluid administration is associated with a hyperdynamic state that is not observed in 
inadequately resuscitated patients (Merx and Weber, 2007).  
Over the 60 years since Waisbren’s initial report, advancements in technology have facilitated 
more detailed and quantitative assessment of haemodynamic dysfunction in sepsis, allowing 
ICU clinicians and pre-clinical scientists to begin probing the molecular underpinnings of 
disease progression. The cardiovascular derangements associated with sepsis progression are 
shown schematically in Figure 1. 
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Figure 1. Cardiovascular derangements associated with sepsis progression. Figure adapted from ‘Sepsis’, Medical Animations by High Impact Graphics 
(HighImpactGraphics, 2011). 
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 Molecular mechanisms of sepsis-associated cardiovascular dysfunction 1.4.2
Release of bacterial products into the systemic circulation causes activation of immune cells – 
predominantly macrophages – via toll-like receptors on the cell surface. Fungal and viral 
infections induce a similar response, via different molecular pathways. Receptor stimulation 
triggers the release of inflammatory mediators, predominantly interleukin-1 (IL-1) and TNFα, 
the primary cytokines implicated in the early stages of sepsis. These cytokines act 
synergistically to activate endothelial cells, smooth muscle cells and leukocytes, stimulating 
production of secondary mediators, including inducible nitric oxide synthase (iNOS), platelet 
aggregating factor (PAF), prostaglandins, leukotrienes and interleukins, which combine to 
produce significant cardiovascular, circulatory and haematological effects.  
Of all the secondary mediators induced during sepsis, iNOS has received particularly intensive 
research attention, both in the laboratory and in the clinic.  Under physiological conditions, 
nitric oxide (NO) is produced in the endothelium by a constitutive endothelial (e) isoform of 
the NOS enzyme. This physiological production of NO, in the picomolar range, is essential for 
regulation of blood pressure and blood flow distribution, and is transient in nature, with a 
critical dependency on calcium transients (Kirkeboen and Strand, 1999). Induction of the high-
output iNOS isoform in endothelial and smooth muscle cells, as well as leukocytes, however, 
results in overproduction of NO, in the nanomolar range, and being independent of calcium 
transients, iNOS activity can be sustained for up to several days (Kirkeboen and Strand, 1999). 
While essentially a protective antimicrobial response, prolonged upregulation of iNOS can 
have severe vasoregulatory, myocardial and cytotoxic consequences.  
The vasoregulatory function of NO hinges predominantly on its activation of the soluble heme-
containing enzyme guanylate cyclase (GC), which catalyses the production of 3’-5’-cyclic 
monophosphate (cGMP). cGMP stimulates vascular smooth muscle relaxation through 
inhibition of calcium entry, and activation of hyperpolarising K+ currents and protein kinase G 
(PKG), which in turn activates myosin light chain phosphatase, leading to dephosphorylation of 
myosin light chains and smooth muscle relaxation (Fig. 2) (Derbyshire and Marletta, 2012). 
Thus, excessive production of NO induces profound systemic vasodilatation – a hallmark of 
sepsis and septic shock.   
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Figure 2. Mechanism of NO-dependent vasodilatation. NO is synthesised from its L-arginine (L-Arg) 
precursor by eNOS. NO is a gaseous mediator that can diffuse to underlying smooth muscle cells to 
activate soluble GC, which in turn catalyses the production of cGMP. cGMP elicits vasodilatation through 
inhibition of voltage-gated Ca2+ channels (VGCC); activation of Ca2+-activated K+ channels (KCa); and 
activation of myosin light chain phosphatase (MLCP), which dephosphorylates myosin light chains (MLC) 
leading to smooth muscle relaxation. 
45  |  G E N E R A L  I N T R O D U C T I O N  
 
In addition to its vasoregulatory functions, NO also regulates numerous other cardiovascular 
and immune processes. Importantly, under oxidative conditions (as encountered in sepsis, 
where reactive oxygen species are generated in large quantities by inflammatory cells), NO can 
react with superoxide molecules to form highly cytotoxic peroxynitrite radicals (Liaudet et al., 
2013). As a consequence of its involvement in haemodynamic, cardiac and homeostatic 
regulation, the role of NO in sepsis has been studied intensively for several decades. 
Translation of this research into clinical practice has largely failed, however, as discussed in 
section 1.5. 
 Global haemodynamics in sepsis 1.4.3
 Haemodynamic alterations in sepsis 1.4.3.1
Sepsis, which can progress to septic shock, is characterised by significant haemodynamic 
alterations. The haemodynamic profile of sepsis is phasic in nature, and depends critically on 
the level of clinical intervention. An initial hypodynamic phase arises in parallel with immune 
activation; early immune mediator release increases vascular permeability to allow leukocyte 
transmigration to sites of infection (Bridges and Dukes, 2005). As a result, intravascular fluid 
leaks into the interstitial space, resulting in hypovolaemia. This, in combination with the 
profound decrease in systemic vascular resistance (SVR) elicited by mediators such as NO and 
PAF, precipitates a substantial drop in blood pressure (Trzeciak and Rivers, 2005).  
Following adequate intravascular fluid resuscitation, a tachycardic response to hypotension is 
initiated, leading to elevated cardiac output, characteristic of the hyperdynamic phase of 
sepsis (Bone, 1991). This increase in cardiac output can mask the myocardial dysfunction that 
also occurs as sepsis progresses, however; Parker and colleagues were among the first to 
demonstrate significantly diminished stroke volume and ejection fraction in septic patients 
with normal cardiac output (Parker et al., 1984). Several mechanisms are postulated to 
contribute to sepsis-associated myocardial dysfunction, including iNOS-mediated formation of 
cytotoxic peroxynitrite radicals, and NO- and cytokine-mediated inhibition of responsiveness 
to catecholamines (Preiser et al., 2001, Khadour et al., 2002).  
Haemodynamic monitoring is now routine clinical practice in critical care wards, and 
measurement of mean arterial pressure (MAP) has been a mainstay of patient evaluation for 
decades. The diagnostic and prognostic usefulness of this parameter is increasingly called into 
question, however. A seemingly normal blood pressure may mask significant haemodynamic 
suppression in a normally hypertensive individual, for example, if patient history is not known. 
Furthermore, it is now known that arterial blood pressure does not reflect regional blood flow 
and tissue oxygenation, which are more sensitive indicators of disease severity; MAP may be 
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maintained by compensatory mechanisms, even when organ perfusion is severely 
compromised (Ahrens, 2006). There is now a growing consensus that blood pressure should be 
measured as a secondary parameter, and that measurements of tissue oxygenation and blood 
flow, particularly at the microcirculatory level, confer greater diagnostic and prognostic 
relevance.  
 Global haemodynamics as a primary endpoint in sepsis 1.4.3.2
Under physiological conditions, the relationship between global haemodynamics and 
microcirculatory flow is relatively loose, owing to the intrinsic myogenic properties of vascular 
smooth muscle  (De Backer et al., 2010). Increases in arterial pressure are buffered by a 
myogenic constrictor response in small arteries and arterioles that ensures constant blood 
flow in microvascular beds (Davis and Hill, 1999). Correspondingly, decreases in arterial 
pressure are buffered by loco-regional vasodilatory responses. Nonetheless, it is reasonable to 
assume the existence of a critical threshold, below which organ perfusion becomes pressure-
dependent: microcirculatory flow would certainly also cease with complete circulatory arrest. 
It is conceivable that microthrombus formation and regional imbalances between 
vasoconstrictor and vasodilatory stimuli could drive up this autoregulatory threshold and that 
pressure-oriented therapy could correspondingly improve organ perfusion. Clinical evidence 
overwhelmingly refutes this hypothesis, however.  
In 1995, Gattinoni and colleagues demonstrated that goal-oriented haemodynamic therapy 
(aimed at elevating either cardiac index or systemic oxygen delivery) did not improve mortality 
in septic patients (Gattinoni et al., 1995). Since then, other studies have shown that pressure-
oriented therapy does not alter cutaneous microcirculatory perfusion, markers of splanchnic 
perfusion, uresis or markers of kidney dysfunction (LeDoux et al., 2000, Bourgoin et al., 2005). 
In 2009, two studies investigating the impact of incrementally elevating MAP through 
noradrenaline infusion concluded that changes in arterial pressure had no effect on sublingual 
microvascular blood flow and regional oxygen delivery (Jhanji et al., 2009, Dubin et al., 2009). 
These latter observations may explain the failure of haemodynamic-oriented therapy to 
improve survival in septic patients (Gattinoni et al., 1995), suggesting that global 
haemodynamic performance may not be particularly indicative of disease progression, since it 
does not appear to reflect perturbations at the microvascular level. Furthermore, dobutamine 
has been shown to confer independent effects on microcirculatory function and MAP 
(Hernandez et al., 2013, De Backer et al., 2006). 
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 Microcirculatory dysfunction in sepsis 1.4.4
Historically, critical care of septic patients, and evaluation of novel interventions in pre-clinical 
models of sepsis have centred on achieving target blood pressures and normalising global 
haemodynamic parameters, as discussed previously. In 2002, however, De Backer and 
colleagues were among the first to demonstrate directly significant alterations in 
microcirculatory perfusion in patients with severe sepsis or septic shock (De Backer et al., 
2002). Since then, sepsis has increasingly come to be understood as a ‘disease of the 
microcirculation’ (Spronk et al., 2004) – a paradigm that is gaining considerable traction in 
clinical research, but is not as frequently addressed in pre-clinical studies, as shown in Figure 3. 
  
Figure 3. Number of publications relating to the microcirculation in sepsis and its sequelae since 1998. 
Source: PubMed; search term “microcirculation” AND “sepsis” OR “severe sepsis” OR “septic shock” OR 
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 The oxygen extraction deficit 1.4.4.1
Following the failure of haemodynamic-oriented treatment regimens to improve mortality in 
septic patients (Gattinoni et al., 1995), it has become increasingly clear that maintaining 
systemic blood pressure is often associated with inadequate organ perfusion, and that 
stabilisation of the former may occur at the expense of the latter (Sakr et al., 2004, Spronk et 
al., 2004). Indeed, indicators of regional oxygenation, such as gastric pH, lactate and acid-base 
balance often remain abnormal despite the restoration of systemic oxygen delivery, and  
multiple organ failure commonly occurs in septic patients even after a stable haemodynamic 
status has been re-established (De Backer et al., 2002). This so-called ‘oxygen extraction 
deficit’ has been the subject of intense debate and investigation for many years, and is 
undoubtedly the result of dysfunction at the site of tissue oxygen exchange; the relative 
contributions of direct cellular impairment and/or redistribution of microcirculatory blood 
flow, however, remain incompletely understood.  
 Mechanisms of microcirculatory dysfunction in sepsis 1.4.4.2
1.4.4.2.1 Cytopathic hypoxia 
Mitchell Fink was among the first to suggest that sepsis pathogenesis was not a problem of 
insufficient oxygen delivery, but rather one of impaired oxygen utilisation as a result of 
mitochondrial dysfunction – a phenomenon he termed ‘cytopathic hypoxia’ (Fink, 1997). This 
conclusion was drawn from previously published observations that in a rat model of cecal 
ligation and puncture, systemic oxygen delivery and partial pressure of oxygen (PO2) in skeletal 
muscle were both severely compromised; administration of albumin solution (to reverse 
hypovolaemia) restored both parameters, but did not affect the decrease in tissue ATP levels, 
or the increase in tissue lactate levels observed in un-resuscitated rats (Astiz et al., 1988). 
Similar effects had been observed in canine (Vallet et al., 1994) and porcine (Hasibeder et al., 
1996) models of endotoxaemia, where intestinal mucosal PO2 remained low despite 
restoration of mesenteric oxygen delivery.  
There is also in vitro evidence to support the theory of cytopathic hypoxia: endotoxin has been 
found to reduce oxygen consumption in cultured hepatocytes (Rosser et al., 1998) and 
erythrocytes (King et al., 1999) despite an adequate supply of oxygen in the culture medium. 
Other studies suggest that mitochondrial dysfunction is not intrinsic to sepsis, however, and is 
merely the result of tissue hypoxia (Fry et al., 1979, Geller et al., 1986). The development of 
mitochondrial depression in septic patients, and its relation to microcirculatory failure and 
localised tissue hypoxia, is still not well understood.  
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1.4.4.2.2 Arteriovenous shunting in sepsis 
An alternative (or perhaps an adjunct) to the ‘cytopathic hypoxia theory’ (Fink, 1997) is the 
‘shunting theory of sepsis’ put forward by Ince and Sinaasappel in 1999. According to this 
theory, oxygen transport is shunted directly from the arterial to the venous system in sepsis, 
bypassing microcirculatory units, and accounting for the oxygen extraction deficit observed 
clinically (Ince and Sinaasappel, 1999). This regional hypoxia was also thought to contribute to 
the mitochondrial dysfunction described by Fink  (Fink, 1997). 
In order to preserve oxygen delivery to critical vascular beds in the brain and myocardium, 
compensatory shunting mechanisms are initiated under pathological conditions, which favour 
derecruitment of compliant beds in the skin and splanchnic areas, for example. While this is a 
vital defence mechanism to preserve heart and brain tissue in acute hypovolaemia, prolonged 
microcirculatory shutdown, in the splanchnic region in particular, inevitably leads to hypoxic 
tissue injury and the development of multiple organ failure (Takala, 1996, Spronk et al., 2004). 
Thus, a process that was initiated as part of an adaptive mechanism may rapidly become 
maladaptive. 
According to the shunting theory of sepsis, recruitment of shunted microcirculatory units could 
be expected to confer significant therapeutic benefit. Correspondingly, a meta-analysis 
published by Buwalda and Ince in 2002 demonstrated that use of vasodilators to open the 
microcirculation and promote microcirculatory flow improved tissue perfusion and oxygen 
extraction both in numerous animal models and in septic patients (Buwalda and Ince, 2002). 
Furthermore, a gap between microcirculatory PO2 and venous PO2 (which would widen if 
oxygen-rich arteriolar blood were shunted directly to the venous circulation) has been 
demonstrated in a porcine model of endotoxaemia (Ince and Sinaasappel, 1999), and in a 
porcine model of haemorrhagic shock (Sinaasappel et al., 1999), though the magnitude of the 
PO2 gap was greater in the former model.   
There are numerous mechanisms by which such shunting could occur. Convective 
arteriovenous shunting through anatomical anastomoses has previously been demonstrated in 
the rat, and may become increasingly active in sepsis (Menger and Vollmar, 1996). 
Alternatively, oxygen may diffuse directly between arterioles and venules in close proximity to 
one another, as observed in the heart under conditions of low coronary flow (Roth and Feigl, 
1981). A third potential mechanism is known as ‘vascular steal’, whereby certain microvascular 
units ‘steal’ flow from others by selective vasodilatation (Shepherd and Kiel, 1992).  
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Microcirculatory heterogeneity is a key feature of sepsis (De Backer et al., 2002) and may be 
exaggerated in certain microvascular beds by microthrombus formation, decreased 
erythrocyte deformability, oedema formation and leukocyte sequestration. Finally, the PO2 
gap between the micro- and venous circulation may be explained by an insufficiently fast 
dissociation between oxygen and haemoglobin in microvascular beds during sepsis; at low 
saturation levels, the oxygen ‘off-load time’ for an erythrocyte can exceed its transit time in 
the microcirculation, such that excessive off-loading occurs in the venous circulation. 
(Gutierrez, 1986).  
1.4.4.2.3 Other factors contributing to microcirculatory failure 
In addition to arteriovenous shunting, several other mechanisms are thought contribute to 
microcirculatory collapse in sepsis: decreased erythrocyte deformability with consequently 
increased viscosity (Astiz et al., 1995); elevated numbers of activated neutrophils with 
decreased deformability and increased aggregability following upregulation of adhesion 
molecules (Linderkamp et al., 1998); activation of the clotting cascade with increased fibrin 
deposition and microthrombus formation (Diaz et al., 1998); and the failure of 
vasoautoregulatory mechanisms (Avontuur et al., 1997).  
The balance between vasoconstrictive and vasodilatory substances may be altered in sepsis. 
Potent vasoconstrictors, such as endothelin, are upregulated under inflammatory conditions 
(Shindo et al., 1998), and may contribute to localised impairment of NO-mediated dilatation. 
This may be compounded by a reduction in NO availability, precipitated by uncoupling of iNOS, 
due to reduced availability of L-arginine substrate (Luiking et al., 2009) which favours the 
formation of peroxynitrite radicals. Moreover, degeneration of the glycocalyx – the layer that 
covers endothelial cells, and regulates adherence of circulating leukocytes – probably also play 
an important role in the development of microvascular dysfunction (Henrich et al., 2010).   
1.4.4.2.4 The role of the endothelium 
The endothelium is a critical regulator of vascular tone and permeability; its activation in sepsis 
precipitates both the inflammatory and coagulation cascades (Aird, 2003). Clinical evaluation 
of endothelial function is generally based on measurements of vasodilatation in response to 
pharmacological stimulation or changes in shear stress, though circulating surrogate markers 
of endothelial activation have often been measured in clinical studies of sepsis  (Deanfield et 
al., 2007). This likely reflects the technical difficulty and impracticality of techniques such as 
laser Doppler flowmetry, plethysmography and flow-mediated dilatation of the brachial artery, 
(Davis et al., 2009). Studies in which the aforementioned techniques have been used, however, 
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have generally shown normal baseline blood flow but impaired reactive hyperaemic responses 
in septic patients, though these studies have been tended to be small, and have neglected to 
compare reactive hyperaemia with L-arginine or circulating markers of endothelial activation 
(Young and Cameron, 1995, Neviere et al., 1996, Kubli et al., 2003, Hartl et al., 1988, Astiz et 
al., 1995, Vaudo et al., 2008, Creteur et al., 2007). More recently, investigators using near-
infrared spectroscopy (NIRS) have found impaired microvascular responsiveness in sepsis, 
though the nature of the relation between NIRS and endothelial NO activity is unclear (Creteur 
et al., 2007).    
 Evaluation of microcirculatory perfusion 1.4.4.3
Until relatively recently, visualisation of the microcirculation in human patients was conducted 
by intravital microscopy (IVM), and was restricted to very superficial beds in the eye or 
nailfold, owing to the bulky nature of the IVM equipment and the requirement for fluorescent 
dyes to visualise blood flow. The perfusion of internal organs was inferred from measurements 
of surrogate markers (using gut tonometry to measure intestinal gases, or blood tests to 
quantify levels of lactate and oxygen saturation, for example). The advent of orthogonal 
polarisation spectral (OPS) imaging in the late 1990s allowed clinicians to visualise directly the 
microcirculation of internal organs for the first time (Groner et al., 1999), and its use has been 
pivotal in establishing the defining role of microcirculatory dysfunction in sepsis pathogenesis.  
OPS imaging is based on the illumination of tissue with linearly polarised green light. Contrast 
is generated by the absorption of the polarised light by haemoglobin in the blood; erythrocytes 
appear black against the white background of surrounding tissue, which reflects the incident 
light. OPS is highly sensitive to internal light scatter, however, which can cause blurring and 
limit visualisation of capillaries. Furthermore, its use in the clinic is limited by the requirement 
for high-powered and bulky light sources. More recently, sidestream dark field (SDF) imaging 
has been introduced (Goedhart et al., 2007). This modality, which operates on a similar but 
more refined basis, can be incorporated into a hand-held device, provides higher quality 
images, is less subject to movement and pressure artefacts, and allows more accurate 
quantification of microcirculatory flow.  
In 2009, Davis et al. introduced a new technique – reactive hyperaemia peripheral arterial 
tonometry (RH-PAT) to measure microvascular endothelial function in a user-independent and 
bedside-compatible manner (Davis et al., 2009). It is at least 50% dependent on endothelial NO 
activity (Nohria et al., 2006), and uses finger probes to measure digital pulse wave amplitudes 
detected by a pressure transducer. The authors found that microvascular reactivity was 
impaired in sepsis and was further exaggerated in severe sepsis (Davis et al., 2009). Subjects 
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with severe sepsis were more likely to have endothelial dysfunction, even after correction for 
known associations and risk factors, such as smoking or diabetes.  
In pre-clinical research, the ability to conduct more invasive intravital microscopy and laser 
Doppler flowmetry imaging has allowed investigators to assess internal microcirculatory flow 
in a variety of animal models of disease. SDF is also used pre-clinically in larger species, such as 
cows and sheep.   
 Microcirculatory perfusion as an endpoint in sepsis 1.4.4.4
A link between microcirculatory perfusion and sepsis severity was initially inferred from 
recordings of big toe temperature in septic patients, several decades ago (Joly and Weil, 1969). 
With the advancement of relevant technology, monitoring of microcirculatory perfusion in the 
ICU is becoming increasingly common and has led to substantial advancements in the 
understanding of microcirculatory dysfunction in sepsis. In a seminal report published in 2002, 
De Backer and colleagues were the first to demonstrate direct evidence of impaired 
microcirculatory flow in the sublingual circulation of septic patients, using OPS imaging (De 
Backer et al., 2002).  The authors observed a decrease in capillary density and in the 
proportion of perfused capillaries in patients with severe sepsis or septic shock, compared with 
healthy volunteers and other non-septic ICU patients. Furthermore these microvascular 
abnormalities were found to correlate strongly with disease severity and outcome: alterations 
were significantly more severe in non-survivors than survivors, and alterations in microvascular 
perfusion during the first day of ICU care were more strongly associated with outcome than 
cardiac output, venous oxygen saturation or arterial pressure. Interestingly, topical application 
of acetylcholine completely reversed the microvascular impairment, supporting the theory 
that compliant circulatory beds are actively shut down to maintain systemic haemodynamics 
during sepsis (Ince and Sinaasappel, 1999).   
Since then there have been numerous reports of microvascular impairment in septic patients. 
In a small study of 49 septic shock patients, haemodynamic and systemic oxygenation variables 
were found to be equivalent between survivors and non-survivors, though microvascular 
perfusion was diminished to a greater extent in the latter (Sakr et al., 2004). The authors 
described an inverse relationship between microcirculatory perfusion and the development of 
multiple organ failure, and statistical analysis confirmed the prognostic value of small vessel 
perfusion 24 h after the onset of septic shock (71% sensitivity, 82% specificity). A 7.8% 
improvement in perfusion correlated with increased survival: ICU mortality was 19% compared 
with 71% in cases where intervention failed to improve perfusion by at least 7.8%. 
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These observations have been recapitulated in numerous clinical studies, using increasingly 
advanced technology, and microvascular alterations are now known to occur very early on in 
sepsis, often evident within a few hours of hospital admission (Trzeciak et al., 2008, Spanos et 
al., 2010). Using SDF imaging, Spanos and colleagues found that microvascular flow and the 
proportion of perfused vessels were significantly lower in patients with sepsis and severe 
sepsis than in healthy volunteers, and furthermore that the perfused vessel density appeared 
to correlate with severity (Spanos et al., 2010).  
In the aforementioned study published by Davis and colleagues, microvascular reactivity in the 
index finger of severe sepsis patients was not significantly different between patients requiring 
vasopressors to maintain haemodynamic stability, and those who were not. In those receiving 
noradrenaline, there was no correlation between RH-PAT index and noradrenaline dose. 
Interestingly, RH-PAT index did not correlate with plasma markers of endothelial activation (e-
selectin and intercellular adhesion molecule 1; ICAM-1), which were both significantly raised in 
septic patients compared with controls. Among severe sepsis patients, however, plasma 
lactate levels correlated inversely (albeit not significantly) with RH-PAT index. In this case, RH-
PAT index did also correlate with arterial pressure. In septic patients there was no significant 
difference in RH-PAT index from baseline to days 2 to 4, though plasma L-arginine 
concentrations (which were markedly decreased at baseline) gradually increased over 4 days. 
Low baseline RH-PAT score significantly correlated with an increase in SOFA score over the first 
4 days. The degree of impairment of baseline microvascular reactivity predicted subsequent 
deterioration in organ function (Davis et al., 2009).  
Despite numerous reports demonstrating the prognostic value of measures of intestinal 
perfusion relative to systemic parameters (Gutierrez et al., 1992, Ivatury et al., 1996, Palizas et 
al., 2009), a 2009 trial in which resuscitation was targeted towards intestinal pH (pHi) failed to 
show any survival benefit relative to cardiac index (CI) targets (Palizas et al., 2009). In this trial, 
however, correction of pHi was only achieved in 7 out of 32 patients (22%) in the pHi group – 
all of whom survived. Furthermore, patients in the pHi group exhibited a higher SOFA score at 
the time of admission than patients in the CI group, and the timing of intervention (up to 48 h 
after ICU admission) varied greatly, such that patients in the former group may have 
experienced prolonged hypoperfusion and irreversible organ damage. This is in line with 
previous observations that pHi-guided therapy is only effective in patients admitted with a 
normal pHi, suggesting that the presence of mucosal acidosis at the time of admission is 
associated with irreversible organ dysfunction (Gutierrez et al., 1992).  
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A major potential factor in the failure of pHi-oriented therapy regimens is the ineffectiveness 
of treatments aimed at normalising pHi. This is reflected in the small proportion of patients in 
the pHi group that actually achieved target pHi values following intervention (22%), and may 
explain why mortality rates associated with severe sepsis and septic shock remain stubbornly 
high. Early intervention is undoubtedly key to limiting regional ischaemia, though as yet, no 
study has provided definitive evidence of a positive impact of therapies such as volume 
resuscitation and catecholamine administration on intestinal perfusion (Dubin et al., 2007, 
Gomersall et al., 2000).  
The superiority of intestinal (or general microcirculatory) perfusion relative to global 
haemodynamic parameters as a predictor of outcome in sepsis has been established 
convincingly (De Backer et al., 2002, Gutierrez et al., 1992, Ivatury et al., 1996, Palizas et al., 
2009, Sakr et al., 2004). Correspondingly (and even more so, given that no clinical intervention 
has been shown unequivocally to mitigate this perfusion failure), pre-clinical research should 
focus on the microcirculation (and particularly the splanchnic circulation) as an indicator of 
effectiveness in the development of novel anti-sepsis interventions. Given the prognostic 
sensitivity of markers of intestinal perfusion, pharmacological treatments that are shown to 
reverse dysfunction in this bed, are likely to have a significant clinical impact.    
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 Poor research translatability 1.5
In the field of sepsis, pre-clinical research output has increased 5-fold over the past 20 years, 
and more than 100 multi-centre clinical trials of sepsis interventions have been conducted 
(Dyson and Singer, 2009). Despite this intense effort, only activated protein C (drotrecogin 
alpha; Xigris®) was approved for the treatment of sepsis, and this was later withdrawn from 
the market after failing to reduce mortality. It is clear that research translatability in the sepsis 
field is lacking considerably, though the reasons for this are not fully understood.  
 Animal models of sepsis 1.5.1
Over several decades, various pre-clinical models have been used to delineate the 
pathophysiological processes underlying sepsis-associated morbidity and mortality. They tend 
to be classified into one of three categories: intravenous infusion models, endotoxaemic 
models, or infectious models (Schultz and van der Poll, 2002). The latter predominantly 
compise experimental pneumonia and experimental peritonitis models, as the lungs and the 
abdomen represent two of the most common sites of infection in septic patients (Martin et al., 
2003). This thesis will focus on endotoxaemia and experimental peritonitis as pre-clinical 
models of sepsis. 
 Intravenous infusion of bacteria 1.5.1.1
Much pre-clinical sepsis research has involved intravenous infusion of large doses of bacteria, 
administered either continuously or as a bolus. This precipitates a rapid and profound drop in 
cardiovascular function, and animals tend to die within hours (Schultz and van der Poll, 2002). 
The hyperdynamic response observed in septic patients and described in section 4.4.1. can be 
reproduced in these animals by limiting the total dose of bacteria, prolonging infusion time, or 
by administering aggressive fluid resuscitation (Schultz and van der Poll, 2002); the resultant 
hyperdynamic state is also associated with improved survival (Fink and Heard, 1990).  
Such studies are limited by a number of factors, however. Firstly, the bacteria used in these 
studies have tended to be serum-sensitive non-virulent strains that cannot multiply in vivo, 
and are thus rapidly killed upon administration (Schultz and van der Poll, 2002). Consequently, 
extremely large doses have been required to overwhelm host defences (Porat et al., 1992), 
such that physiological responses do not correlate well with the clinical syndrome; septic 
patients tend to have an infectious focus from which multiplying bacteria continuously 
disseminate over time (Schultz and van der Poll, 2002). Moreover, because mortality is 
relatively rapid in bacterial infusion models, the time for disease progression is limited, 
precluding comprehensive analysis of pathological mechanisms. The cytokine profile of such 
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models also varies across species and deviates greatly from the clinical situation: cytokine 
responses tend to be transient and of much greater magnitude in baboons, mice and rats than 
in septic humans, making it difficult to extrapolate results (Cross et al., 1993).   
 Endotoxaemic models 1.5.1.2
Systemic administration of the bacterial endotoxin lipopolysaccharide (LPS) initiates a 
physiological response that largely mirrors that observed in septic patients. Small sub-lethal 
doses of LPS induce a hyperdynamic cardiovascular response, while larger lethal doses 
precipitate a hypodynamic state (Schultz and van der Poll, 2002).  
The LPS model confers several advantages over the administration of live bacteria. Firstly, LPS 
is stable, ensuring reproducible administration and easy storage. Secondly the quantity of LPS 
units infused can be easily titrated, and does not require bacterial culture and quantification. A 
major disadvantage of endotoxaemic models, as with intravenous infusion models, is the lack 
of infectious focus, however. Species differences are also observed: small mammals and 
baboons are relatively insensitive to LPS and require much larger doses than rats, sheep and 
chimpanzees (Schultz and van der Poll, 2002).  
Nonetheless, a significant advantage of the LPS model is that it can be administered in low 
doses to healthy human volunteers in a controlled and reproducible manner, with minimal 
risk. Such experiments have contributed greatly to our understanding of cytokine networks 
and the initiation of inflammatory pathways (Schultz and van der Poll, 2002), and the 
haemodynamic effects of LPS are now well documented. Human subjects typically exhibit a 
hyperdynamic cardiovascular response, characterised by elevated cardiac index and heart rate, 
with decreased SVR and blood pressure (Suffredini et al., 1989).  
 Peritonitis models 1.5.1.3
The two most commonly used models of experimental peritonitis are cecal ligation and 
puncture (CLP), in which faecal peritonitis is induced surgically (Wichterman et al., 1980), and 
the fecal peritonitis model in which bacteria are suspended in a fibrin clot that is implanted 
into the abdominal cavity (Ahrenholz and Simmons, 1980). Intraperitoneal administration of 
virulent Escherichia coli (E. coli) has also been used to mimic peritonitis in pre-clinical models 
(Schultz and van der Poll, 2002). Animals typically develop a hyperdynamic response with 
increased cardiac output and decreased SVR, similar to human sepsis; thereafter they develop 
bacteraemia and cardiovascular collapse. There are several advantages to CLP over other 
methods of inducing peritonitis. Firstly, it is relatively simple, circumventing the need to grow 
and quantify bacteria; secondly it is clinically similar to problems such as perforated 
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appendicitis or diverticulitis – common causes of sepsis. Its polymicrobial nature is also more 
akin to the clinical situation; a large sample size can be used to compensate for problems of 
variability. The cytokine profile of experimental peritonitis models is similarly more 
representative of that observed in septic patients (Schultz and van der Poll, 2002).  
 Species selection and reproducibility 1.5.1.4
A broad range of animals has been used in pre-clinical sepsis research. While larger species 
facilitate high-volume resuscitation, small mammals (particularly mice) are often chosen for 
reasons of cost and practicality, the ease of genetic manipulation (facilitating mechanistic 
studies) and the homogeneity of genetic backgrounds, as well as the fact that they tend to be 
pathogen-free (Schultz and van der Poll, 2002). While genomic responses to inflammation may 
differ (Seok et al., 2013), physiological responses are well conserved between humans and 
rodents. In these animals, the primary endpoint has tended to be mortality, though with 
technological advancement, more complex assessment of haemodynamic function and 
immunological status has been rendered more feasible. Larger mammals, such as pigs, sheep, 
dogs and primates are often used in studies that require more invasive monitoring. The 
immunological similarities between primates and humans render this species more valuable in 
the assessment of cytokine responses.  
A significant paradox of sepsis research centres on the control of confounding variables. While 
researchers must necessarily aim to limit the influence of confounding factors (such as age, 
gender, environment and genetic variation), in order to delineate the role of a particular 
protein or pathway in sepsis pathogenesis, the clinical situation is always heterogeneous: 
patients are exposed to different environmental factors and pharmacological stimuli, have 
massively different ages and a wide range of co-morbidities. Furthermore, in order to ensure 
consistency, the infectious or inflammatory insult must be titrated in pre-clinical studies, 
whereas septic patients will be exposed to vastly divergent levels of infectious material.  
The difficulty of recapitulating an enormously complex and heterogeneous syndrome in a pre-
clinical model is unquestionable. Nonetheless, animal research has led to the successful 
development of treatments for numerous complex diseases, including heart failure (Dell'Italia, 
2011) and cancer (Hayes et al., 2014). That animal models can help to elucidate certain aspects 
of sepsis pathogenesis seems indubitable; that pre-clinical models currently do not confer 
sufficient clinical translatability, however, is equally certain, and significant refinement will be 
required to determine the probable clinical impact of novel interventions.   
58  |  G E N E R A L  I N T R O D U C T I O N  
 
 Notable cases of failed translatability  1.5.2
 Blockade of NO production 1.5.2.1
The vasodilatory shock state elicited during sepsis progression was originally thought to result 
from excessive NO production by iNOS; pharmacological blockade of NO production was 
hypothesised to represent a viable treatment strategy, and correspondingly has been shown 
repeatedly to attenuate sepsis-associated hypotension in rats (Nava et al., 1992, Hwang and 
Yeh, 2003), mice (Ullrich et al., 2000) and sheep (Lorente et al., 1993b). Cardiac function and 
systemic haemodynamics were also found to be preserved in iNOS knockout mice injected 
with endotoxin, relative to wildtype controls (Ullrich et al., 2000), and genetic ablation of eNOS 
has similarly been associated with improved global haemodynamic performance in 
endotoxaemic mice (Connelly et al., 2005). Strikingly, however, infusion of methylene blue (a 
non-specific NOS inhibitor) was found to improve arterial pressure, stroke volume and left 
ventricular stroke work without altering outcome in septic patients (Kirov et al., 2001). 
Similarly, a large-scale multi-centre trial of NG-monomethyl-L-arginine (L-NMMA) was aborted 
in phase III because of excessive mortality in the treatment group, despite a reduction in the 
requirement for vasopressor therapy and an increase in MAP (Lopez et al., 2004).  
There are several possible explanations for the failure of these trials. Firstly, several recently 
published studies have found no net increase in NO synthesis in septic patients (Luiking et al., 
2009, Kao et al., 2009, Villalpando et al., 2006). The formation of peroxynitrite radicals 
resulting from the reaction of NO with superoxide molecules produced in sites of excessive 
inflammation may prevent elevation of plasma NO levels. Another possibility is the reduced 
availability of L-arginine, the substrate for NOS and the precursor of NO: sepsis has been 
reported to be an ‘arginine-deficient state’, although reports of arginine levels have varied 
widely (Davis et al., 2009). An alternative explanation is an imbalance between iNOS and eNOS 
in the microvasculature (McGown and Brookes, 2007); a relative deficiency in eNOS-derived 
NO could compromise microvascular endothelial function.  
It should be noted, however, that while the L-NMMA trial was aborted owing to excessively 
high mortality rates in the treatment group, post-hoc analysis revealed a slight improvement in 
mortality rates in patients receiving low doses of the drug (Lopez et al., 2004). The observation 
that MAP was raised in both high-dose and low-dose groups, however, suggests that survival 
may not have been directly linked to arterial pressure. Indeed a concomitant decrease in 
cardiac output was observed, though it is unclear whether this was representative of a 
physiological reflex to raised MAP or a direct effect of L-NMMA on the heart. Whatever the 
underlying mechanism, these studies emphasise the poor prognostic value of systemic 
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haemodynamic parameters. Given that endothelium-derived NO is essential for normal 
microvascular function, it is possible that excessive and non-selective blockade of NO 
production could severely compromise microcirculatory endothelial function in spite of 
improved systemic circulation, perhaps accounting for the increased mortality observed in 
patients treated with high doses of L-NMMA (Watson et al., 2004, Lopez et al., 2004). This is 
supported by the observation that sepsis-induced cardiac dysfunction is attenuated in female 
mice, who exhibit higher levels of cardiac eNOS phosphorylation during sepsis compared with 
male counterparts (Chen et al., 2014).  
 Activated protein C 1.5.2.2
Recombinant human activated protein C (APC, or drotrecogin alfa), an anticoagulant and anti-
inflammatory agent, is the only pharmacological intervention to have been approved for the 
treatment of sepsis. APC inactivates factors Va and VIIIa in the clotting cascade, preventing the 
generation of thrombin, thereby disrupting feedback between the coagulation system and the 
inflammatory cascade (Matthay, 2001): inhibition of thrombin decreases inflammation by 
inhibiting platelet activation, neutrophil recruitment and mast-cell degranulation. APC has also 
been shown to have direct anti-inflammatory properties, including inhibition of cell adhesion 
and monocyte-induced cytokine production (Matthay, 2001). 
Reduced levels of APC are frequently observed in patients with sepsis, and are associated with 
an increased risk of mortality (Fourrier et al., 1992, Lorente et al., 1993a, Boldt et al., 2000); 
consequently, it was hypothesised that restoration of APC could be beneficial in septic 
patients. Correspondingly, administration of APC to baboons injected with E. coli was found to 
prevent hypotension, limit coagulation and immune cell infiltration, attenuate liver 
histopathology and reduce mortality (Taylor et al., 1987). It was similarly found to attenuate 
leukocyte-induced lung injury in rats treated with LPS (Murakami et al., 1996).  
Early studies in humans appeared promising: administration of drotrecogin alfa resulted in a 
19.4% reduction in the relative risk of death, and an absolute risk reduction of 6.1% (Bernard 
et al., 2001). The occurrence of serious bleeding events (intracranial haemorrhage, a life-
threatening bleeding episode, or a requirement for 3 or more units of blood) was significantly 
higher in the treatment group, however: 3.5%, compared with 2% on placebo. With open-label 
use after the trial, intracranial haemorrhage occurred in 13 out of 520 patients (Warren et al., 
2002). Furthermore, subsequent clinical trials were unequivocally disappointing (Abraham et 
al., 2005, Nadel et al., 2007, Ranieri et al., 2012), and drotrecogin alfa (trade name Xigris®) was 
withdrawn from the market by its manufacturers Eli Lilly and Co. in 2011. 
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 Others 1.5.2.3
Numerous other agents that have attenuated the global haemodynamic response to sepsis in 
pre-clinical studies have later failed in clinical trials. Aspirin and indomethacin were found to 
prevent hypotension in dogs (Fletcher and Ramwell, 1977) and cats (Parratt and Sturgess, 
1975) injected with E. coli, but non-steroidal anti-inflammatory drugs (NSAIDs) have failed to 
confer a survival benefit in clinical trials (Bernard et al., 1997, Memis et al., 2004). A host of 
other interventions, including heparin, IL-1 receptor antagonists, statins and numerous 
anticoagulants and anti-inflammatory agents have shown improved outcome in animal models 
of sepsis and later failed in clinical trials (Fink, 2014), though an in-depth discussion of these 
studies is beyond the remit of this thesis. 
 Potential reasons for poor research translatability 1.5.3
Pre-clinical studies have historically been conducted on the assumption that sepsis is merely 
the result of exaggerated inflammation, as discussed in section 1.4. Numerous 
immunomodulatory drugs that have appeared to confer promising results in pre-clinical 
models of sepsis, however, have later failed in clinical trials (van der Poll, 2001). This is 
undoubtedly attributable – at least in part – to the failure of several pre-clinical sepsis models 
to recapitulate the cytokine profile of human sepsis, as discussed in section 1.5.1.2. Based on 
the results of bacterial infusion models, it was hypothesised that mortality was the result of a 
‘cytokine storm’. Indeed, one pre-clinical study found that blockade of cytokines with 
methylprednisolone reduced mortality in primates infused with extremely high doses of E. coli 
(Hinshaw et al., 1981); other investigators similarly demonstrated that anti-TNFα therapy 
improved survival in baboons injected with bacteria (Tracey et al., 1987), suggesting that 
cytokine blockade could be beneficial in sepsis. However, clinical trials of steroids (Cronin et 
al., 1995) and anti-TNFα treatment (Bernard et al., 2014) have shown no effect in septic 
patients, and some studies have indicated that mortality is actually enhanced by anti-
inflammatory treatment (Fisher et al., 1996, Bone et al., 1987).  
Other potential reasons for the failure of clinical translatability are manifold. Pathogenesis in 
pre-clinical models (particularly intravenous infusion models) tends to be extremely acute, 
whereas the clinical profile is sub-acute or intermittent (Schultz and van der Poll, 2002). The 
absence of a septic focus undoubtedly also limits the clinical relevance of infusion and 
endotoxaemic models. Another potential factor, that has not received as much consideration 
as issues of species relevance, is that pre-clinical research may have focussed on sub-optimal 
endpoints. Crude mortality endpoints may not be particularly useful if animals are dying by 
different mechanisms than humans (particularly as mainstay clinical interventions are 
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infrequently used in pre-clinical models) and the limited relevance of immunological endpoints 
is underscored by the failure of immunomodulatory drugs in clinical trials, as well as the 
observation that the genomic responses to inflammation differ greatly between mice and 
humans (Seok et al., 2013). 
Furthermore, although the physiological sequelae of sepsis are reproduced in animals, and 
systemic haemodynamics are routinely monitored in pre-clinical models of sepsis and septic 
shock, it is now clear that these parameters do not sufficiently predict the onset of organ 
failure (Sakr et al., 2004). Refinement of pre-clinical models to incorporate endpoints with 
greater clinical relevance may help to identify more efficacious drug targets – a critical goal of 
sepsis research, given the massive and growing healthcare burden associated with the 
syndrome. This is particularly urgent in the context of increasing antibiotic-resistance in sepsis-
associated pathogens, since antibiotic therapy is currently the only causal line of treatment, 
with no specific anti-sepsis drugs currently available. Increased understanding of the vascular 
changes that underlie sepsis pathogenesis will facilitate the identification of novel drug targets. 
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 A potential role for TRPV channels in sepsis 1.6
In addition to the refinement of pre-clinical models, there is a strong requirement for 
identification of novel drug targets in sepsis, given the dearth of specific anti-sepsis drugs 
currently available. There is now increasing evidence that several thermosensitive depolarising 
cation-permeable transient receptor potential (TRP) channels, most notably of the vanilloid 
(TRPV) subfamily, can influence physiological systems compromised in sepsis, and may 
represent potential therapeutic targets. 
 TRPV channels: an overview 1.6.1
The superfamily of mammalian TRP channels comprises six subfamilies established on the basis 
of sequence homology: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPA (ankyrin), 
TRPP (polycystin), and TRPML (mucoliptin) (Earley and Brayden, 2010). All proteins are 
expressed as six-transmembrane domain subunits, which form functional homo- or hetero-
tetramers, further diversified by complex transcriptional regulation and splicing, as well as 
considerable post-translational modification (Clapham, 2003).  
TRP channels, originally identified as cellular sensors in Drosophila mutants (Swanson and 
Cosens, 1981), are gated by temperature, light, pressure and chemical stimuli (Earley and 
Brayden, 2010), and exhibit broad tissue distribution as well as highly diverse functions, 
ranging from audio-visual transmission to nociception and thermoregulation (Clapham, 2003). 
In recent years there has been growing interest in the vasoregulatory and inflammatory 
properties of TRP channels, and much research has focussed on the role of heat-sensitive 
TRPV1 in these settings, though other TRPV channels, most notably TRPV4, are similarly 
emerging as important regulators of vascular function, whose activity may be altered under 
inflammatory conditions. 
 Regulation of endothelial Ca2+ levels by TRP channels 1.6.2
Endothelium-dependent vasodilatation can occur through several different mechanisms, most 
of which are regulated by intracellular Ca2+: NO production by eNOS is enhanced through a 
Ca2+-calmodulin-dependent mechanism; Ca2+-dependent activation of phospholipase A2 (PLA2) 
liberates arachidonic acid from cellular membranes, providing a substrate for the biosynthesis 
of vasodilatory molecules such as prostacyclin (PGI2) and epoxyeicosatrienoic acids (EETs); and 
finally, elevated endothelial Ca2+ levels can directly activate Ca2+-sensitive K+ channels to 
initiate hyperpolarisation, which can spread electrically through myoendothelial junctions to 
hyperpolarise and relax underlying smooth muscle (Sullivan and Earley, 2013).   
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Coupling of these vasodilatory systems to vascular TRP channels could represent important 
mechanisms of vasoregulation. A common pathway for endothelial stimuli involves an increase 
in intracellular Ca2+. Typically, there is an initial rapid Ca2+ transient representative of 
intracellular store release via IP3 and/or ryanodine receptors, followed by a sustained Ca
2+ 
elevation representative of Ca2+ influx from the extracellular space. For many years the 
molecular identity of the Ca2+ influx channels was unknown. The discovery of TRP channels, 
however, has provided significant new insight into the mechanisms of Ca2+ influx into 
endothelial and other cells. Indeed, TRP channels have been implicated in many endothelial 
functions, including control of vascular tone, regulation of vascular permeability, 
mechanosensation, vasoactive responses to oxidative stress, angiogenesis and vascular 
remodelling (Nilius et al., 2003, Yao and Garland, 2005). Indeed, members of all TRP families 
(with the exception of TRPML) have been identified in endothelial cells.  
 TRPV1 as a potential regulator of vascular function in sepsis 1.6.3
TRPV1, predominantly expressed in sensory nerves (Caterina et al., 1997), but also thought to 
be present in cardiovascular tissues (Baylie and Brayden, 2011), has been studied in the 
context of sepsis for a number of years. The importance of sensory nerve input in sepsis was 
initially inferred from two observations: first, the exacerbated inflammatory response to 
infection following sensory denervation of experimental animals (Bowden et al., 1996); and 
second, the raised plasma levels in septic patients of neuropeptides that are released 
downstream of TRPV1 activation (Joyce et al., 1990, Beer et al., 2002). More recently, an 
upregulation of TRPV1 and the neuropeptide calcitonin gene-related peptide (CGRP) has been 
demonstrated in the tongue and mesenteric perivascular nerves, repectively, of endotoxaemic 
rats (Orliac et al., 2007). This suggests that changes in TRPV1 and neuropeptide expression 
may play an important role in sepsis.  
Indeed, a role for TRPV1 in mediating the fever response to endotoxin has been demonstrated 
both in sensory-denervated rats (Romanovsky, 2004), and TRPV1 knockout (KO) mice (Iida et 
al., 2005). TRPV1 has also been shown to protect against sepsis-induced cardiovascular 
dysfunction: Wang and colleagues (2008) demonstrated that recovery from endotoxin-induced 
hypotension and tachycardia in anaesthetised mice was strongly inhibited by the TRPV1 
antagonist capsazepine (Wang et al., 2008a). Additionally, 24- and 48-hour survival of 
conscious LPS-treated rats was similarly improved following administration of a TRPV1 
antagonist. Conversely, Ang and colleagues reported improved survival and attenuated organ 
dysfunction in septic mice pre-treated with capsazepine (Ang et al., 2010). A 5-fold higher dose 
of the drug was used in the latter study, however; since the selectivity of capsazepine is known 
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to be compromised at higher concentrations (Teng et al., 2004), the physiological effects 
recorded in the latter study may have been independent of TRPV1.  
Further investigation in our laboratory has demonstrated that TRPV1 KO mice exhibit 
significantly enhanced hypotension compared to wildtype (WT) counterparts at 4 h post-LPS 
administration, and early signs of liver dysfunction, including significant liver plasma 
extravasation and raised levels of plasma aspartate aminotransferase, were apparent in LPS-
treated TRPV1 KO but not WT mice (Clark et al., 2007). However, given that induction of 
cytokines, such as IL-6, only occurs approximately 6 h after the induction of endotoxaemia in 
mice, and haematological changes become pronounced after 24 h (Xiao et al., 2006), it seems 
likely that a 4-h end-point is too early to fully assess the functional effects of TRPV1 deletion in 
a murine model of sepsis. Furthermore, the possibility of developmental compensation for 
TRPV1 gene ablation cannot be ruled out. Selective and tissue-specific TRPV1 antagonism in 
vivo may be helpful in elucidating this further. 
A more recent study, using the cecal ligation and puncture (CLP) model of sepsis (thought to 
better recapitulate the polymicrobial insult generally encountered in human patients) found 
that at 24 h post-CLP, TRPV1 KO mice exhibit enhanced hypotension compared to WT controls, 
and plasma markers of heart, liver, kidney and pancreas dysfunction were significantly raised 
in the former group (Fernandes et al., 2012). Decreased mononuclear cell integrity and 
enhanced peritoneal apoptosis were observed at the primary site of infection in the KO mice. 
Moreover, macrophages isolated from TRPV1 KO mice exhibited an impaired ability to 
phagocytose latex beads in vitro, following stimulation with LPS. This process in WT mice was 
found to be dependent on substance P – a neuropeptide released downstream of TRPV1 
activation (Fernandes et al., 2012). These data suggest that deletion of the TRPV1 gene leads 
to impaired bacterial clearance in sepsis, accelerating the transition from local infection to a 
full systemic inflammatory response syndrome, and the onset of organ damage and failure.  
Thus far, the longer-term effects of TRPV1 deletion on vascular function in sepsis have not yet 
been investigated. It is possible that, in addition to immune cell regulation, TRPV1 may also 
mediate vasoactive effects: given its ability to cause both vasoconstriction and vasodilatation, 
depending on its cellular localisation, TRPV1 may contribute to recovery from septic 
hypotension through the former mechanism, or the maintenance of organ perfusion through 
the latter. This may form a basis for understanding why septic TRPV1 KO mice appear to 
exhibit both exaggerated hypotension and accelerated organ dysfunction (Clark et al., 2007). 
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 TRPV4 as a potential regulator of vascular function in sepsis 1.6.4
TRPV4, originally identified as an ‘osmosensor’ in the kidney by three different groups 
simultaneously (Strotmann et al., 2000, Liedtke et al., 2000, Wissenbach et al., 2000), is 
expressed in numerous tissues, including the heart and vasculature (Wissenbach et al., 2000). 
Its expression in both endothelial and smooth muscle cells is now well established (Baylie and 
Brayden, 2011), and in addition to hypotonicity, it is gated by various physical and chemical 
stimuli, including shear stress, arachidonic acid metabolites (particularly EETs) and 
endocannabinoids (Nilius et al., 2004) –  all of which may be altered under inflammatory 
conditions. Recent reports linking excessive TRPV4 activation to lethal oedema formation, 
hypotension and endothelial failure, suggest it may play a key role in sepsis pathogenesis.  
Hydrostatic stress is known to increase vascular permeability through stimulation of 
endothelial Ca2+ influx, Ca2+-dependent activation of myosin light chain kinase (MLCK) and 
subsequent contraction of endothelial cells (Yin et al., 2008). As a mechanosensitive channel, 
numerous studies have implicated TRPV4 in the Ca2+ influx that occurs in response to raised 
hydrostatic pressure. Alvarez and colleagues showed that TRPV4 activation increases 
permeability in the lung microvasculature and preferentially causes barrier disruption in 
alveolar septal regions (Alvarez et al., 2006). Channel activation has also been shown to 
increase paracellular permeability with disruption of epithalial tight junctions (Reiter et al., 
2006). The TRPV4 agonist 4α-phorbol 12,13-didecanoate (4αPDD) has been shown to cause 
pulmonary oedema in the absence of raised hydrostatic pressure, though it did not increase 
permeability further when pressure was already raised, suggesting convergent mechanisms 
that centre on TRPV4 (Yin et al., 2008). This is supported by the observation that pressure-
induced Ca2+ influx and lung oedema are dramatically reduced in TRPV4 KO mice (Yin et al., 
2008).  
Furthermore, pressure-induced oedema formation in isolated lungs was attenuated by low-
Ca2+ buffer, the TRPV4 blocker ruthenium red (RR), and ablation of the TRPV4 gene; gadolinium 
– a non-selective blocker of stretch-activated ion channels – did not enhance the inhibition 
further, suggesting that TRPV4 is exclusively responsible for the hyperpermeability response to 
raised hydrostatic pressure (Jian et al., 2008). Hyperpermeability and plasma extravasation are 
key features of sepsis pathogensis, and it is possible that under inflammatory conditions, 
endogenous activators of TRPV4 could precipitate significant organ oedema in the absence of 
raised hydrostatic pressure.  
TRPV4 has been implicated in both flow- and agonist-induced vasodilatation, in several 
different vascular beds (Kohler et al., 2006, Hartmannsgruber et al., 2007, Loot et al., 2008, 
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Zhang et al., 2009, Mendoza et al., 2010, Adapala et al., 2011, Zhang and Gutterman, 2011). Its 
coupling to Ca2+-sensitive K+ channels stimulates endothelial hyperpolarisation upon channel 
activation, which spreads to the underlying smooth muscle via myoendothelial gap junctions. 
In 2008, Willette and colleagues demonstrated that systemic activation of TRPV4 caused 
profound hypotension and circulatory collapse; 0.3 mg/kg GSK1016790A (a selective TRPV4 
agonist) administered intravenously caused death in 100% of WT mice (Willette et al., 2008). 
Mice heterozygeous for TRPV4 exhibited an attenuated response to the agonist (the lethal 
dose was raised to 1 mg/kg), while no cardiovascular derangements were observed in TRPV4 
KO mice. Continuous intravenous infusion of GSK1016790A also caused a profound drop in 
mean arterial pressure and systemic vascular resistance in dogs, who exhibited similar 
circulatory failure.  
The authors suggested that the lethal effects of GSK1016790A were associated with 
endothelial barrier failure: massive haemorrhages were observed in the lung, kidney and 
intestine of animals treated with higher doses of the drug, though there was no evidence of 
microvascular injury in the heart, brain, liver or skeletal muscle, suggesting a heterogeneous 
response to TRPV4 activation. It is possible that the absence of epithelial TRPV4 expression in 
the latter tissues could account for this phenomenon: co-operativity between epithelial and 
endothelial channels (as encountered in the gut, kidney and lung) could facilitate barrier 
breakdown.  
Administration of 10 nM GSK1016790A to cultured human umbilical vein endothelial cells 
(HUVECs) was found to cause rapid cell retraction and condensation, and subsequent 
detachment, supporting the hypothesis that circulatory collapse in response to systemic TRPV4 
activation is associated with endothelial barrier failure (Willette et al., 2008).  
In 2012, Sonkusare and colleagues investigated the molecular mechanisms of TRPV4-mediated 
vasoregulation in more detail. Using transgenic mice expressing a Ca2+-biosensor exclusively in 
the endothelium, the authors demonstrated the existence of basal endothelial Ca2+ pulses in 
isolated mesenteric arteries, that dramatically increased in frequency in response to 10 nM 
GSK1016790A (Sonkusare et al., 2012). Administration of 10 nM GSK1016790A activated 
approximately three sparklets per cell, and this was sufficient to hyperpolarise the underlying 
smooth muscle and cause maximal relaxation of pressurised arteries. This dilatory response 
was unaffected by inhibitors of eNOS and cyclo-oxygenase, though charybdotoxin – an 
inhibitor of large-conductance Ca2+-sensitive IK+ channels – abolished dilatation in response to 
3 nM GSK1016790A, and greatly reduced the dilation to 10 nM GSK1016790A.  
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Perforated patch clamping revealed an outward current in response to 10nM GSK1016790A 
that was substantially reduced by charybdotoxin and further reduced by subsequent addition 
of apamin – a blocker of small-conductance Ca2+-sensitive SK+ channels. In fact, 10nM 
GSK1016790A was found to increase the density of IK+ and SK+ currents to a similar degree to 
dialysis with 3 µM Ca2+. Together, these results demonstrate a specific link between TRPV4 
activation and endothelium-dependent hyperpolarisation, and may represent a molecular 
basis for the profound drop in blood pressure and systemic vascular resistance encountered in 
sepsis (Sonkusare et al., 2012).   
Interestingly, the systemic and regional haemodynamic effects of TRPV4 activation are 
differentially regulated by NOS activity. Intravenous injection of GSK1016790A in rats was 
shown to cause a decrease in mean arterial pressure and systemic vascular resistance, while 
causing an acute and transient increase in pulmonary arterial pressure, followed by a drop. In 
the presence of L-NAME, however, GSK1016790A produced an enhanced decrease in systemic 
arterial pressure, and large dose-dependent increases in pulmonary artery pressure, followed 
by a small drop (Pankey et al., 2014).  These observations suggest that under pathological 
conditions characterised by increased oxidative stress (which can inactivate NO), TRPV4-
mediated Ca2+ entry may promote pulmonary vasoconstriction, increase hydrostatic pressure 
in the lung, precipitating oedema formation and limiting adequate oxygen perfusion. 
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 Hypotheses and Aims 1.7
Given the dearth of effective clinical treatments for sepsis and septic shock, it is clear that 
more relevant pre-clinical models are essential to better understand disease progression and 
to test the effectiveness of novel pharmacological or genetic interventions. The hypotheses of 
this study were as follows: 
1) Microvascular blood flow represents a more sensitive and clinically relevant endpoint 
in pre-clinical sepsis studies than global haemodynamics 
2) Inflammation-induced upregulation of TRPV1 mediates protective effects through the 
ability of the receptor to regulate vascular function under inflammatory conditions 
3) Blockade of TRPV4 will attenuate sepsis-associated endothelial failure and circulatory 
collapse  
On the basis of these hypotheses, the aims of this study were as follows: 
1) To investigate alterations in microvascular function following the onset of sepsis, and 
to relate these alterations to changes in global haemodynamic, biochemical and 
haematological parameters  
2) To establish a robust model for assessing microvascular blood flow in sepsis, and to 
incorporate this model into a multi-parameter monitoring system, using gold standard 
monitoring techniques, to allow microvascular perfusion and global haemodynamics to 
be measured in the same animal in vivo, facilitating paired comparison and reducing 
the number of animals required 
3) To use the aforementioned model to determine the impact of TRPV1 and TRPV4 
modulation on sepsis-associated cardiovascular dysfunction in a murine model of 
sepsis 
4) To establish in vitro models for assessing vascular TRPV1 and TRPV4 expression and 
activity under basal and inflammatory conditions, to elucidate the mechanisms by 
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CHAPTER 2 | GENERAL METHODS  
 Animals 2.1
Mice were maintained on a 12-h light/dark cycle (7am–7pm, and 7pm–7am, respectively) and 
given access to food (normal chow) and water ad libitum. All experiments were carried out 
under license (PPL 70/7049) in accordance with the Animals (Scientific Procedures) Act, 1986, 
and UK Home Office regulations. In each experiment, animals were age- and gender-matched, 
and the researcher was blinded to genotype throughout the practical and analytical stages of 
experimentation. All treatments were administered in a randomised manner. 
 Origin of genetically altered mice  2.1.1
 TRPV1 knockout mice 2.1.1.1
C57/BL6 mice, either genetically unaltered (WT) or with a non-functional TRPV1 receptor gene 
(TRPV1 KO), were bred in house from mice generously donated to Professor Sue Brain by 
Merck, Sharp & Dohme (Harlow, UK). TRPV1 KO mice were originally generated by Merck, 
Sharp & Dohme via replacement with a neomycin cassette of an exon on chromosome 11B3 
encoding part of the fifth and the entire sixth transmembrane domain of TRPV1, including the 
interconnecting pore-forming loop, as shown in Figure 4 (Caterina et al., 2000). 
  





Figure 4. Strategy for TRPV1 (previously VR1) gene disruption, as conducted by Caterina et al. (2000). 
Black and grey vertical bars denote transmembrane and pore-loop domains of TRPV1, respectively. 
Exons encoding the carboxy-terminal portion of TRPV1 are indicated by vertical bars on the genomic 
maps. Part of the 5th and the entire 6th transmembrane domain of TRPV1 are replaced with a neomycin 
casetter. RV, Eco RV; H3, Hind III; Xb, Xba I; Xh, Xho I; Sp, Spe I; aa, amino acid. Figure adapted from 
Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor, Caterina et al. (2000). 
Science (Caterina et al., 2000).   
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TRPV1 KO mice show no aversion to drinking water supplemented with 100 µM capsaicin, and 
exhibit a reduced sensitivity to thermal pain and reduced inflammatory hyperalgesia (Caterina 
et al., 2000, Davis et al., 2000). They are otherwise phenotypically indistinguishable from WT 
littermates, with regard to general appearance, behaviour, blood pressure, gross anatomy and 
life span (Caterina et al., 2000, Davis et al., 2000).   
 TRPV4 knockout mice 2.1.1.2
C57/BL6 mice with a non-functional TRPV4 receptor gene (TRPV4 KO) were re-derived from 
frozen embryos generously donated by Dr Andy Grant, Wolfson Centre for Age-Related 
Disease, King’s College London, and were originally derived from a colony generated by Liedtke 
& Friedman in Germany (Liedtke and Friedman, 2003). Disruption of the TRPV4 gene was 
achieved through cre-lox-mediated excision of exon 12 of the TRPV4 gene, encoding 
transmembrane domains 5 and 6 and the putative pore-forming loop, and subsequent 
insertion of a neomycin cassette.  
TRPV4 KO mice are viable and fertile and are indistinguishable from WT littermates on a 
macroscopic level, although KO mice do exhibit altered osmotic regulation and mechanical 
sensitivity (Liedtke and Friedman, 2003). 
 Breeding 2.1.2
A heterozygous breeding strategy was employed to generate WT, KO and heterozygous 
littermates. TRPV1 KO mice were born in the expected Mendelian ratios of genotype and 
gender, though TRPV4 KO mice were not: only 5 male TRPV4 KOs were born following multiple 
rounds of breeding by 8 heterozygous pairs.   
Mice were weaned at 3 weeks of age and were split into cages according to gender. WT and 
KO littermates were housed together until experimentation. Following the induction of sepsis, 
mice were all singly-housed.  
 Genotyping 2.1.3
2-mm ear punches were taken from mice at 3 weeks of age, both to individually mark mice and 
procure a tissue sample. DNA was extracted by digesting tissue samples in DirectPCR lysis 
reagent (Viagen, 102-T) with proteinase K at 55°C overnight. Samples were then heated to 
85°C for 45 min, centrifuged, and either used directly or stored at -20°C. Following in vivo 
experiments, post-mortem genotypes were confirmed through similar methods. 
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For PCR amplication, 2 µl genomic DNA was added to 18 µl ReddyMixTM PCR Master Mix 
(Thermoscientific, AB-0575/LD/A) containing specific primers (500nM each). PCR products 
were resolved on a 2% agarose gel at 80 V for 50 min. 
 TRPV1 knockout mice  2.1.3.1
PCR amplification of WT and mutant TRPV1 was performed on genomic DNA samples using the 
following primers: 
a. TRPV1 WT forward: 5’-CCT GCT CAA CAT GCT CAT TG-3’  
b. TRPV1 KO forward: 5’-TGG ATG TGG AAT GTG TGC GAG-3’ 
c. TRPV1 common reverse: 5’-TCC TCA TGC ACT TCA GGA AA-3’ 
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The following thermocycling conditions were used to amplify PCR products: 
 Temp (°C) Time 
Initial denaturation 94 5 min 









Final extension 72 5 min 
 
Table 2. PCR thermocycling conditions for amplification of TRPV1 WT and KO DNA 
 
The TRPV1 WT forward primer (binding exclusively to wildtype DNA) and TRPV1 common 
reverse primer (binding downstream of the neomycin cassette, and so common to both 
genotypes) produced an amplicon of 984 bp. The TRPV1 KO forward primer (binding in the 
neomycin cassette) and TRPV1 common reverse primer produced an amplicon of 450 bp. Both 
bands were observed in samples from heterozygous mice (Fig. 5). 
 
 
Figure 5. Agarose gel visualised under UV illumination to show products of PCR amplification from 
TRPV1 KO (450 bp), WT (984 bp) and heterozygous (Het) mice (450 bp and 984 bp). 
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 TRPV4 knockout mice 2.1.4
TRPV4 WT, KO and heterozygous mice were distinguished by PCR amplification of two distinct 
transcripts: a long transcript of 1.1 kb, present in mutant TRPV4 DNA, and a short transcript of 
251 bp from within exon 12 of WT DNA. The following primers and thermocycling conditions 
were used for amplification of the long transcript: 
a. TRPV4 long forward: 5’-CAT GAA ATC TGA CCT CTT GTC CCC-3’ 
b. TRPV4 long reverse: 5’-TTG TGT ACT GTC TGC ACA CCA GGC-3’ 
 
 Temp (°C) Time 
Initial denaturation 94 5 min 








2 min 30 s 
Final extension 72 10 min 
Table 3. PCR thermocycling conditions for amplification of TRPV4 KO DNA 
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Amplification of the short transcript was achieved with the following primers and 
thermocycling conditions: 
a. TRPV4 short forward: 5’- AGG GCG ATA AGC ATG TTC AAC AGG-3’ 
b. TRPV4 short reverse: 5’- TGC ACC AAC ATG AAG GTC TGT GAC G-3’ 
 
 Temp (°C) Time 
Initial denaturation 94 5 min 









Final extension 72 5 min 
Table 4. PCR thermocycling conditions for amplification of TRPV4 WT DNA 
 
In WT samples, short transcript primers produced a band of 251 bp, and no long transcript was 
produced. KO samples produced a band of 1.1 kb with the long transcript primers only. Both 
bands were observed in samples from heterozygous mice (Fig. 6). Products were visualised 
following electrophoretic separation on a 1% agarose gel (80 V, 30–60 min), and ethidium 
bromide staining under UV illumination.  
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Figure 6. Agarose gel visualised under UV illumination to show products of PCR amplification of TRPV4 
WT, KO and Het DNA. with short transcript primers were loaded into the top wells; products of 
amplification with long transcript primers into the lower wells. A single band of 1.1 kb indicates TRPV4 




Anaesthesia was induced with inhaled 3% isoflurane (Abbott Laboratories, UK), and was 
maintained under 1.8 – 2.2% isoflurane, delivered by air pump. A deep level of anaesthesia 
was confirmed by the absence of a paw-pinch reflex. Intramuscular buprenorphine 
hydrochloride (Vetergesic; Alstoe Animal Health, UK) and subcutaneous saline resuscitation 
were administered in all recovery procedures, and cervical dislocation or terminal venous 
bleed were carried out under isoflurane-induced anaesthesia for terminal procedures. All 
procedures were carried out using a homeothermically-controlled heating mat coupled to a 
rectal temperature probe (Harvard Instruments, UK). Viscotears liquid gel (Novartis, UK) was 
used to protect eyes during prolonged anaesthesia (>1 min).  
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 Sepsis Models 2.3
Two models of sepsis were employed for this study: intravenous endotoxaemia and 
polymicrobial peritonitis. Both will be referred to as ‘sepsis’ throughout this thesis.  
 Lipopolysaccharide-induced endotoxaemia 2.3.1.1
Endotoxaemia was induced by intravenous injection of lipopolysaccharide (LPS; 12.5mg/kg) 
from Salmonella typhimurium (Sigma, L7261). Injections of approximately 100 µl (pre-warmed 
to 37°C) were administered into the tail vein (using a 29 G needle and insulin syringe) under 
inhaled isoflurane anaesthesia. A heating mat set to 37°C was used in order to dilate the tail 
vein for improved accessibility. Buprenorphine hydrochloride (15 µg/kg, i.m.) was 
administered into the two hind-limbs to provide post-operative analgesia and 0.9% (w/v) 
saline was administered subcutaneously to provide fluid resuscitation. Mice were placed in a 
recovery chamber at 27°C for up to 24 h and were monitored frequently. An arbitrary severity 
score of 1–5 (based on mobility, facial expression, piloerection and aversion to touch) was 
employed to assess animal welfare. Any mouse reaching a score of 5 was immediately 
terminated.  
 Cecal ligation and puncture 2.3.1.2
Polymicrobial peritonitis was induced by cecal ligation and puncture, as described previously 
(Rittirsch et al., 2009). Mice weighing 25–30 g were anaesthetised under inhaled isoflurane 
delivered by air pump, and placed in the supine position on a homeothermically-controlled 
heating pad. Buprenorphine hydrochloride (15 µg/kg, i.m.) was administered into the two 
hind-limbs to provide post-operative analgesia. The abdominal region was shaved and 
disinfected with chlorhexidine, and sterile surgical drapes were used to isolate a small 
abdominal region. Following midline laparotomy (1 cm), the cecum was exteriorised onto 
moist sterile gauze and a silk ligature was placed distal to the ileocecal valve, and tightened 
(bowl continuity was preserved). A single through-and-through puncture using a 19 G needle 
was then made in the ligated portion of the cecum, and gentle pressure was used to express a 
small droplet of faecal matter through each puncture site. The cecum was then returned to the 
abdominal cavity, which was closed using 5.0 Vicryl sutures. A step-by-step summary of the 
procedure is shown in Figure 7. For control sham operations, the ligature was not tightened, 
and no puncture was made. Saline (0.9% w/v) or Hartmann’s fluid was administered 
subcutaneously to provide fluid resuscitation, and animals were allowed to recover at 27°C for 
up to 24 h with frequent monitoring.  




Figure 7. Critical steps in the CLP procedure developed by Rittirsch et al. (a) The abdominal area was 
shaved and disinfected with chlorhexidine. (b) A 1-cm midline incision was made with sterile scissors. (c) 
The cecum was exteriorised (onto moist sterile gauze in the current study). (d) The terminal third of the 
cecum was ligated with a silk ligature. (e) A single through-and-through puncture was made using a 19 G 
needle, and gentle pressure was applied with blunt forceps to express a small droplet of faecal matter 
through each puncture site. (f) The cecum was returned to the abdominal cavity and the incision closed 
with 5.0 Vicryl sutures (metal clips were not used in the current study). Figure adapted from 
Immunodesign of experimental sepsis by cecal ligation and puncture, Rittirsch et al. (2009). Nature 
Protocols (Rittirsch et al., 2009). 
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 Haemodynamic assessment by radiotelemetry 2.4
PA-C10 telemetry probes (Data Sciences International; DSI, USA) were implanted into 10–12-
week-old mice weighing 25–30g, under inhaled isoflurane anaesthesia using aseptic technique. 
Mice were placed in the supine position on a homeothermically-controlled heating mat, and 
the thorax was shaved and disinfected with chlorhexidine. Buprenorphine hydrochloride (15 
µg/kg, i.m.) was administered into the two hind-limbs to provide post-operative analgesia. A 
small thoracic incision was made and the carotid artery was isolated by gentle blunt dissection. 
Telemeter catheters were placed in the left carotid artery and secured with three silk sutures. 
The body of the telemetry probe was placed in a subcutaneous pocket equidistant between 
the fore- and hind-limb, and the incision was closed using a 5.0 Vicryl suture. Mice were then 
placed in a recovery cabinet at 27°C for 4 h, before being moved to a holding room, where 
they were allowed to recover for at least 10 days before the start of haemodynamic 
monitoring. The viability of each haemodynamic trace was checked, and mice with significant 
dampening or loss of signal were excluded from analysis, as shown in Figure 8. All 
implantation, monitoring and data analysis was conducted in a blinded fashion, and 
assignment of telemetry probes was randomized.  
PA-C10 telemetry probes allow continuous and remote monitoring of blood pressure, heart 
rate and locomotor activity in freely moving conscious animals. Data were acquired 
continuously at 500 Hz using standard acquisition software (DSI, USA). Baseline recording was 
carried out over weekends in order to minimise disruption.  
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Figure 8. Representative traces of mean arterial pressure (MAP). Upper panel: acceptable pressure 
trace, indicating accurate positioning of pressure catheter. Lower panel: disrupted signal due to 
movement of the pressure catheter, leading to exclusion of this mouse from analysis.  
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 Measurement of cardiac function by echocardiography 2.5
Echocardiographic monitoring of cardiac function was performed in vivo under isoflurane 
anaesthesia by Dr Anna Starr. Mice were placed on a homeothermically-controlled table and 
limb leads were attached for electrocardiogram gating. Images were acquired in the left lateral 
decubitus position with a 30 MHz linear probe (Visualsonic Vevo 770™, 30 MHz linear signal 
transducer). Two-dimensional images in parasternal long- and short-axis projections were 
recorded with guided M-mode recordings at the midventricular level in both views. 
Interventricular, septal and left ventricular posterior wall dimensions were taken in diastole 
and systole, in addition to left ventricular internal dimensions.  
 Measurement of microcirculatory perfusion 2.6
A detailed description of microcirculatory perfusion monitoring, including images of the set-up 
used, is provided in Chapter 3. Briefly, male mice aged 12–16 weeks were anaesthetised by 
inhaled isoflurane (2%, delivered by continuous air pump) and were placed in the supine 
position on a homeothermically-controlled heating mat, coupled to a rectal temperature 
probe. A small abdominal incision was made through which a portion of the small intestine 
was exteriorised onto a parafilm-coating heating mat. The intestine was pinned out through 
the gut wall to expose the mesenteric vasculature, and gently sprayed with saline pre-warmed 
to 37°C. Care was taken to avoid stretching or puncturing any blood vessels, and mice with 
significant bleeding were immediately terminated and excluded from analysis (approximately 
7% throughout the course of this study). An additional heating mat was placed over the body 
of the anaesthetised mouse, and core temperature was continuously monitored.  
Mesenteric blood flow was measured using a full-field laser perfusion imaging system 
(moorFLPI, Moor Instruments, UK) and moorFLPI Measurement software (Moor Instruments, 
UK). The following acquisition settings were used:  
- High resolution capture (100 frames; 1 second/frame) 
- Exposure time 20 ms 
- Automatic gain 
- Flux palette 0 – 5000 units  
- Background threshold 60 flux units  
After baseline recording, vasoactive drugs were administered topically or systemically. Data 
were analysed using moorFLPI Review software (V 4.0; Moor Instruments, UK) and GraphPad 
Prism (V 5.0; GraphPad Software Inc, USA). Vessels within the field of view were designated as 
1st, 2nd or 3rd order branches and regions of interest, in which flux over time was measured, 
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were defined in each visible vessel (Fig. 9). Results are expressed as mean area und the curve 
(AUC) over time ± SEM. 
 
 







 order descendants of the superior mesenteric artery, and regions of interest were drawn as 
indicated by red squares, in order to measure blood flow in individual vessels.  
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 Ex vivo analysis and tissue collection 2.7
 Termination 2.7.1
Animals were terminated by exsanguination via the vena cava, followed by cervical dislocation. 
Venous blood samples were analysed immediately following venupuncture. Samples were 
then centrifuged (1200 rpm, 4 min), and the separated plasma fraction was snap-frozen in 
liquid nitrogen.  
 Analysis of blood biochemistry by iSTAT blood-gas analyser 2.7.2
Blood gases, biochemistry and composition were measured from 100 µl venous blood samples 
using a handheld iSTAT Point-of-Care analyser (Abbott Laboratories, USA) and EC8+ cartridges 
(Quality Clinical Reagents, UK) within 1 min of collection from the inferior vena cava (IVC).  
 Tissue collection 2.7.3
 Assessment of oedema formation 2.7.3.1
Tissues were excised immediately after terminal IVC bleed and cervical dislocation and were 
weighed on a microbalance, before placement in a drying oven at 50°C, until a constant dry 
weight was reached (approximately 3 days). Dry organs were re-weighed, and ratios of wet 
weight:dry weight were calculated to determine the level of tissue oedema. 
 Tissue preparation for Western blot analysis 2.7.3.2
Following cervical dislocation and puncture of the inferior vena cava, animals were perfused 
with ice-cold saline injected into the left ventricle of the heart. Tissues were then excised, 
snap-frozen in liquid nitrogen and stored at -80°C. Frozen samples were lysed by mechanical 
homogenisation with stainless steel beads (30 Hz, 2-4 min) in RIPA buffer [20 mM Tris-HCl, pH 
7.5; 150 mM NaCl; 1 mM Na2EDTA; 2.5 mM sodium pyrophosphate; 1 mM β-
glycerophosphate; 1 mM Na3VO4; 1% NP-40; 1% sodium deoxycholate; 1 µg/ml leupeptin; 
Complete EDTA-free protease inhibitor cocktail (1 tablet/ 10 ml)]. Samples were then 
centrifuged and the pellet discarded. Supernatants were mixed with 4x Laemmli buffer [Final 
concentration: 2% (w/v) SDS; 10% (w/v) glycerol; 30mM Tris-Cl (pH 6.8); 0.01% (w/v) 
bromophenol blue; 5% (w/v) β-mercaptoethanol] and boiled at 95°C for 5 min prior to use. 
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 SDS-PAGE and Western Immunoblotting 2.8
Protein concentration was determined by bicinchoninic acid (BCA) assay (Thermoscientific, 
23227), using a bovine serum albumin (BSA) standard curve range diluted in RIPA buffer, as per 
kit instructions. 30 µg protein was added to each well of a 6% SDS-polyacrylamide gel and size-
separated by electrophoresis at 200 V for 60 min. Proteins were transferred onto a 
polyvinylidene fluoride (PVDF) membrane (GE Healthcare, RPN303F) by semi-dry transfer at 45 
mA/membrane for 2 h and non-specific binding sites were blocked in Tris-buffered saline (TBS) 
containing 0.1% Tween-20 (TBS-T) and 10% non-fat milk. Membranes were incubated with 
primary antibody on an orbital shaker at 4°C overnight, washed (4 x 10 min) with TBS-T, and 
then incubated with horse radish peroxidase (HRP)-conjugated secondary antibody at RT for 1 
h. Immunblots were developed using enhanced chemiluminescence (ECL; Thermoscientific, 
32209) and a dark room imaging system, and signals were captured on autoradiographic film 
(GE Healthcare, 95017). Digital representations were generated by optical scanning. Only 
linear contrast adjustments were used, and were applied to the image as a whole. Details of 
the antibodies used are found in Table 5.  
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Antibody Manufacturer Catalogue 
No 
Species Vehicle (in PBS) Working 
dilution 
Primary antibodies 
Anti-TRPV1 Alomone Labs ACC-030 Rabbit 1% BSA, 0.05% 
NaN3 in PBS 
1 : 200 
Anti-TRPV1 Abcam ab45759 Mouse 1% BSA, 0.05% 
NaN3 in PBS 
1 : 200 
Anti-TRPV1 Abcam ab31895 Rabbit 1% BSA, 0.05% 
NaN3 in PBS 
1 : 200 
Anti-TRPV1 Biorbyt orb13755 Rabbit 1% BSA, 0.05% 
NaN3 in PBS 
1 : 100 
Anti-TRPV1 Biorbyt orb32072 Rabbit 1% BSA, 0.05% 
NaN3 in PBS 
1 : 100 
Anti-β-actin Sigma   1% non-fat milk in 
TBS-T 
1 : 2000 
Secondary antibodies 
Anti-rabbit Cell Signaling #7074 Goat 1 % non-fat milk in 
TBST-T 
1 : 2000 
Anti-mouse Sigma A4416 Goat 1% non-fat milk in 
TBST-T 
1 : 5000 
Table 5. List of antibodies used in Western blot analysis 
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 Cell isolation and culture 2.9
 Bovine aortic endothelial cells 2.9.1
Bovine aortic endothelial cells (bAEC) were isolated from fresh bovine aortae obtained from 
ABP Beef abattoir (Guildford, UK). Adherent fatty tissue was removed from the vessel, and the 
aorta was cut lengthways between intercostal arteries. Endothelial cells from the luminal 
surface of the vessel were scraped using the blunt side of a scalpel into pre-warmed 
Dulbecco’s modified Eagle’s medium (DMEM; PAA, E15-009) containing 0.2 mg/ml collagenase 
type 1A (Sigma, C9891), and incubated at 37°C for 20 min. The digest was then centrifuged 
(1200 rpm, 5 min) and the pellet resuspended in DMEM supplemented with 10% foetal bovine 
serum (FBS), 1% penicillin/streptomycin and 2 mM L-glutamine (complete DMEM) and seeded 
into a T75 (75 cm2) flask pre-coated with 0.5% gelatin  (Sigma, G1393). Cells were allowed to 
adhere at 37°C in a 5% CO2 humidified atmosphere for 4 h, before the culture medium was 
changed, and replaced every 48 h until cells reached confluency (approximately 1 week). The 
purity of endothelial cell cultures was determined on the basis of their characteristic 
cobblestone morphology. 
 Murine pulmonary endothelial cells 2.9.2
TRPV1 WT and KO mice were terminated by cervical dislocation under isofluorane-induced 
anaesthesia. Blood was flushed out of vessels by gentle cardiac perfusion with ice-cold 
phosphate-buffered saline (PBS), and lungs were harvested into ice-cold complete DMEM. 
Lungs were minced finely with a sterile scalpel blade and scissors, and digested at 37°C for 60 
min with gentle agitation in 10 ml complete DMEM containing 0.18 U/ml Liberase Blendzyme 
3TM (Roche, 05401119001) and 0.1 mg/ml DNase I (Roche, 11284932001). The digest was 
gently sheared through a 5 ml serological pipette and passed through a 70 µm filter. The 
filtered digest was centrifuged at 1200 rpm for 5 min at RT, and the pellet resuspended in PBS 
containing 0.5 % BSA and 2 mM EDTA (MACS® wash buffer). The resulting suspension was 
passed through a 40 µm strainer and centrifuged at 1200 rpm for a further 5 min at RT. The 
pellet was resuspended in 500 µl  MACS® wash buffer and incubated with 1 µg/ml CD31 
antibody (BD Pharmingen, 553369) for 15 min at 4°C. Following centrifugation (1200 rpm, 5 
min, RT) the pellet was resuspended in 500 µl MACS® wash buffer and incubated with MACS® 
goat anti-rat IgG Microbeads (Miltenyi Biotech, 130-048-501) for 15 min at 4°C. The suspension 
was made up to 1 ml with MACS® wash buffer and centrifuged at 1200 rpm for 5 min at RT. 
The pellet was resuspended in 500 µl MACS® wash buffer and added to a MACS® separation 
column placed in a MACS® magnetic separator. The column was rinsed several times with 
MACS® wash buffer, and the flow-through discarded, before bound cells were eluted by 
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plunger. After a final centrifugation step (1200 rpm, 5 min, RT) cells were resuspended in 
endothelial basal medium (EBM) supplemented with endothelial growth supplement cocktail 
(EGM-2 MV BulletKit; Lonza, CC-3202), and plated into 6-well plates pre-coated with 0.5% 
gelatin. Experimentation was performed once cells had reached at least 80% confluency 
(approximately 7 days).  
 Murine aortic smooth muscle cells 2.9.3
TRPV1 WT and KO mice were terminated by cervical dislocation under isofluorane-induced 
anaesthesia. Blood was flushed out of vessels by cardiac perfusion with ice-cold phosphate 
buffered-saline (PBS) and the aorta was isolated, cleaned of surrounding fat tissue and cut 
open lengthways. Endothelial and adventitial layers were removed by scraping both sides of 
the vessel with a sterile scalpel blade, and the aorta was then cut into small pieces and 
digested for 60 min at 37°C with gentle agitation in DMEM containing 1.5 mg/ml collagenase 
type 2 (Worthington Labs, LS004196). The digest was passed through a 70 µm strainer and 
centrifuged at 1200 rpm for 5 min at RT. Cells were washed once more in DMEM and re-
centrifuged, and the pellet was resuspended in DMEM containing 20% FBS. After 3 days, FBS 
was reduced to 10% and the cells were used after 7 days.  
 Human umbilical vein endothelial cells 2.9.4
Primary human umbilical vein endothelial cells (HUVEC) were kindly donated by Dr Bijal Patel 
(King’s College London, UK). Cells were isolated by collagenase digest similar to the isolation of 
bAEC, described above, and were used at passage 4.  
 Murine bone marrow-derived macrophages 2.9.5
Bone marrow-derived macrophages (BMDM) were isolated from a colony of TRPV4 WT and KO 
mice at the Wolfson Centre for Age-Related Diseases (King’s College London). Mice were 
terminally anaesthetised with sodium pentobarbital (100 mg/kg, i.p.) and femur and tibia 
bones were removed and separated following gentle dissection of overlying skin and muscle. 
Isolated bones were cleaned with an ethanol swab and transferred to a dish of DMEM. The 
ends of all four bones (two from each hind-limb) were cut with sterile scissors. A 10-ml syringe 
with a 25-G needle containing ice-cold Ca2+/Mg2+-free PBS was inserted into the bone marrow 
cavity, and the bone marrow flushed out with 2–5 mL PBS. Cells were centrifuged at 2000 rpm 
for 7 min at RT, and the pellet resuspended in DMEM containing macrophage colony-
stimulating factor (25 ng/mL of 500 U/mL stock; Sigma-Aldrich; DMEM-MCSF). The suspension 
was passed through a 40-µm filter and the flow-through made up to 25 mL with DMEM-MCSF 
supplemented with 10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 2 mM L-
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glutamine (complete DMEM-MCSF). Cells were then plated in a 15-cm dish and incubated at 
37°C in a 5% CO2 humidified atmosphere. After 5–7 days, culture supernatants were gently 
aspirated, and cells were gently washed with pre-warmed PBS. Following 5-min incubated at 
37°C in PBS, cells were gently scraped off the plastic dish, centrifuged at 1500 rpm for 7 min at 
RT, and resuspended in complete DMEM-MCSF and plated onto glass coverslips (200,000 
cells/coverslip) for imaging.  
 Immortalised cell lines 2.9.6
In addition to primary cultures, a number of immortalised cell lines were used: mouse skin 
endothelioma cells (sEnd1) were originally obtained from Dr E.F. Wagner (European Molecular 
Biology Laboratory, Heidelberg, Germany). Human embryonic kidney (HEK) cells and HEK cells 
stably expressing rat TRPV1 (HEK-TRPV1) were kindly supplied by Dr A. Grant (King’s College 
London, UK). 
 General cell culture 2.9.7
All cells were maintained in complete DMEM or EBM at 37°C in a 5% CO2 humidified incubator. 
Subculture was performed on confluent cells by washing twice with pre-warmed PBS, and 
incubating at 37°C with trypsin EDTA (1 ml/75 cm2; PAA Laboratories, L11-004) or accutase (1 
ml/75 cm2; PAA, L11-007) until complete detachment was achieved (1-5 min). Cells were then 
suspended in complete DMEM or EBM and replated for use in assay.  
 Measurement of mRNA expression 2.10
 Sample preparation 2.10.1
Murine aortae were lysed in TRIzol® reagent (Invitrogen 15596-026) by mechanical 
homogenisation (30 Hz, 2 min) with stainless steel beads (Qiagen 69989). Monolayers of bAEC, 
HUVEC and sEnd1 were washed with ice cold PBS and then lysed directly in TRIzol® reagent (1 
ml/10 cm2). Total RNA was extracted using chloroform and a series of alcohol washes as per 
manufacturer’s instructions, and purified by sodium acetate/ethanol precipitation. RNA was 
then reverse-transcribed to cDNA using Ready-to-Go You-Prime First-Strand Beads (GE 
Healthcare, 27-9264-01), as per manufacturer’s instructions. Briefly, 2 µg RNA was brought to 
a volume of 30 µL in diethylpyrocarbonate (DEPC)-treated water, and heated at 65°C for 10 
min. The RNA solution was then transferred to a tube of first-strand reaction mix beads and 1 
µM Oligo(dT)20 primer (Life Technologies, AM5730G) was added. Samples were incubated at 
RT for 1 min. Tubes were then gently vortexed and incubated at 37°C for 1 h. DNA purity was 
assessed in a NanoDrop 1000 spectrophotometer (Thermo Scientific). Lysates of dorsal root 
ganglia (DRG) isolated from the same mice were prepared in a similar manner.    
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 Primers and PCR conditions 2.11
TRPV1 cDNA was amplified using the following primer pairs:  
1. Murine TRPV1 (predicted product size: 246 bp) 
a. Forward: 5'-ctgatcgaggatgggaagaa-3' 
b. Reverse: 5'-aatgagcatgttgagcagga-3' 
2. Bovine TRPV1 (predicted product size: 173 bp) 
a. Forward: 5’- gaatcacgggaatctcagga-3’ 
b. Reverse: 5’ gagcagtccatgagggatgt-3’ 
3. Human TRPV1 (predicted product size: 201 bp) 
a. Forward: 5’- caaccagctgggcatcgtgaagt-3’ 
b. Reverse: 5’- agcttcagcgtcgggtgcagttt-3’ 
TRPV4 cDNA was amplified using the following primer pairs: 
1. Murine TRPV4 (predicted product size: 172 bp) 
c. Forward: 5'- acaagaagcgcctgactgat-3’ 
d. Reverse: 5'- tctctgaagggcgagttgat-3’ 
4. Bovine TRPV4 (predicted product size: 245 bp) 
a. Forward: 5’- taccgcaccacaatggacta-3’ 
b. Reverse: 5’ accaaggcaaagaccatgac-3’ 
5. Human TRPV4 (predicted product size: 226 bp) 
a. Forward: 5’- aggtgtgcaatgaggaccagaccaa-3’ 
b. Reverse: 5’- atgagggcaatgagcatgttgagga-3’ 
Thermocycling was performed as described in Table 1. PCR products were visualised by 1% 
agarose gel electrophoresis (80 V, 50 min) and ethidium bromide staining under UV 
illumination. 
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 Measurement of intracellular calcium  2.12
 Microplate-based live imaging 2.12.1
 Experimental set-up 2.12.1.1
Cells were plated in black 96-well plates (Corning, NY, USA) at an approximate density of 
30,000 cells/well and allowed to adhere overnight. Cells were then loaded with 2.5 µM Fura-2-
acetyoxymethyl ester (Fura-2/AM; Merck Chemicals, 344906) in the presence of 2 mM 
probenecid in Hank’s balanced salt solution (HBSS, pH 7.4) containing Ca2+, Mg2+ and 20 mM 
HEPES. After 1 h, the loading solution was replaced with HBSS, and fluorescence in each well 
was measured using a FlexStation® 3 Microplate Reader (Molecular Devices, Sunnydale, CA). 
Emission intensity ratios at 340 nm/380 nm excitation wavelengths (response ratio) were 
measured every 6 s for 180 s.  
   Cell treatments.  2.12.1.2
Prior to assay, cells were either left untreated, or were incubated with lipopolysaccharide (LPS; 
100 ng/ml; 1 –24h). Following 20 s measurement of baseline intracellular calcium levels, drugs 
were added by an internal automated pipettor system.  
 Single-cell live imaging  2.12.2
Cells were plated onto circular glass coverslips (13 mm diameter) and allowed to adhere 
overnight. Cells were incubated with 2.5 µM Fura-2/AM and 2 mM probenecid in HBSS, in the 
dark at 37°C for 1 h. Coverslips were then mounted in a laminar flow perfusion chamber, and 
continuously perfused at a rate of 4 ml/min with either HBSS, HBSS + capsaicin, HBSS + 
GSK1016790A, or HBSS + positive control (either 1 µM ionomycin or 100 µM ATP). Baseline 
recordings were taken for 30 s, and drugs were perfused for 2 min and washed out for 2 min. 
The temperature of the perfusion buffer was maintained at 37°C by a regulated Peltier device 
(Marlow Industries, Dallas, TX) and monitored by a thermocouple. Images of a group of cells 
were captured every 2 s (excitation 340 nm and 380 nm; emission 520 nm) using a Zeiss 
Axiovert microscope, an ICCD video camera (Stanford Photonics, California, USA) and video 
microscopy acquisition software EasyRatioPro (Photon Technology International, New Jersey, 
USA).  
 Analysis 2.12.3
Analysis of emission intensity ratios at 340 nm/380 nm excitation (response ratio) in individual 
cells was performed with EasyRatioPro analysis software (Photon Technology International, 
USA). All cells non-responsive to positive control were excluded from analysis. Analysis of 
ratios in microplate wells was performed with Softmax Pro analysis software (Molecular 
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Devices, LLC, USA). Baseline fluorescence intensity was subtracted from readings post-drug 
administration in order to obtain relative response. A ratio change of 0.1 or greater was 
considered responsive (Alexander et al., 2013). All subsequent analysis was performed in 
Microsoft Excel and GraphPad Prism. 
 Assessment of cell viability by MTT assay 2.13
Cell viability was assessed by MTT assay, as described in greater detail in section 5.2.6. Cells 
were plated in 96-well plates and allowed to reach 80% confluency. 10 µL MTT (in saline) was 
added to each well (final concentration: 5 mg/mL), and cells were incubated at 37°C for 4 h. 
The formazan product was solubilised in DMSO, and absorbance was read at 560 nm in a 
FlexStation® 3 Microplate Reader (Molecular Devices, Sunnydale, CA). 
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CHAPTER 3 | A NOVEL APPROACH TO 
MEASURING MURINE MESENTERIC BLOOD 
FLOW IN SITU 
 Introduction 3.1
While care of septic patients has traditionally centred on achieving target blood pressures and 
a normal macrohaemodynamic status, it is now becoming increasingly clear that monitoring 
systemic parameters does not reliably predict mortality: such assessments fail to reflect the 
status of the microcirculation, where impaired flow is associated with significant tissue 
damage and poor outcome (De Backer et al., 2010). Indeed, persistent disruption of 
microcirculatory perfusion following the restoration of macrohaemodynamic parameters has 
been shown to correlate strongly with organ failure and death (Sakr et al., 2004).  
This has been demonstrated in animal models of shock, as well as in human patients. 
Endotoxaemic sheep in which mean arterial pressure (MAP) was restored through 
noradrenaline infusion nevertheless exhibited mesenteric flow disruption and severe 
mitrochondrial dysfunction (Andersson et al., 2012). Furthermore, in rats subjected to 
haemorrhagic shock and subsequent blood volume restoration, survival was found to be 
strongly related to the level of skeletal muscle perfusion, but not to macrohaemodynamic 
paramters (Zhao et al., 1985). Similarly, De Backer and colleagues have shown that sublingual 
circulation is compromised to a greater extent in non-survivors of septic shock than survivors 
(De Backer et al., 2010), and numerous studies have shown that elevating arterial pressure 
with vasopressors does not necessarily improve regional perfusion (Dubin et al., 2009, Jhanji et 
al., 2009, Gattinoni et al., 1995). 
These observations have given rise to an emerging theory that systemic stabilisation in sepsis 
may actually be achieved at the expense of the microcirculation, where impaired flow leads to 
regional hypoxia and eventually multiple organ dysfunction syndrome, or MODS (Spronk et al., 
2004). The exact mechanisms underlying microcirculatory shutdown in sepsis are not well 
understood; active shunting, microthrombus formation and endothelial dysfunction are all 
likely to contribute. What is clear, however, is that microcirculatory dysfunction is at the heart 
of sepsis-associated pathology (Spronk et al., 2004), and clinical practice has adapted in line 
with this growing realisation: assessment of microcirculatory perfusion (by measurement of 
proxies, such as blood lactate levels or gut tonometry) has become common clinical practice, 
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and recently direct measurement of sublingual blood flow by sidestream dark field imaging has 
emerged as a robust predictor of outcome in patients (Trzeciak et al., 2008, Spanos et al., 
2010).  
Despite this shift in clinical practice, however, pre-clinical models of sepsis rarely assess 
microcirculatory parameters directly, and where they have been evaluated, methods are often 
either exceedingly complex and invasive, and therefore limited to larger species, or subject to 
significant confounding factors, such as dissection-induced tissue damage. As such, it is clear 
that more relevant pre-clinical models are required, in order to increase understanding of the 
pathological microvascular changes that occur in septic shock. Owing to the ease of genetic 
modification in mice, it is particularly crucial to develop more clinically relevant models in this 
species, in order to gain specific mechanistic insight into the involvement of particular proteins 
in sepsis pathogenesis. Furthermore, a greater understanding of the relationship between 
haemodynamic variables (including blood pressure and cardiac output), microcirculatory 
perfusion and haematological indices or organ function and metabolic disturbances is crucial in 
this syndrome. Systematic multi-parameter modelling, with a focus on clinically relevant 
endpoints, would be immensely valuable for early proof-of-concept investigations, and could 
help to refine the development of novel treatment strategies.  
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 Hypothesis 3.1.1
We hypothesise that microcirculatory flow is a more sensitive marker of sepsis progression 
that global haemodynamic parameters, and that the latter may be maintained at the expense 
of the former. 
 Aims 3.1.2
The aims of this study were as follows: 
1. To establish a robust model of quantitative microcirculatory flow assessment in the 
mouse 
2. To measure microcirculatory blood flow in healthy and septic mice, and to evaluate 
the physiological relationship between microvascular function, global haemodynamic 
variables and haematological markers 
3. To determine the prognostic value of microcirculatory blood flow relative to global 
haemodynamic parameters, through reference to systemic markers of organ 
dysfunction 
4. To determine the clinical relevance of using microvascular blood flow as a pre-clinical 
endpoint through use of standard clinical interventions 
5. To elucidate the mechanisms of microcirculatory flow impairment in sepsis using 
vasodilatory and anti-coagulant agents 
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 Methods 3.2
 Experimental design 3.2.1
The mouse model is essential for delineating the involvement of specific proteins in sepsis 
pathogenesis. While it is clear that rodents do not necessarily recapitulate the genomic 
responses to sepsis encountered in humans (Seok et al., 2013), they nevertheless exhibit highly 
similar pathophysiological sequelae, most notably a profound inflammatory response with 
subsequent thermoregulatory and cardiovascular perturbations. As such, the mouse 
represents a useful tool for early proof-of-concept studies in a mammalian system that largely 
mirrors the sepsis-induced pathophysiological changes that occur in human patients.  
The two most widely used pre-clinical models of sepsis and septic shock involve either 
administration of a bacterial endotoxin (typically lipopolysaccharide, or LPS) to stimulate 
systemic endotoxaemia, or cecal ligation and puncture (CLP) to induce polymicrobial 
peritonitis, as described previously (Rittirsch et al., 2009). Both are associated with 
comparative advantages and disadvantages. LPS is highly stable, ensuring reproducible 
administration and easy storage. Furthermore, the quantity of LPS infusion can be easily 
titrated to induce a highly reproducible inflammatory response. The immunological profile of 
the LPS model is dissimilar to the polymicrobial sepsis syndrome encountered clinically (Seok 
et al., 2013), however, perhaps as a result of the bypassing of opsonisation and bacterial 
processing steps; the model is also limited by its lack of infectious focus, and species 
differences in susceptibility to LPS (Schultz and van der Poll, 2002). CLP, conversely, represents 
a polymicrobial insult more similar to the abdominal peritonitis encountered in humans. It has 
a septic focus from which bacteria are disseminated, though exact and consistent titration of 
insult severity may be more difficult to achieve. Based on these advantages and disadvantages, 
as well as their wide use in sepsis research, both models were investigated for comparison in 
this study.  
The murine mesenteric bed was chosen for assessment of microcirculatory function on the 
strength of several important factors, not least its accessibility and its significant contribution 
to peripheral vascular resistance. Low mesenteric flow is known to correlate strongly with 
multiple organ failure and mortality, both in animal models (Baykal et al., 2000) and in human 
patients  (Takala, 1997); clinically, gut ischaemia is known as the ‘motor of multiple organ 
failure’ (Carrico et al., 1986),  probably because impaired mesenteric blood flow is associated 
with intestinal hyperpermeability. This breakdown in barrier function facilitates the leakage of 
endotoxins and microorganisms into the lymphatic and cardiovascular circulation, which can 
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exacerbate the inflammatory response (Sautner et al., 1998). Furthermore, gastric perfusion is 
known to correlate well with sublingual perfusion (Marik, 2001) – a robust indicator of 
outcome in patients (De Backer et al., 2010). Consequently, we have developed a novel 
approach to quantifying mesenteric blood flow in situ, in both healthy and septic mice.  
 Animals 3.2.2
Male C57-BL/6 mice (10–14 weeks; 25–30 g) were bred in-house or purchased from Charles 
River (UK). Sepsis was induced by LPS or CLP, as described in section 2.3. Naïve mice were used 
as controls in the LPS model; sham-operated mice (in which the cecum was exteriorised but 
not ligated or punctured) were used as controls for CLP.  
 Laser speckle contrast imaging 3.2.3
 Experimental set-up 3.2.3.1
Mice were anaesthetised under isoflurane (2% by air pump) and core temperature was 
recorded and controlled by a rectal probe coupled to a homeothermic heating mat. Mice were 
maintained at the temperature at which they initially presented. Hair was removed from the 
abdomen by electrical shaver, and a small midline incision was made. A portion of the small 
intestine was gently exteriorised onto a parafilm-coated heating mat, and was pinned out 
through the gut wall to expose the mesenteric vasculature, as shown in Figure 10. Care was 
taken not to stretch or puncture blood vessels, and if bleeding was seen to occur, mice were 
terminated immediately and excluded from analysis (approx. 5% of total).  The exposed 
vascular bed was kept moist with saline (0.5 ml, aerosolised) pre-warmed to 37C. An 
additional heating mat was placed over the anaesthetised animal. 
Mesenteric blood flow was recorded using a moorFLPI full-field laser perfusion imaging system 
and review software (Moor Instruments, Devon, UK) either in naïve animals, or at 6 or 24 h 
after the induction of sepsis. The following acquisition modes and settings were used: high 
resolution capture (25 frames, 1 s/frame); exposure 20 ms; automatic gain; flux palette set at 
0–5000; background threshold 60 flux units. The moorFLPI was positioned approximately 25 
cm above the region of interest, and zoom and focus were adjusted appropriately to acquire 
high-resolution images of the region of interest. No further investigator intervention or 
microdissection was necessary. All assessment and analysis was performed in a blinded 
manner. Baseline recordings were taken over 5 min. 
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Figure 10. Experimental set-up involving exteriorisation of a section of the small intenstine through a 
small abdominal incision, and careful pinning through the gut wall to expose the mesenteric vascular 
bed. Mice were placed on a parafilm-coated homeothermic blanket coupled to a rectal temperature 
probe. The exposed mesenteric bed was moistened with pre-warmed aerosolised saline solution, and an 
additional heating blanket was placed over the mouse prior to recording.  
 
 
98  |  A  N O V E L  A P P R O A C H  T O  M E A S U R I N G  M U R I N E  
M E S E N T E R I C  B L O O D  F L O W  I N  S I T U  
 Theory of laser speckle contrast imaging 3.2.3.2
Laser speckle contrast imaging (LSCI) is based on the random speckle patterns produced when 
tissue is illuminated by laser light. In regions of high blood flow, the speckle pattern generated 
by moving red blood cells becomes blurred, reducing contrast in that region. Correspondingly, 
high contrast speckle patterns are associated with low flow (Fig. 11).  Automated processing of 
the contrast images generates real-time, high-resolution, colour-coded flux images, as well as 
absolute flux values, which correlate with blood flow in each region of interest (Briers, 2001).  
The excitation wavelength of incident light corresponds to the isobestic point of the absorption 
spectra of oxy- and deoxy-haemoglobin, such that emission is independent of the oxidative 
state of haemoglobin. This method confers several advantages over other methods of 
measuring microcirculatory perfusion: 
1. Images are captured in real-time, allowing observation of very acute changes in blood 
flow. Traditional laser Doppler flowmetry techniques, by contrast, are associated with 
much slow processing speeds.  
2. Images may be captured over a relatively large area, whereas laser Doppler and SDF 
probes are restricted to limited fields of view (often a single vessel), and are 
particularly sensitive to ‘drift’, which disrupts continuity of recording.  
3. LSCI, using a full-field laser perfusion imager (moorFPLI), is not subject to user bias. 
The device is not hand-held, there is no contact between the probe and the vessel 
(eliminating the pressure artefact associated with SDF probes), and quantification is 
automated.  
4. The technique does not require the fluorescent dyes necessary for intravital 
microscopy, nor does it require a high level of microdissection, eliminating numerous 
confounding factors.  
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Figure 11. Laser speckle contrast imaging for quantification of blood flow. Left hand panel: illumination 
of slow-moving red blood cells generates a high-contrast speckle pattern, which is processed as a ‘low 
blood flow’ area (colder colours) on a colour-coded image. Right hand panel: illumination of fast-moving 
red blood cells generates a blurred speckle pattern, which is processed as ‘high blood flow’ (warmer 
colours). Quantification of absolute flux values is automated.  Figure adapted from ‘Medical Animation 
of Red Blood Cells’, Tom Guthery; Medical Animations. Flix Productions (Guthery, 2007).  
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 Blood flow analysis 3.2.3.3
3.2.3.3.1 Mesenteric blood flow 
Flux over time was analysed offline by moorFLPI Review software (V3; Moor Instruments, 
Devon, UK) and vessels were designated as 1st, 2nd or 3rd order branches of the mesenteric 
vascular tree (Fig. 12). Regions of interest in which flux over time was measured were defined 
in each visible vessel, and a mean value was obtained for each level of mesenteric branching in 
each vascular bed. Results were analysed in moorFLPI Review software (V4.0), Microsoft Excel 
and GraphPad Prism. Results are expressed as mean area under the curve (AUC; flux 
units.time) ± SEM. 
3.2.3.3.2 Ear blood flow 
A polygon tool was used to select the precise outline of both ears as regions of interest (Fig. 
13) in moorFLPI Review software (V3). Mean flux across both ears was calculated for each 
mouse at each time point over a 3-min baseline recording using Microsoft Excel and GraphPad 
Prism. Results are expressed as mean area under the curve (AUC; flux units.time) ± SEM. 
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 (2), or 3
rd
 (3) order branches of the mesenteric vascular tree. Regions of interest were placed as 
indicated by white boxes over each visible vessel, and a mean value of flux over time was calculated for 
each level of mesenteric branching. 
 
 
Figure 13. Regions of interest for assessment of subcutaneous ear blood flow. A polygon tool was used 
to draw the precise outline of each ear, in which flux over time was recorded. A mean flux values across 
both ears was calculated for each mouse. 
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 Fluid resuscitation of septic animals 3.2.4
Aggressive fluid resuscitation is one of the only clinical interventions known to improve 
survival in septic patients (Rivers et al., 2001). In order to determine the clinical relevance of 
using mesenteric blood flow as an endpoint measure, a resuscitation protocol was employed in 
the more clinically relevant CLP model. Following CLP surgery, mice were randomised to 
receive either no intervention, or Hartmann’s solution containing 5% dextrose (40 ml/kg, s.c.) 
at 0 h, 3 h, 6 h and 18 h post-sepsis (under brief isoflurane anaesthesia), based on a regimen 
known to attenuate mortality in septic mice (Zanotti-Cavazzoni et al., 2009). Control sham and 
non-resuscitated mice were briefly anaesthetised at identical time points, and a sham injection 
was administered. Mesenteric blood flow and blood biochemistry were assessed at 24 h post-
CLP, as described in sections 3.2.1 and 3.2.6, respectively. Subcutaneous blood flow in the ear 
was also measured over a 3-min baseline with mice in the prone position, and settings 
identical to those described in section 3.2.1, with the exception of the flux palette, which was 
set at 0–1000.  
  Systemic administration of vasoactive agents 3.2.5
Further mechanistic studies were undertaken using the LPS model. In order to validate the use 
of the mesenteric blood flow model for assessment of acute vasoactive responses to 
systemically administered drugs, an intravenous catheter was introduced into the left jugular 
vein of LPS-treated mice under isoflurane anesthesia (2% by air pump), immediately prior to 
blood flow measurement at 24 h post-LPS. After a 5-min baseline recording, a bolus dose of 
saline (100 µl over 10 s) was administered intravenously, followed 5 min later by a bolus dose 
of noradrenaline bitartrate (30 µg/kg in saline; 100 µl over 10 s; Sigma-Aldrich). Responses to 
noradrenaline were recorded over a further 5 min. 
 Topical administration of vasoactive agents 3.2.6
The impact of a topical vasodilator was also assessed in LPS-treated mice, in order to 
determine reversibility of mesenteric flow perturbations. After 5 min baseline, recording was 
paused and sodium nitroprusside (SNP; 10 µM in saline, pre-warmed to 37°C) was 
administered to the mesentery as an aerosolised spray (2 pump compressions, approx. 200 µl, 
from a distance of 10 cm). Recording was immediately resumed for a further 5 min.  
An aerosolised delivery method was chosen to prevent interference with laser reflection by 
large droplets of liquid, and to ensure even coverage of the exposed vascular bed.  
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 Systemic anticoagulant administration  3.2.7
Given that microcirculatory flow impairment is likely to reflect a combination of disseminated 
intravascular coagulation and arterio-venous shunting, we aimed to elucidate the relative 
contributions of both factors by pre-treating septic mice with systemic anticoagulant therapy. 
Heparin (100 U/kg in 100 µl saline, i.p.; Sigma) was administered 5 min prior to the induction 
of sepsis by LPS or CLP, as described in section 2.3.  
 Termination and analysis of blood biochemistry 3.2.8
Following mesenteric blood flow recording, a venous blood sample was drawn from the 
inferior vena cava, and animals were terminated by cervical dislocation. Blood biochemistry 
was assessed immediately from 100 µl venous blood using a hand-held iSTAT® point-of-care 
analyser (Abbott Laboratories, IL, USA), with CG8+ cartridges (Abbott Laboratories). In a small 
sub-set of experiments, an arterial blood sample was drawn from the left ventricle of the 
heart, in addition to a venous sample, for comparison of arterial and venous blood 
composition. For fluid resuscitation experiments additional CG4+ cartridges (Abbott 
Laboratories) were used for quantification of blood lactate levels.  
 Acute thrombosis modelling 3.2.9
In order to assess other potential applications of the mesenteric blood flow model, changes in 
blood flow were measured in response to an acute thrombotic stimulus. Mice were set-up as 
described in section 3.2.2.1. After a 3-min baseline, recording was paused and a 1-mm2 square 
of filter paper soaked either in FeCl3 (20% in saline) or saline was applied to a chosen vessel for 
10 s. The filter paper was then removed, and recording was resumed for a further 30 min. This 
model is thought to induce a ‘mixed thrombus’, composed of fibrin, activated platelets and 
erythrocytes (Lockyer and Kambayashi, 1999). On a microscopic level, FeCl3-induced 
thrombosis is associated with separation of endothelial cell junctions and endothelial 
denudation, which in turn leads to platelet adherence and activation, thrombin generation and 
activation of the coagulation cascade  (Kurz et al., 1990).  
 Multi-parameter monitoring in murine sepsis models 3.2.10
Mice were implanted with telemetry probes, and cardiac function was assessed via 
echocardiography by Dr Anna Starr, as described in sections 2.4 and 2.5. A multi-parameter 
monitoring system encompassing haemodynamic, microcirculatory and haematological 
assessment (shown schematically in Figure 14) was developed to allow comprehensive 
cardiovascular assessment in a single mouse, facilitating paired comparison.













Figure 14. Schematic representation of multi-parameter monitoring of sepsis progression in a single mouse. Following implantation of a telemetry catheter (a), 
baseline haemodynamics are recorded remotely in unrestrained ambulatory mice (b). Basal cardiac function is measured under isoflurane anaesthesia by 
echocardiography (c). Sepsis is then induced either by LPS or CLP (d), and haemodynamics (e) and cardiac function (f) are re-recorded in the same mice under 
pathological conditions. Mice are then terminally anaesthetised at a time point of interest, and mesenteric blood flow is measured by laser speckle contrast imaging 
(g). Intravenous or topical drug administration may be used to determine vasoactivity. Mice are then terminated by venupuncture, and blood samples obtained from 
the inferior vena cava are analysed by iSTAT point-of-care analyser (h). Further biochemical and histological investigation may then be carried out.  
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 Results 3.3
 Mice anaesthetised for mesenteric blood flow assessment are 3.3.1
homeothermically and haemodynamically stable.  
Core temperature (Fig. 15) and mesenteric blood flow (Fig. 16) were found to remain stable 
over the recording period (and for up to 60 min) in control and septic mice, validating the use 
of this model for investigating acute responses to vasoactive stimuli, independent of 
fluctuations in temperature or haemodynamic status. LPS-treated mice exhibited a 
hypothermic phenotype at 6 h that was further exaggerated by 24 h. CLP-treated mice became 
gradually, but less severely, hypothermic over 24 h. These observations are consistent with 








Figure 15. Core temperature, monitored by rectal probe, remained stable throughout the recording 
period. CLP-treated mice (a) were slightly more hypothermic than sham-operated mice, though 
hypothermia was more marked in LPS-treated mice (b), where core temperature dropped in a time-
































































Figure 16. Absolute flux values recorded over 5-min baseline in healthy and septic mice. Top panel: flux values in sham- or CLP-operated mice (6 h or 24 h post-
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 order mesenteric vessels. Absolute flux values were found to be stable over recording period in both models of sepsis and in all vessel types. Data are 
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 Mesenteric blood flow declines in a time-dependent manner in both 3.3.2
models of sepsis 
Blood flow was significantly reduced in a time-dependent manner in both models of sepsis 
(Fig. 17). In the CLP model, blood flow was reduced by a 20–30% range at 6 h, and by a 65–70% 
range at 24 h post-sepsis; in LPS-treated mice, it was reduced by 25–35% at 6 h, and by 40–
55% at 24 h.   
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Figure 17. Mesenteric blood flow in healthy and septic mice. (a) Representative flux images taken 
during baseline recording. Cold colours indicate low flow, warmer colours higher flow. (b–d) Mesenteric 
blood flow in CLP model expressed as total area under the curve (AUC; x10
3
 flux units.time) over 5 min 






 order vessels, respectively. (e–g) Mesenteric blood flow in LPS 
model expressed as total area under the curve (AUC; x10
3







 order vessels, respectively. AUC for each animal is represented as an individual symbol, 
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 Comparison of mesenteric perfusion with indices of global haemodynamics  3.3.2.1
Mesenteric blood flow data was analysed in parallel with haemodynamic data. As shown in Fig. 
18, mean arterial pressure (MAP), heart rate (HR) and locomotor activity, recorded by 
radiotelemetry, as described in section 2.4, followed normal diurnal variation prior to the 
induction to sepsis (Fig. 18; left hand panel). Following induction of sepsis, LPS-treated mice 
became steadily more hypotensive, while mice subjected to CLP showed a more gradual 
decrease in MAP that was less marked than in the LPS model (Fig. 18; right hand panel). This 
likely reflects the accelerated nature of the LPS model, which bypasses bacterial processing 
and opsonisation steps, and is consistent with previous haemodynamic assessments in murine 
endotoxaemia (Rees et al., 1998). In both models, however, MAP was found to stabilise after 9 
h, with equivalent values at 6 h and 24 h post-sepsis (CLP mean ± SEM: 91.8 ± 2.6 mmHg vs 
86.4 ± 5.3 mmHg at 6 h and 24 h, respectively, n = 11, ns; LPS mean ± SEM: 76.4 ± 8.3 mmHg vs 
77.0 ± 6.5 mmHg at 6 h and 24 h, respectively, n = 11, ns). Cardiac output, measured by 
echocardiography, was similarly decreased at 6 h post-sepsis in both models, but did not 
decline significantly thereafter (CLP mean ± SEM: 19.7 ± 1.5 ml/min vs 18.3 ± 1.6 ml/min at 6 h 
and 24 h, respectively, n = 8, ns; LPS mean ± SEM: 22.0 ± 1.9 ml/min vs 22.0 ± 1.1 ml/min at 6 h 
and 24 h, respectively, n = 8, ns).  Conversely, mesenteric blood flow was found to decline 
continuously in both models of sepsis, and was significantly diminished at 24 h post-sepsis 
compared with the 6 h time point (Fig. 17b–g). 
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Figure 18. Assessment of systemic haemodynamics and locomotor activity in the same mice under 
naïve and septic conditions. (a) Mean arterial pressure, (b) heart rate and (c) locomotor activity, before 
and after induction of sepsis (at time 0: LPS, 12.5mg/kg or cecal ligation and puncture, CLP) or sham 
procedures. Boxed regions denote periods of darkness. Data were acquired by radiotelemetry in 
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 Markers of organ dysfunction and metabolic acidosis increase in line with 3.3.3
reduced mesenteric perfusion 
Consistent with impaired microcirculatory perfusion, blood urea was found to be markedly 
elevated at 24 h post-LPS and –CLP, compared with the 6-h time point (Table 6). A waste 
product of protein and amino acid metabolism, urea production can be variable and is largely 
dependent on protein intake. Since food intake was largely abolished following the induction 
of sepsis (as described more extensively in Chapter 6), this is unlikely to account for the 
changes in urea observed here. Reabsorption of urea from the proximal and distal nephron is 
known to be substantial in conditions of reduced renal perfusion (Rosner and Bolton, 2006), 
which likely explains the elevated blood levels measured here.  
Blood pH was also significantly reduced in a time-dependent manner in both models of sepsis 
(Table 6). Both partial pressure of CO2 (PCO2) and bicarbonate levels were decreased by 6 h 
post-LPS and -CLP, indicative of metabolic acidosis. By 24 h, however, PCO2 in CLP-treated mice 
became elevated (albeit non-significantly), consistent with respiratory acidosis. Venous oxygen 
saturation (SO2) did not change significantly over the course of sepsis in either model, 
however. Mice also became severely hypoglycemic over the 24-h time period, indicative of 
metabolic disturbance similar to that observed in humans subjected to experimental 
endotoxemia (van der Crabben et al., 2009), and haematocrit and haemoglobin levels were 
also reduced following the induction of sepsis. These data and all other blood biochemistry are 
summarised in Table 6. 
Consistent with metabolic acidosis the arterio-venous PCO2 gradient had increased at 24 h 
post-CLP relative to sham-operated animals (mean ∆PCO2 ± SEM: 14.23 ± 4.13 mmHg vs 1.90 ± 
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Sham 6 h CLP 24 h CLP Naïve 6 h LPS 24 h LPS 
Urea (mmol/L) 4.79 ± 0.29 6.08 ± 0.67 17.03 ± 4.26* 4.57 ± 0.37 8.10 ± 1.45 36.47 ± 2.89***
,###
 
pH 7.292 ± 0.01 7.225 ± 0.02 7.149 ± 0.03** 7.286 ± 0.03 7.245 ± 0.02 7.125 ± 0.03** 
Base excess (mmol/L) -11.87 ± 0.80 -17.00 ± 0.97 -15.21 ± 1.19 -11.0 ± 0.78 -12.60 ± 1.72 -17.19 ± 1.22*** 
HCO3
-
 (mmol/L) 15.06 ± 0.68 10.67 ± 0.90 13.59 ± 0.84 16.89 ± 0.58 14.62 ± 1.80 12.53 ± 0.98 
PCO2 (mmHg) 30.91 ± 1.32 25.80 ± 2.12* 40.96 ± 4.73 39.94 ± 2.60 33.24 ± 3.93** 41.49 ± 3.72 
TCO2 (mmol/L) 15.93 ± 0.75 11.67 ± 1.02 15.50 ± 0.68 18.44 ± 0.93 15.80 ± 1.93 13.71 ± 1.06** 
SO2 (%) 84.43 ± 2.80 83.67 ± 3.84 84.11 ± 3.36 84.00 ± 3.67 88.00 ± 5.29 78.50 ± 3.43 
Glucose (mmol/L) 13.24 ± 0.87 4.17 ± 0.62*** 2.68 ± 0.40*** 9.45 ± 1.65 2.27 ± 0.66*** 2.20 ± 0.34*** 
Na
+
 (mmol/L) 147.3 ± 0.83 150.3 ± 0.88 151.9 ± 0.01** 152.6 ± 1.15 155.7 ± 0.88 152.8 ± 0.89 
K
+
 (mmol/L) 4.122 ± 0.21 3.067 ± 0.15 4.167 ± 0.40 3.425 ± 0.43 3.233 ± 0.43 3.608 ± 0.36 
Cl
-
 (mmol/L) 121.7 ± 1.07 127.3 ± 0.88 126.3 ± 1.46 109.0 ± 2.08 130.0 ± 1.53 124.7 ± 3.68 
Anion gap (mmol/L) 15.67 ± 0.47 16.67 ± 0.67 16.78 ± 1.88 16.67 ± 0.69 17.00 ± 00 24.00 ± 3.08** 
Haemoglobin (g/dl) 11.71 ± 0.51 10.47 ± 0.99 9.84 ± 0.60  12.39 ± 0.75 13.25 ± 1.92 10.33 ± 0.61 
Haematocrit  (%PCV) 33.11 ± 1.12 25.33 ± 2.96 29.67 ± 0.88 35.50 ± 2.18 27.00 ± 2.52 28.78 ± 1.85 
 
Table 6. Blood biochemistry in healthy and septic mice. Blood gas and biochemistry were measured from venous blood samples by iSTAT point-of-care analyser in naïve and 
sham-operated animals, and at 6 h and 24 h post-LPS and -CLP. Data are presented as mean ± SEM. *p<0.05, **p<0.01 and ***p<0.001 relative to sham/naïve; 
###
p<0.001 relative 
to 6-h time point, 1-way ANOVA and Bonferroni post-hoc test, n = 3–16.  
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; SO2, venous oxygen saturation; PCV, packed cell volume. 
113  |  A  N O V E L  A P P R O A C H  T O  M E A S U R I N G  M U R I N E  
M E S E N T E R I C  B L O O D  F L O W  I N  S I T U  
 Assessment of mesenteric perfusion can be conducted in concert with 3.3.4
haemodynamic analysis 
The presence of a telemetry probe in the flank of a mouse had no bearing on the absolute flux 
values recorded. This allows measurement of both mesenteric blood flow and haemodynamic 
performance in the same mouse, facilitating direct comparison between the two parameters. 
The non-parallel relationship between microcirculatory perfusion and global haemodynamics 
is demonstrated clearly in Figure 19, which suggests that normalization of arterial pressure 
may be achieved at the expense of the microcirculation. 































Figure 19. Representative blood pressure traces and corresponding mesenteric blood flow images from two LPS-treated mice. Blood pressure traces were collected immediately 
prior to blood flow recording at 24 h post-LPS. Whereas Mouse 1 exhibited compromised mean arterial pressure (MAP) and pulse pressure, mesenteric perfusion was less severely 
disrupted relative to Mouse 2, which exhibited a profound decrease in mesenteric perfusion, despite normal pressure. This demonstrates that MAP alone is insufficiently 
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 Fluid resuscitation attenuates CLP-induced microvascular disturbance 3.3.5
Given the continued deterioration of mesenteric blood flow over the 24-h period, 
compared with the apparent preservation of macrocirculatory haemodynamics (Fig. 18) 
and global oxygen saturation (Table 7), we aimed to ascertain whether sepsis-induced 
impairment of microcirculatory blood flow was sensitive to fluid resuscitation – a mainstay 
clinical intervention known to improve microcirculatory perfusion, organ function and 
survival in patients (Rivers et al., 2001) and septic mice (Hollenberg et al., 2001). 
This intervention modestly, but significantly, improved perfusion in 1st order mesenteric 
vessels (Fig. 20a), and a similar pattern of improvement was observed in 2nd and 3rd order 
vessels [mean area under the curve (AUC; x103 flux units.time): 220.9 ± 52.3 vs 406.7 ± 78.0 
in 2nd order vessels, ns; 140.8 ± 33.5 vs 342.9 ± 44.1 in 3rd order vessels, p<0.05]. Volume-
resuscitated mice also exhibited modest improvements in hypothermia (Fig. 20d), arbitrary 
severity score (based on posture, mobility, aversion to touch and piloerection, assigned in a 
blinded fashion; Fig. 20c), metabolic acidosis, and urea and lactate production (Table 7). 
Interestingly, measurement of perfusion by the same method in a different microvascular 
bed – the ear – revealed a significant decrease in blood flow in CLP-treated mice that was 
also reversed by fluid resuscitation (Fig. 20b&e). However, sepsis-associated 
hypernatraemia, evident in CLP-treated mice, was found to be exaggerated by fluid 
resuscitation (probably due to the crystalline nature of the fluid). The small decrease in 
haematocrit observed in unresuscitated CLP-treated mice was exaggerated in resuscitated 
mice, likely as a consequence of fluid loading and intravascular volume expansion.  
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Figure 20. Impact of Hartmann’s fluid resuscitation on sepsis parameters. Hartmann’s resuscitation 
(40 mg/kg, s.c.; Resus) was administered immediately after CLP and at 3 h, 6 h and 18 h thereafter. 
Control sham- and CLP-treated animals were given a bolus injection immediately post-surgery but 
received sham injections at later corresponding time points. (a) Blood flow in 1
st
 order mesenteric 
vessels expressed as area under the curve (AUC) over 5-min baseline recording. (b) Subcutaneous 
ear blood flow expressed as AUC over 3-min baseline recording. Data for individual animals are 
represented as individual symbols (n = 5–9), with group mean denoted by horizontal line. *p<0.05, 
**p<0.01,***p<0.001, relative to sham, #P<0.05, relative to CLP, 1-way ANOVA + Bonferroni post-
hoc test. (c) Severity score (scale 0–5, arbitrary units) assigned in a blinded fashion based on 
voluntary mobility, gait, aversion to touch, facial expression and piloerection. (d) Core temperature 
measured by rectal probe during blood flow recording period. Data are presented as mean ± SEM (n 
= 5–9). (e) Representative flux images of subcutaneous ear blood flow. Cold colors represent areas of 
low blood flow; warmer colors, areas of high blood flow.  
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Sham CLP CLP Resus 
Urea (mmol/L) 4.40 ± 0.33 15.82 ± 6.42 6.55 ± 0.99 
pH 7.309 ± 0.02 7.126 ± 0.05** 7.220 ± 0.02 
Base excess (mmol/L) -10.80 ± 0.97 -15.17 ± 1.58 -13.25 ± 1.10 
HCO3
-
 (mmol/L) 15.52 ± 0.79 13.97 ± 1.04 14.36 ± 1.10 
PCO2 (mmHg) 30.94 ± 1.85 43.42 ± 5.99 35.56 ± 3.37 
TCO2 (mmol/L) 16.4 ± 0.81 15.17 ± 1.17 15.63 ± 1.24 
SO2 (%) 88.00 ± 2.61 88.20 ± 2.18 89.50 ± 1.23 
Glucose (mmol/L) 13.50 ± 0.95 3.07 ± 0.57*** 3.40 ± 0.35*** 
Na
+








 (mmol/L) 120.0 ± 1.03 124.5 ± 1.77 128.1 ± 1.19** 
Anion gap (mmol/L) 15.20 ± 0.73 17.67 ± 2.84 15.88 ± 0.88 
Haemoglobin (g/dl) 11.70 ± 0.56 9.82 ± 1.34 9.49 ± 0.56 
Haematocrit  (%PCV) 34.14 ± 1.16 31.27 ± 1.48 27.88 ± 1.65* 
Lactate (mmol/L) 3.92 ± 0.25 4.94 ± 0.51 3.61 ± 0.28
# 
 
Table 7. Impact of fluid resuscitation on blood biochemistry in CLP model of sepsis. Blood gas and 
biochemistry measured from venous blood samples by iSTAT point-of-care analyser in sham-
operated animals, and at 24 h post-CLP either with (Resus) or without repeated fluid resuscitation 
with Hartmann’s solution. Data are presented as mean ± SEM. **p<0.01 and ***p<0.001 relative to 
sham; 
#
p<0.05 relative to CLP, 1-way ANOVA and Bonferroni post-hoc test, n = 5–9.  
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; SO2, venous oxygen 
saturation; PCV, packed cell volume.  
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 Intravenous administration of noradrenaline does not increase 3.3.6
mesenteric perfusion in endotoxaemic mice 
Intravenous bolus administration of noradrenaline, known to raise mean arterial pressure 
in endotoxaemic mice (Rees et al., 1998) and humans (Jhanji et al., 2009), did not increase 
mesenteric perfusion in either naïve or LPS-treated mice. On the contrary, it caused a 
marked decrease in blood flow (Fig. 21) that was comparatively sustained in LPS-treated 
mice. These data support the notion that improvement in global haemodynamic 
parameters does not necessarily result in improved regional perfusion, and that the 
pharmacological activity of vasopressors such as noradrenaline (α1 adrenoceptor-mediated 
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Figure 21. Effect of systemic administration of noradrenaline on blood flow in naïve and septic 
mice. (a) Representative flux images at baseline and following intravenous administration of saline 
(100 µl) and noradrenaline (NA; 30 µg/kg in 100 µl saline) Cold colours indicate low flow; warmer 
colours, high flow. Blood flow over time in (b) 1
st
 order, (c) 2
nd
 order, and (d) 3
rd
 order branches of 
the mesenteric vascular tree. Following a 5-min baseline recording, saline was administered 
systemically, via an intravenous catheter in the left jugular vein, followed by a bolus injection of NA 5 
min later. Black circles represent naïve mice; red squares, septic mice (12.5 mg/kg LPS, i.v., 24 h). 
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 Topical administration of a vasodilatory agent reverses the decrease in 3.3.7
mesenteric blood flow induced by LPS 
In order to test our hypothesis that the mesenteric bed is actively shut down in order to 
preserve global circulation, we applied sodium nitroprusside (SNP), a nitric oxide donor, 
directly to the exposed mesenteric vasculature by aerosolised spray. 10 µM SNP was found to 
reverse LPS-induced microvascular impairment in all order branches of the mesenteric vascular 
tree (Fig. 22). These data suggest that active vasoconstriction accounts, at least in part, for the 
reduced mesenteric perfusion observed in sepsis, and are consistent with the effects of topical 
vasodilators applied to the sublingual microvasculature in septic patients (De Backer et al., 
2002). 
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Figure 22. Effect of topical administration of vasodilator SNP on mesenteric blood flow in 
endotoxaemic mice (12.5 mg/kg LPS, i.v., 24 h). Representative flux images taken at baseline (a) and 
following topical administration of 10 µM SNP (2 pumps of aerosolised spray; approx. 200 µl; b) in 
endotoxaemic mice 24 h post-LPS. (c) Flux recorded over 5-min baseline and following topical 
administration of SNP, indicated by dotted line. Data are presented as mean ± SEM (n = 12). (d) Area 
under the curve (AUC; x10
3
 flux units.time) for each mouse over 5-min baseline recording and 5-min 
response to SNP. Measurements for each animal are denoted by individual symbols connected by a 
solid line (n = 12), and comparisons of baseline AUC with AUC post-SNP were assessed by Student’s 
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 Bolus systemic administration of heparin does not improve mesenteric 3.3.8
perfusion in sepsis 
In order to elucidate the role of coagulation in sepsis-associated microvascular perturbations, a 
systemic bolus of heparin was administered at the time of sepsis induction. Mesenteric blood 
flow was assessed 24 h after the induction of sepsis or sham surgery. Heparin had no effect on 
mesenteric blood flow in LPS-treated mice (Fig. 23a). In CLP-treated mice, however, it 
appeared to exaggerate the decline in blood flow (Fig. 23b). Heparin was not observed to have 







Figure 23. Impact of heparin on mesenteric blood flow in septic mice. Mesenteric blood flow expressed 
as total area under the curve (AUC; x10
3







order mesenteric vessels in 24 h after the induction of sepsis by CLP (a) or LPS (b) either in the presence 
or absence of 100 U/kg heparin (Hep). Data for each animal are denoted by individual symbols, with 
horizontal bars denoting group mean (n = 5–12). Comparisons of control mice (black) and mice treated 
with heparin (grey) were performed in each vessel type. *p<0.05, 1-way ANOVA + Bonferroni post-hoc 
test. 
 
 Wider applications of the model 3.3.9
In order to assess other potential applications of the model, we used the ferric chloride model 
of acute thrombosis. Topical application of FeCl3 (but not saline) induced a steady decline in 
blood flow over 30 min, resulting eventually in almost complete occlusion of the vessel. 
Representative images are shown in Figure 24; FeCl3 reproducibly stimulated thrombus 




















































































Figure 24. Ferric chloride model of acute thrombosis. Representative images of mesenteric blood flow following topical administration of a 1-mm
2
 square of filter 
paper soaked in 20% FeCl3 (indicated by white arrow head). Cold colours indicate low flow, warmer colours higher flow. Almost complete occlusion of the affected 
vessel was achieved within 30 min.  
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 Summary 3.4
The key findings from this study are: 
1. Laser speckle contrast imaging can be used in concert with other standard 
haemodynamic techniques to robustly assess microcirculatory perfusion in septic 
mice. 
2. Microcirculatory flow, as quantified in the mesenteric and ear vascular beds, 
diminishes in a time-dependent manner in both models of sepsis. 
3. Microcirculatory flow more closely correlates with end organ perfusion and 
metabolic disturbances than global haemodynamics. 
4. Stabilisation of macrocirculatory haemodynamic parameters is likely to occur at 
the expense of microcirculatory perfusion, and is therefore insufficiently predictive 
of outcome. By extension, strategies aimed at elevating MAP pharmacologically 
may adversely affect microcirculatory perfusion. 
5. Aggressive fluid resuscitation measurably improves microcirculatory perfusion and 
end organ function, consistent with clinical observations. 
6. Topical administration of a vasodilatory agent can reverse sepsis-induced 
microcirculatory impairment, supporting the theory that compliant vascular beds 
are actively shut down in sepsis.  
7. Systemic administration of the anticoagulant heparin had no effect on mesenteric 
perfusion in the LPS model, but exacerbates microcirculatory disturbances in the 
CLP model of sepsis. 
8. The model described represents a novel approach to microcirculatory monitoring 
that can be used in concert with haemodynamic and haematological assessment. 
It is robust, reproducible and clinically relevant; moreover its use is not restricted 
to sepsis research: while we anticipate that its incorporation into pre-clinical sepsis 
models will facilitate more sophisticated and clinically relevant proof-of-concept 
studies, it may also be applied in in situ studies of vasoactivity or thrombosis.   
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 Discussion 3.5
 Refinement of pre-clinical sepsis models 3.5.1
A strong research drive and extensive media coverage have served to bring sepsis into public 
prominence in recent years. The failure of the PROWESS-SHOCK trial (Ranieri et al., 2012) and 
the withdrawal of activated Drotrecogin alfa – the only approved anti-sepsis drug – in 2011, 
have prompted much ‘soul-searching’ amongst critical care specialists and pre-clinical research 
scientists (Dolgin, 2012). A significant factor in the lack of effective treatments for septic shock, 
in addition to the limitations of related clinical trials (Khamsi, 2012), is the problem of research 
translatability; numerous interventions that have proved beneficial in animal models have 
failed to translate into improved outcome in humans (Raven, 2012). Patient and pathogen 
heterogeneity, and the confounding effects of clinical intervention complicate the process of 
developing a relevant model in which to investigate disease mechanisms. Pre-clinical focus on 
endpoints with low prognostic value, however, may also have contributed significantly to this 
issue. While research has tended to centre on global haemodynamics and crude mortality 
endpoints, models which focus on the mechanism of death, specifically perfusion failure, may 
be more clinically relevant. The aim of this study, therefore, was to investigate changes in 
microcirculatory blood flow in sepsis and its relation to haemodynamic and haematological 
indices, with a view to characterising the prognostic sensitivity of this parameter. 
Because murine models facilitate gene modification, they currently represent the only viable 
option for conducting mechanistic pre-clinical proof-of-concept research. Therefore, it is of 
paramount importance to optimise the systems available to us by limiting confounding 
influences, and to employ animal models to their full capacity, extracting as much information 
as possible from a single individual. With this in mind, we aimed to establish a robust model 
for assessing microcirculatory perfusion in a septic mouse, and to incorporate this model into a 
multi-parameter monitoring systemic for direct comparison (in the same animal) of 
microvascular and global haemodynamic parameters, as presented schematically in Figure 14. 
The method described represents a novel application of laser speckle contrast imaging 
technology, allowing simultaneous and real-time visualisation of blood flow across entire 
sections of the mesenteric bed in situ, with no dissection of perivascular tissue, and minimal 
mechanical disruption to the vessels. This represents a significant advantage over traditional 
laser Doppler techniques that are limited to measurements in single vessels, often requiring 
extensive microdissection and probe-tissue contact, as well as conferring significantly lower 
processing speeds. Additionally, this technique does not require the use of fluorescent dyes, 
necessary for intravital microscopy, and furthermore, allows automated quantification of flow 
within specified regions of interest, both at baseline and following topical or intravenous 
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administration of a pharmacological agent. As such, this model represents a practical 
substitute to the sidestream dark field imaging technique that is used clinically, as it does not 
require high-level operating expertise, and is not subject to inter-operator variability or probe-
tissue contact artefacts.  
Both core temperature and mesenteric blood flow remained stable throughout the recording 
period, and for up to 60 min, validating the use of the model for assessing acute changes in 
vasoactivity in response to interventions, independent of changes in temperature or 
haemodynamic status. The presence of a telemetry probe in the flank of the mouse had no 
bearing on the flow values recorded.  
We have demonstrated that this model is stable and reproducible, validating its use for 
assessment of acute vasoactive responses to intervention; it is also compatible with gold-
standard techniques for cardiovascular evaluation, including radiotelemetry and 
echocardiography. Importantly, we have demonstrated that mesenteric blood flow diminishes 
in line with the development of metabolic acidosis and organ failure in sepsis, and that this is 
attenuated by an established clinical intervention, suggesting that our model represents a 
more clinically relevant and prognostic endpoint for pre-clinical sepsis research. 
 Mesenteric blood flow declines in a time-dependent manner in sepsis, 3.5.2
and may be actively shut down to preserve global haemodynamics 
Mesenteric blood flow declined in a time-dependent manner in both models of sepsis. LPS-
treated mice exhibited a hypothermic phenotype at 6 h that was further exaggerated by 24 h; 
CLP-treated mice became gradually, but less severely hypothermic over 24 h, consistent with 
previous reports (Clark et al., 2007, Coldewey et al., 2013, Saito et al., 2003). Interestingly, 
whereas CLP induced less severe hypothermia than LPS, mesenteric blood flow was actually 
compromised to a greater extent in the former model, suggesting that microvascular 
impairment is the result of cardiovascular pathology, rather than an incidental effect of 
decreased core temperature.  
While disseminated intravascular coagulation, vessel remodelling and hypovolaemia may all be 
expected to contribute to the observed changes in microvascular blood flow, our data suggest 
an important role for active vasoconstriction and shunting of blood away from the mesenteric 
bed during sepsis.  It is especially noteworthy that in both models, sepsis-induced hypotension, 
and LPS-induced bradycardia stabilised after 9 h, with MAP values at 24 h equivalent to those 
at 6 h post-sepsis, despite a continued decline in mesenteric perfusion. Similarly, the decrease 
in cardiac output observed in both models by 6 h post-sepsis did not decline significantly 
thereafter. This suggests that systemic stabilisation may be achieved at the expense of the 
127  |  A  N O V E L  A P P R O A C H  T O  M E A S U R I N G  M U R I N E  
M E S E N T E R I C  B L O O D  F L O W  I N  S I T U  
microcirculation, as proposed previously (Spronk et al., 2004). Correspondingly, whilst CLP-
treated mice appear to have less severe haemodynamic dysfunction than LPS-treated mice, 
microcirculatory function appeared further diminished in the former. While MAP in CLP-
treated mice was not significantly different from baseline at 6 h post-sepsis, a marked 
decrease in mesenteric perfusion was observed at this time point, as exemplified in Figure 19.  
While acute arterio-venous shunting may be essential to preserve global circulation and 
perfusion of heart and brain tissue in acute hypovolaemia, prolonged microcirculatory shut-
down, most notably in the splanchnic region, inevitably leads to hypoxic tissue injury and the 
development of organ failure (Takala, 1996, Spronk et al., 2004). Clinically described as ‘the 
motor of multiple organ failure’ (Carrico et al., 1986), the gut represents an important 
microcirculatory bed in septic shock, where impaired flow is known to correlate strongly with 
poor outcome both in animal models (Baykal et al., 2000) and septic patients.(Takala, 1997, 
Spronk et al., 2004). This likely reflects the fact that impaired perfusion of the intestine, and 
associated hyperpermeability, facilitates the leakage of microorganisms and endotoxin from 
the gut lumen into the lymphatic and cardiovascular circulation, exacerbating the 
inflammatory state (Sautner et al., 1998). The observation that sepsis-induced microvascular 
impairment can be reversed by the application of a topical vasodilator further supports the 
theory that compliant vascular beds are actively shut down in sepsis in order to preserve global 
circulation. Circulatory bypassing of microvascular beds could also explain why venous oxygen 
saturation (SO2) was did not decrease in either model of sepsis.  
Although beyond the scope of this study, future research in which an arterial catheter is used 
to measure blood pressure in parallel will blood flow measurements could shed further light 
on the clinical benefits of dilating regional vascular beds. If peripheral vasodilatation (in the 
gut, for example) can be achieved without compromising arterial pressure beyond the 
threshold required for global oxygen delivery, this may represent a potential therapeutic 
strategy in the treatment of sepsis.  
Administration of norepinephrine – known to raise arterial pressure – far from increasing 
regional perfusion actually diminished mesenteric blood flow, suggesting firstly that prolonged 
vasopressor use may accelerate organ failure, and secondly that treatment strategies targeted 
at global haemodynamics may not be effective, as demonstrated previously (Gattinoni et al., 
1995). The theory that increasing global oxygen delivery will necessarily increase regional 
delivery seems overly simplistic, and due consideration must be given to the regional 
pharmacological activity of specific vasopressors; noradrenaline-mediated constriction of small 
vessels may exacerbate regional ischaemia, for example. While other vasopressors, such as 
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dobutamine, may have less severe effects on microcirculatory blood flow (Hernandez et al., 
2013), these data highlight the importance of monitoring loco-regional perfusion directly, 
especially when administering vasopressor therapy.  
Our data emphasise that stabilisation of macrocirculatory parameters may not indicate halting 
of syndrome progression, and therefore should not be used as a prognostic marker in isolation. 
This conclusion is supported by clinical evidence: numerous trials of interventions that improve 
hemodynamic performance in animal models (Ullrich et al., 2000, Connelly et al., 2005) and 
humans, have failed to confer a survival benefit in clinical trials (Kirov et al., 2001, Lopez et al., 
2004, Gutierrez et al., 1992). We have demonstrated that direct measurement of mesenteric 
perfusion – known to confer high prognostic value in the clinic (Gutierrez et al., 1992, Ivatury 
et al., 1996, Palizas et al., 2009) – is not only feasible in a murine model, it is also more 
sensitive to syndrome progression.  
 Microcirculatory shut-down may become maladaptive and precipitate 3.5.3
metabolic disturbance and organ failure 
While mesenteric blood flow did not appear to mirror changes in global haemodynamic status, 
it did reflect time-dependent changes in metabolic disturbance and organ dysfunction: blood 
pH decreased and blood urea levels increased in a time-dependent manner in line with 
diminished perfusion.  
Both blood pH and bicarbonate levels were decreased in both models of sepsis, indicative of 
metabolic acidosis. Consistent with compensation for metabolic acidosis, partial pressure of 
CO2 (PCO2) was found to decrease at 6 h in both models, presumably as a result of tachypnea – 
a common feature of sepsis, and a criterion for diagnosis (Bone et al., 1992a) that results in 
early respiratory alkalosis. The increased workload associated with tachypnea can lead to 
fatigue and eventual failure of the respiratory muscles, and diversion of blood flow towards 
the respiratory muscles and away from other vital organs can result in organ injury (Kellum, 
2007). By 24 h, PCO2 levels had increased relative to the 6-h time point in both models, 
suggesting failure of compensatory mechanisms. In the CLP model, PCO2 levels had increased 
above baseline levels (albeit non-significantly), indicative of respiratory acidosis (Kellum, 2004). 
The raised anion gap, particularly in the LPS model, is also indicative of acid accumulation.  
Metabolic acidosis may arise by a number of different mechanisms, including 
hyperchloraemia, lactic acidosis, and renal failure (Kellum, 2004). Hyperchloraemia can occur 
in sepsis if bicarbonate is lost through the GI tract or kidneys, resulting in chloride retention; 
equally, elevated chloride levels may also be the result of saline resuscitation (administered at 
the time of sepsis). Both lactic acidosis and renal failure are consequences of poor organ 
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perfusion and insufficient oxygen delivery. While lactate was only measured in the fluid 
resuscitation experiments, non-resuscitated CLP-treated mice exhibited elevated lactate levels 
relative to sham controls. Furthermore, the time-dependent rise in blood urea levels observed 
in both models of sepsis is indicative of impaired renal perfusion and kidney dysfunction 
(Rosner and Bolton, 2006).  
Surprisingly, given that sepsis is associated with plasma extravasation, which tends to induce 
haemoconcentration, both haematocrit and haemoglobin levels were found to decrease 
following the induction of sepsis. One possible explanation for this phenomenon is breakdown 
of the endothelial glycocalyx, a carbohydrate-rich layer overlying the vascular endothelium, 
previously shown to be degraded in sepsis (Steppan et al., 2011, van den Berg et al., 2003). 
Shedding of this layer, estimated to be 0.2 to 0.5 µm thick (van den Berg et al., 2003), may lead 
to an increase in intravascular space, and consequently to haemodilution. A decrease in 
haemoglobin levels has also been observed in septic patients (Jansma, 2013). These 
observations, and ours, may be linked with reports of hyporesponsiveness to erythropoietin 
(EPO) in sepsis (Nissenson et al., 2006), which would limit the production of erythrocytes by 
bone marrow. Acute kidney injury, frequently encountered in sepsis (Zarjou and Agarwal, 
2011), may also impair EPO production by interstitial kidney fibroblasts. Haemolysis may also 
be a factor in the sepsis-associated haemodilution observed here: fibrin strands generated as a 
result of disseminated intravascular coagulation can destroy erythrocytes (Bull and Kuhn, 
1970); the complement system, which is also activated in sepsis, has also been associated with 
haemolysis (Adamzik et al., 2012), as has LPS itself (Poschl et al., 2003). Sepsis has also been 
associated with eryptosis, or the suicidal death of erythrocytes (Lang et al., 2010). 
Overall, a good agreement between mesenteric perfusion and markers of acid-base 
disturbance and organ dysfunction was observed, suggesting that microcirculatory blood flow 
is a more sensitive marker of syndrome progression than haemodynamic indices.  
 Microcirculatory blood flow is a clinically relevant endpoint in pre-clinical 3.5.4
sepsis models 
In order to determine the clinical relevance of the mesenteric microcirculation model, we 
tested its ability to reflect improved outcome in response to fluid resuscitation – an 
intervention that has been shown definitively to increase survival in patients (Rivers et al., 
2001). In the more clinically relevant CLP model, a resuscitation protocol was employed based 
on one known to attenuate mortality in septic mice (Zanotti-Cavazzoni et al., 2009). This 
intervention modestly, but significantly, improved mesenteric perfusion, as well as a number 
of other clinical parameters: fluid-resuscitated mice also exhibited modest improvements in 
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hypothermia, arbitrary severity score (assigned in a blinded fashion), metabolic acidosis, and 
urea and lactate production. Interestingly, measurement of perfusion by the same method in a 
different microvascular bed – the ear – revealed a significant decrease in blood flow in CLP-
treated mice that was reversed by fluid resuscitation. Measurement of blood flow in the ear 
may represent a less invasive method for repeated-measures testing of microcirculatory 
function over a specific time-course, given that it does not require terminal anaesthesia, 
although further validation of this endpoint is required.  
Whether the observed improvement in microcirculatory perfusion was simply the result of 
improved global haemodynamic performance is uncertain; MAP and cardiac output (although 
not measured in this study) would undoubtedly have increased with fluid loading. Our own 
experiments with noradrenaline, however, as well as numerous other studies (Dubin et al., 
2009, Jhanji et al., 2009), have demonstrated that raising MAP does not increase regional 
perfusion per se. It is likely, therefore, that correction of hypovolaemia played a more 
important role in the microvascular changes observed here. Indeed, although 
macrohaemodynamics and microcirculatory flow are both affected by hypovolaemia, and tend 
to improve in parallel with fluid resuscitation, their relative changes are not well correlated, 
and fluid resuscitation is thought to have direct beneficial effects on the microcirculation in 
patients (Hernandez et al., 2012b). 
Irrespective of the mechanism involved, these data suggest that the mesenteric model is 
clinically relevant and may be adapted to a comparatively hyperdynamic murine model of 
sepsis. The extent to which a mouse can reflect the truly hyperdynamic state that occurs in 
continuously infused patients is undoubtedly severely limited by its size. Murine models may 
be used effectively to understand the pathophysiological changes that occur when sepsis is 
allowed to progress unimpeded, however, and to establish the impact of pharmacological or 
genetic modification in the absence of other interventions. To mimic more closely the 
resuscitated intensive care situation, larger species should be used, where administration of 
large volumes of fluid in addition to pharmacological agents is more feasible.  
 Bolus systemic administration of heparin does not improve mesenteric 3.5.5
blood flow in murine models of sepsis 
Disseminated intravascular coagulation is a common feature of sepsis and septic shock 
(Semeraro et al., 2012), and microvascular thrombus formation is likely to contribute to 
regional ischaemia and organ dysfunction. An anti-coagulant – heparin – was administered at 
the time of sepsis, in order to determine the impact on mesenteric blood flow. Surprisingly, 
heparin had no effect on blood flow in the LPS model. Although heparin acts immediately 
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following intravenous administration, its half-life in plasma is approximately 40–90 minutes 
(Rang et al., 2007); while evidence of coagulopathy is already present at 6 h post-sepsis in mice 
(Corral et al., 2005), it is possible that by 24 h after LPS protective effects had worn off, with 
pro-coagulant systems predominating. In the CLP model, heparin-treated mice exhibited an 
exaggerated impairment in blood flow relative to untreated controls. In this model, initial 
transient coagulation may help to contain bacteria within the septic focus, facilitating 
destruction by immune cells; the early actions of heparin in this case, may have accelerated 
the systemic dissemination of bacteria, exacerbating the inflammatory response.  
Whether the mesenteric flow impairments recorded here are truly independent of coagulation 
(and predominantly the result of active shunting), or whether our experimental design was 
unsuited to the detection of measurable changes following anti-coagulant administration 
remains unclear. Unfortunately, continuous infusion of heparin over a 24-h period, which may 
have prevented coagulopathy in later stages, was not feasible in these models. Furthermore, 
while repeated bolus dosing may have been beneficial, the dissection required for the 
experimental set-up may have induced excessive bleeding and produced artefactual results. It 
is equally possible that later administration of a thrombolytic agent, rather than an anti-
coagulant, could have reversed the impaired mesenteric flow observed in both models. 
Nonetheless, the failure of anti-coagulant therapies to improve survival in clinical trials 
(Freeman et al., 2003), combined with their associated bleeding complications, suggests that 
the coagulation cascade may not represent a fruitful avenue of research for potential sepsis 
treatments.  
 Use of murine models in sepsis research 3.5.6
Recent reports of divergent genomic responses to inflammation between mice and men (Seok 
et al., 2013), compounded by associated media furore, have called into question the validity of 
mouse models of inflammatory conditions, including sepsis. Early diagnosis and intervention 
are certainly key to limiting sepsis-associated mortality (Brown et al., 2013, Bravi et al., 2012), 
and investigation of diagnostic biomarkers must necessarily be conducted in humans, as 
described recently (Ma et al., 2013b). Calls for murine models of inflammation to be 
abandoned entirely, however, are certainly injudicious. As the only species in which genetic 
modification is both feasible and reliable, the mouse retains enormous value in delineating the 
involvement of particular proteins in sepsis pathogenesis, and physiological responses to 
inflammation are largely conserved between species. Furthermore, much of the recent 
criticism of murine studies of inflammation (Seok et al., 2013) has itself been flawed: it is 
doubtful that meaningful conclusions may be drawn from a comparison of the leukocyte gene 
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expression profiles of a heterogeneous, co-morbid population of patients, with a 
homogeneous cohort of age-matched and genetically similar mice, as argued recently 
(Osuchowski et al., 2014).  
Because animal models currently represent the only viable option for conducting pre-clinical 
research, it is critical that we optimise the systems available to us by limiting confounding 
influences, and that we employ animal models to their full capacity, extracting as much 
information as possible from a single individual transitioning from health to disease. 
Importantly, the cardiovascular consequences of sepsis observed in this study – hypotension, 
microcirculatory impairment, metabolic acidosis – are in line with clinical observations, 
validating the mouse model for investigation of physiological processes in sepsis. 
This study has demonstrated a novel comprehensive approach to modelling sepsis 
pathogenesis, which encompasses multi-parameter monitoring in individual animals. We have 
shown that a number of biological measurements can be performed in a single mouse without 
compromising data quality or reproducibility, and without incurring undue suffering. While 
results, in sepsis research in particular, should always be interpreted with caution, and never 
over-extrapolated, proof-of-concept studies in well-designed mouse models with clinically 
relevant endpoints can provide valuable information on the likely impact of a particular 
intervention on a physiological system, and can inform the design of relevant clinical trials. This 
is particularly important in the later stages of sepsis, where mortality rates are unacceptably 
high, and where there is a strong requirement for adjunct therapies. 
 Concluding remarks 3.5.7
To our knowledge, this study represents the first comprehensive multi-parameter assessment 
at all levels of the cardiovascular system in a single mouse. Mice were found to exhibit both 
haemodynamic disruption and microvascular impairment following the induction of sepsis, 
though the latter correlated more closely with markers of organ dysfunction and metabolic 
acidosis.  
The comprehensive multi-parameter model developed in this study and shown schematically 
in Figure 14, confers a number of significant advantages to previous methods employed in pre-
clinical sepsis research. Firstly, all monitoring is undertaken remotely or under anaesthetic, 
eliminating the risk of stress artefacts associated with blood pressure measurements obtained 
through tethering or tail cuff recording. Secondly, it enables in situ monitoring of all levels of 
the cardiovascular system – cardiac, macrohemodynamic, microcirculatory and haematological 
– in a single animal, from the naïve state through disease progression. This study has 
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demonstrated the feasibility of conducting a paired study that mimics perioperative recording 
of the transition from health to disease. This type of analysis provides a much more 
comprehensive assessment of health, and, as demonstrated, can be achieved without mutual 
interference. Furthermore, the mesenteric model is not limited to sepsis research, and can also 
be applied to in situ studies of acute thrombogenesis/thrombolysis or vasoactive responses to 
systemic or topical stimuli, negating the need for dissection and organ bath preparations, 
which can lead to tissue damage artefacts. Finally, use of this model is in keeping with the 
remit of the National Centre for the Replacement, Refinement and Reduction (NC3Rs) of 
Animals in Research: multi-parameter monitoring reduces the number of mice required for a 
study, and use of a more clinically relevant and prognostic endpoint represents a refinement of 
pre-clinical modelling.  
In summary, this study has demonstrated that microcirculatory perfusion is severely 
compromised in sepsis, in a manner which correlates closely with end organ damage (the 
ultimate cause of death in septic patients); results indicate that macrocirculatory parameters 
alone may have limited prognostic value. The author believes that quantification of 
microcirculatory blood flow, as described, provides a humane pre-mortality endpoint, whilst 
simultaneously improving the clinical translatability of pre-clinical sepsis studies. Information 
gained using this comprehensive and clinically relevant method of monitoring sepsis 
parameters, with particular focus on microcirculatory function, will help to refine the 
development of novel interventions, and limit attrition in later stages. 
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 Properties of TRPV1 4.1.1
Transient receptor potential vanilloid 1 (TRPV1), originally termed vanilloid receptor type 1 
(VR1), was identified by Caterina et al. in 1997 and characterised as a sensor of noxious 
heat (> 42°C) (Caterina et al., 1997). It is additionally and uniquely activated by capsaicin 
(Caterina et al., 1997), the active ingredient in chilli peppers, as well as other structurally 
related vanilloids (such as resiniferatoxin; RTX) (Caterina et al., 1997), protons (Tominaga et 
al., 1998), and endovanilloids, including anandamide and arachidonic acid-derived 
lipoxygenase products (Ross, 2003, Holzer, 2008). Activation of TRPV1 is competitively 
antagonised by capsazepine, a synthetic analogue of capsaicin, though since its initial 
characterisation (Bevan et al., 1992, Urban and Dray, 1991) several potent and more 
selective TRPV1 antagonists have been developed. Widely expressed, and implicated in a 
wide range of physiological processes, the receptor has received much research interest 
since its initial characterisation. It is predominantly studied in the contexts of nociception 
and thermosensation, though wider roles for TRPV1, particularly in the cardiovascular 
system, are emerging.  
 Structure, function and expression of TRPV1 4.1.1.1
TRPV1 subunits have large intracellular N- and C-termini, with a short hydrophobic pore-
forming region spanning transmembrane domains 5 and 6 (Fig. 25) (Caterina et al., 1997). 
The N-terminus contains multiple ankyrin repeat domains, essential for channel function, 
and proposed to bind cytosolic proteins, including calmodulin (Lishko et al., 2007). The C-
terminus contains a TRP domain, suggested to function as a molecular determinant of 
subunit tetramerisation (Garcia-Sanz et al., 2004), which, in the case of TRPV1, is 
predominantly homomeric (Kedei et al., 2001). Also in the C-terminus is a binding site for 
membrane lipid phosphatidylinositol-4,5-bisphosphate (PIP2), which can both positively and 
negatively regulate channel activity, depending on its positioning in the upper or lower 
leaflet of the cell membrane (Senning et al., 2014). 
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Figure 25. Structural features of the TRPV1 subunit. TRPV1 subunits comprise 6 transmembrane 
domains with a re-entrant pore-forming loop between domains 5 and 6, and cytosolic N- and C-
termini. The N-terminus contains three ankyrin (Ank) repeat domains and a Ca
2+
-calmodulin (CaM) 
binding site. The C-terminal contains a binding site for phosphatidylinositol 4,5-bisphosphate (PIP2). 
Grey circles represent potential phosphorylation sites for protein kinases A and C; red circles 
represent binding sites for vanilloids, including capsaicin. Heat- and acid-sensing residues are located 
on extracellular loops.  
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Consistent with the observation that intradermal injection of capsaicin causes intense pain 
in humans and pain-related behaviour in experimental animals (Baumann et al., 1991), 
TRPV1 is predominantly localised in nociceptive C and Aδ afferents (Caterina et al., 1997). 
These fibres [typically small- to medium-diameter neurons projecting from dorsal root, 
trigeminal and nodose sensory ganglia (Caterina et al., 1997)] characteristically contain 
neuropeptides, such as calcitonin gene-related peptide (CGRP), substance P (SP), 
neurokinin A and somatostatin (Alawi and Keeble, 2010). Nociceptor occupation triggers 
non-specific cation influx and neuron depolarisation, which in turn induces an afferent 
impulse conduction and pain sensation, as well as neuropeptide release (Holzer, 1988). Na+ 
influx is sufficient to mediate the former response, whereas Ca2+ influx, and thus 
extracellular Ca2+, is required for neuropeptide release (Holzer, 2008). 
In addition to its neuronal expression, there is increasing evidence of TRPV1 expression in 
non-neuronal tissues, including keratinocytes (Southall et al., 2003), urothelial cells (Birder 
et al., 2001), vascular smooth muscle (Ma et al., 2011), endothelium (Golech et al., 2004), 
and inflammatory cells, such as lymphocytes (Saunders et al., 2007) and macrophages 
(Chen et al., 2003, Fernandes et al., 2012), as well as a number of brain regions (Mezey et 
al., 2000). Its functions and indeed its very presence in these tissues, however, remain a 
topic of intense debate and form the subject of much current investigation. 
 Receptor desensitisation 4.1.1.2
The response of TRPV1 to capsaicin exhibits profound and Ca2+-dependent desensitisation 
by two distinct and independent mechanisms: prolonged capsaicin exposure induces ‘acute 
desensitisation’ involving a calmodulin-dependent inactivation of the ionic current, 
whereas repeated application of capsaicin causes ‘tachyphylaxis’, or a reduction in the 
maximal current amplitude (Koplas et al., 1997) likely due to receptor internalisation and 
degradation (Sanz-Salvador et al., 2012). In addition to causing desensitisation or 
endocytosis of the channel itself, capsaicin is also known to cause neurotoxicity and 
defunctionalisation following repeated application to nerve terminals both in vivo (Jancso 
et al., 1977) and in vitro (Wood et al., 1988). This necrosis is thought to occur through ionic 
overload and mitochondrial dysfunction, and is specifically TRPV1-dependent (Caterina et 
al., 1997). Indeed, experimental denervation by capsaicin has emerged as a highly useful 
tool for investigating the importance of TRPV1 and sensory nerve input in numerous 
physiological systems. 
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 TRPV1 and cardiovascular regulation 4.1.2
The efferent-like function of capsaicin-sensitive sensory nerve fibres was first described in 
the 1960s, with several reports of stimulus-induced release of locally-acting neuropeptides 
from peripheral nerve terminals (Holzer, 1988). TRPV1-positive sensory nerves project 
predominantly to cardiovascular and renal tissues, and are found in close proximity with 
blood vessels in almost all vascular beds (Wang, 2005). A significant proportion of these 
afferents contain the highly vasoactive neuropeptides CGRP and SP, which are synthesised 
in the dorsal root ganglia (DRG) that contain the cell bodies of capsaicin-sensitive sensory 
neurons (Wang, 2005). Local release of  CGRP (Brain et al., 1985) and SP (Maggi, 1995) 
forms a key component of neurogenic vasodilatation. 
The contribution of neurogenic vasodilatation to blood pressure regulation (through 
modification of peripheral resistance vessels) was first suggested in 1988 (Kawasaki et al., 
1988). This seminal study described a non-adrenergic, non-cholinergic vasodilatory 
response to peripheral nerve stimulation, which was proposed to contribute to the 
regulation of vascular tone in mesenteric resistance beds, and was abolished following 
depletion of CGRP from perivascular nerve endings (Kawasaki et al., 1988). The role of 
TRPV1-positive sensory nerve fibres in blood pressure regulation has since been the subject 
of intense investigation, and recent studies have shown that sensory nerves interact with 
and counterbalance several pro-hypertensive neurohormonal systems [including the renin-
angiotensin-aldosterone system (Wang and Li, 1999), the sympathetic nervous system 
(Wang et al., 2001) and the endothelin system (Ye and Wang, 2002)] to maintain normal 
blood pressure. More recently, however, deletion of TRPV1 has been associated with 
exaggerated hypertension induced by high fat feeding, perhaps as a result of exaggerated 
vascular remodelling (Marshall et al., 2013).  
Interestingly, while capsaicin has generally been reported to cause vasorelaxation, there 
have also been reports of TRPV1-mediated vasoconstriction in mesenteric (Scotland et al., 
2004), coronary (Szolcsanyi et al., 2001) and skeletal muscle (Kark et al., 2008) arteries, and 
in the mouse knee joint (Keeble and Brain, 2006). Scotland et al. (2004) described a 
contractile response to both increased intraluminal pressure and TRPV1 activation in small 
mesenteric resistance arteries that was sensitive to antagonists capsazepine and ruthenium 
red and was abolished following sensory denervation with a single intraperitoneal injection 
of 50 mg/kg capsaicin (Scotland et al., 2004). This response was found to be dependent on 
138  |  T H E  R O L E  O F  T R P V 1  I N  S E P S I S - A S S O C I A T E D  
M I C R O V A S C U L A R  D Y S F U N C T I O N  
activation of vascular smooth muscle neurokinin 1 (NK1) receptors by SP, and was 
suggested by the authors to contribute to myogenic tone regulation. 
It is unclear, however, how or why endogenous activation of TRPV1 in this context causes 
preferential release of SP over CGRP (a potent vasodilator) (Brain et al., 1985) or indeed 
why the SP released should act on vascular smooth muscle NK1 receptors to cause 
vasoconstriction, rather than endothelial NK1 receptors to cause vasodilatation, as is more 
commonly observed (Maggi, 1995, Lembeck and Holzer, 1979, Gamse et al., 1980, Gazelius 
et al., 1981).  
One possible explanation is that the response reported by Scotland et al. (Scotland et al., 
2004) is regionally restricted, and that the role of TRPV1 in vascular regulation may vary 
according to the type and localisation of circulatory system (Inoue et al., 2008). 
Alternatively, in light of reports of a direct vasoconstrictor effect of capsaicin on vascular 
smooth muscle (Holzer, 1991, Szolcsanyi et al., 2001, Kark et al., 2008), the possibility that 
myogenic constriction is mediated through a non-neuronal mechanism warrants further 
elucidation. Given that the authors did not consider the effect of intraperitoneal capsaicin 
on non-neuronal TRPV1, which may also be desensitised through such treatment, it is 
possible that the myogenic constriction observed may indeed have been mediated by direct 
effects of TRPV1 activation in vascular smooth muscle cells. This would certainly be 
consistent with previous publications indicating no direct role for periarterial nerves in the 
vascular myogenic response (Bayliss, 1902, Johansson, 1989, Marshall et al., 2013). 
In addition to its activity in perivascular nerves, TRPV1 may also contribute to vascular 
function directly. There have been numerous reports of TRPV1 expression in vascular 
endothelium (Golech et al., 2004, Yang et al., 2010a, Bratz et al., 2008) and smooth muscle 
tissue (Cavanaugh et al., 2011, Czikora et al., 2012, Kark et al., 2008), where it is thought to 
contribute particularly to microvascular regulation.  
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 TRPV1 as a key player in the relationship between infection, 4.1.3
inflammation and cardiovascular dysfunction 
 Neurogenic inflammation 4.1.3.1
The release of neuropeptides from sensory nerve terminals following TRPV1 activation has 
long been recognised to play an important role in the inflammatory milieu. CGRP and SP, in 
particular, are considered pro-inflammatory mediators, eliciting increased blood flow (Brain 
et al., 1985) and plasma extravasation (Lembeck and Holzer, 1979), respectively, 
characteristic of neurogenic inflammation. Activation of NK1 receptors by SP has also been 
implicated in microvascular leukocyte recruitment under inflammatory conditions (Cao et 
al., 2000, Costa et al., 2006), and in the upregulation of interleukin-8 (IL-8) – a 
chemoattractant and potent proangiogenic factor (Zhao et al., 2002). These processes 
appear to be highly significant in the pathogenesis of a number of conditions, including 
rheumatoid arthritis, colitis, asthma and migraine (Holzer, 2008).  
Release of somatostatin, on the other hand, is associated with an anti-inflammatory effect, 
which involves an auto-inhibitory mechanism in which it acts on sensory nerve terminals to 
prevent further neuropeptide release (Helyes et al., 2007, Pinter et al., 2006). In addition to 
its prejunctional effects, somatostatin also acts postjunctionally: binding of somatostatin to 
G-protein coupled receptors on endothelial, inflammatory and immune cells inhibits the 
action of pro-inflammatory neuropeptides at their effector sites (Pinter et al., 2006).  
 Direct stimulation of pro-inflammatory cytokine production 4.1.3.2
In addition to mediating neurogenic inflammation, TRPV1 may also be functional in 
inflammatory cells themselves. Receptor expression has been detected in human 
leukocytes (Spinsanti et al., 2008) and mast cells (Stander et al., 2004), and Biro et al. have 
demonstrated TRPV1-induced production of pro-inflammatory cytokine IL-4 in murine mast 
cells (Biro et al., 1998). In humans, Stander et al. (2004) observed sporadic mast cell 
expression of TRPV1 under basal conditions, though in skin samples from patients with 
mastocytosis (an inflammatory skin condition) almost all mast cells showed TRPV1 
immunoreactivity, which was confirmed by qRT-PCR and Western blot analysis (Stander et 
al., 2004). These data were interpreted as indicative of an ‘autocrine loop of receptor 
upregulation’ that may stimulate a pro-inflammatory state through increased cytokine 
production.   
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Interestingly, despite historically having been considered a pro-inflammatory receptor, a 
number of recent studies suggest that TRPV1 may confer protective effects in some 
inflammatory settings (Alawi and Keeble, 2010).  
 Evidence of a protective role for TRPV1 in sepsis 4.1.3.3
The importance of sensory nerve input in sepsis was first inferred from two observations: 
first, the exacerbated inflammatory responses to infection following sensory denervation of 
experimental animals (Bowden et al., 1996); and second, the raised plasma levels of 
neuropeptides CGRP and SP in septic patients (Joyce et al., 1990, Beer et al., 2002). More 
recently, an upregulation of TRPV1 and CGRP in tongue tissue and mesenteric perivascular 
nerves, repectively, has been demonstrated in endotoxaemic rats (Orliac et al., 2007), 
suggesting that changes in TRPV1 and neuropeptide expression may contribute to the 
physiological responses to sepsis.  
Indeed, a role for TRPV1 in mediating a fever response to endotoxin has been 
demonstrated both in sensory denervated rats (Romanovsky, 2004) and TRPV1 KO mice 
(Iida et al., 2005). Interestingly, and perhaps counterintuitively, TRPV1 has also been 
implicated in protection against sepsis-induced cardiovascular dysfunction. Wang et al. 
demonstrated that recovery from endotoxin-induced hypotension and tachycardia in 
anaesthetised mice was strongly inhibited by both capsazepine and selective NK1 receptor 
antagonism (Wang et al., 2008a). 24- and 48-h survival of conscious rats treated with 
lipopolysaccharide (LPS) was similarly improved, suggesting that TRPV1 may mediate 
cardiovascular protection in this setting via the release of SP. In support of this, plasma 
levels of SP were significantly raised in LPS-treated rats, compared with vehicle-treated 
controls (Wang et al., 2008a). 
Further investigation in our laboratory has revealed that TRPV1 KO mice exhibit significantly 
enhanced hypotension compared to WT counterparts at 4 h post-LPS administration, with 
early signs of liver dysfunction, including significant liver plasma extravasation and raised 
levels of plasma aspartate aminotransferase, apparent in LPS-treated TRPV1 KO but not WT 
mice (Clark et al., 2007). However, given that induction of cytokines, such as IL-6, only 
occurs 6 h after the induction of endotoxaemia in mice, and haematological changes 
become pronounced after 24 h (Xiao et al., 2006), it seems likely that a 4-h end point is too 
early to fully assess the functional effects of TRPV1 deletion in a murine model of sepsis. 
Furthermore, the possibility of developmental compensation for TRPV1 gene ablation 
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cannot be ruled out. Selective and tissue-specific TRPV1 antagonism in vivo may be helpful 
in elucidating this further. 
A more recent study, using the cecal ligation and puncture (CLP) model of sepsis found that 
at 24 h post-CLP, TRPV1 KO mice exhibit enhanced hypotension compared to WT controls, 
and plasma markers of heart, liver, kidney and pancreas dysfunction were significantly 
raised in the former group (Fernandes et al., 2012). Decreased mononuclear cell integrity 
and enhanced peritoneal apoptosis were observed in the septic focus of KO mice, as well as 
decreased macrophage NK1-dependent phagocytosis. Moreover, isolated macrophages 
from TRPV1 KO mice exhibited an impaired ability to phagocytose latex beads in vitro, 
following stimulation with LPS. This process in WT mice was found to be dependent on SP 
(Fernandes et al., 2012). These data suggest that deletion of the TRPV1 gene leads to 
impaired bacterial clearance in sepsis, accelerating the transition from local infection to a 
full systemic inflammatory response syndrome, and the onset of organ damage and failure.  
In contrast with reports described above, a recent study by Wang and Wang found no 
difference in haemodynamic performance between LPS-treated TRPV1 WT and KO mice. 
Immunohistochemical and blood marker analysis, in contrast, revealed markedly 
exaggerated organ dysfunction and tissue neutrophil recruitment in the latter (Wang and 
Wang, 2013). These data are consistent with results outlined in Chapter 3, showing that 
arterial pressure is insufficiently indicative of syndrome progression. A possible reason for 
this discrepancy in results obtained by Wang and Wang compared with previous 
investigations is the nature of haemodynamic monitoring techniques employed: while 
reports of exaggerated hypotension in LPS-treated TRPV1 KO mice have used either 
invasive catheterisation under anaesthesia (Wang et al., 2008a) or the tail-cuff method 
(Clark et al., 2007, Fernandes et al., 2012), known to induce significant stress artefacts, 
Wang and Wang used radiotelemetry in unrestrained conscious mice – known to represent 
the gold standard in haemodynamic monitoring  (Morton et al., 2003). Nonetheless, while 
the receptor may not play a significant role in haemodynamic regulation in sepsis, TRPV1-
mediated protection against inflammation-induced organ damage is now well established.  
The endogenous agonist for this protective response has yet to be identified, although the 
endocannabinoid anandamide is a potential candidate, as several studies have reported 
increased anandamide production by macrophages and endothelial cells during 
endotoxaemia (Batkai et al., 2004, Varga et al., 1998). Although activation of cannabinoid 
receptor CB1 by anandamide elicits profound hypotension (Varga et al., 1996), it has been 
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demonstrated ex vivo that the vasodilatory response to anandamide in rat mesenteric 
arteries occurs predominantly through TRPV1 (Zygmunt et al., 1999) and this is supported 
by in vivo studies demonstrating that the cardiac depressor response to methanandamide is 
attenuated by capsazepine (Wang et al., 2005).  
Thus far, the longer-term effects of TRPV1 deletion on vascular function in sepsis have not 
yet been investigated. It is possible that, in addition to immune cell regulation, TRPV1 may 
also mediate vasoactive effects: given its ability to cause both vasoconstriction and 
vasodilatation, depending on its cellular localisation, TRPV1 may contribute to recovery 
from septic hypotension through the former mechanism, or the maintenance of organ 
perfusion through the latter. This may form a basis for understanding why septic TRPV1 KO 
mice appear to exhibit both exaggerated hypotension and accelerated organ dysfunction 
(Clark et al., 2007), though this requires further investigation.  
 Hypotheses 4.1.4
Previous findings within our laboratory as well as others suggest that TRPV1 is protective in 
the setting of sepsis. Given the growing body of evidence establishing TRPV1 as a potential 
regulator of vascular function – particularly in small resistance arteries, where dysfunction 
correlates strongly with adverse outcome in sepsis –  we hypothesise that TRPV1 may 
mediate protective effects through its ability to regulate vascular function in inflammatory 
conditions. 
 Aims 4.1.5
The aims of this study were as follows: 
1. To use a novel model of microcirculatory assessment, described in Chapter 3, to 
determine the impact of TRPV1 deletion on microcirculatory blood flow 
2. To relate any changes in blood flow to other measurements of disease severity, 
including blood markers of acidosis and organ dysfunction, and other macroscopic 
clinical parameters 
3. To determine the impact of topical TRPV1 agonism on mesenteric blood flow in 
healthy and septic wildtype mice 
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 Methods 4.2
 Animals 4.2.1
Male wildtype (WT) and TRPV1 knockout (KO) mice were bred in house from heterozygous 
crosses, as described in section 2.1. Mice were used between 10 and 14 weeks of age 
(approx. 25–30g). 
 Induction of sepsis 4.2.2
Experimental sepsis was induced by intravenous injection of lipopolysaccharide (LPS; 12.5 
mg/kg) from Salmonella typhimurium (Sigma, L7261). Injections of approximately 100 µl 
(pre-warmed to 37°C) were administered into the tail vein under inhaled isoflurane 
anaesthesia, as described in section 2.3.3.1. Mice were placed in a recovery chamber at 
27°C for up to 24 h and were monitored frequently. An arbitrary severity score of 1–5 
(based on mobility, facial expression, piloerection and aversion to touch) was employed to 
assess animal welfare. Any mouse reaching a score of 5 was immediately terminated.  
Given its ability to recapitulate the cardiovascular alterations associated with sepsis (as 
demonstrated in Chapter 3), the LPS model was chosen based on its practicality, and to 
prevent any confounding influence of divergent responses to surgery between genotypes.  
 In situ monitoring of mesenteric blood flow 4.2.3
Mesenteric blood flow was measured in naïve and septic mice 24 h post-LPS, as described 
in Chapter 3; a rectal probe coupled to a homeothermic heating mat was used to maintain 
mice at the temperature at which they presented. After 5 min baseline recording, the 
mesenteric bed was gently sprayed (2 pump compressions from a distance of 
approximately 10 cm) with either 10 µM capsaicin dissolved in saline containing 1% DMSO 
or vehicle, pre-warmed to 37°C. This concentration, approximately 10-fold higher than the 
EC50 for TRPV1 in heterologous expression systems (Caterina et al., 1997), was chosen 
based on the aerosolised and relatively diffuse delivery mode. Responsiveness to capsaicin 
was measured over a further 5 min; a venous blood sample was subsequently drawn from 
the inferior vena cava, and animals were terminated by cervical dislocation. Blood 
biochemistry was assessed immediately from 100 µl venous blood using a hand-held iSTAT® 
point-of-care analyser (Abbott Laboratories, IL, USA), with CG8+ cartridges (Abbott 
Laboratories). Results were analysed in moorFLPI Review software (V4.0) and GraphPad 
Prism, as described in section 3.2.7.1. Results are expressed as mean area under the curve 
(AUC) over time ± SEM. 
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 Results 4.3
 TRPV1 KO mice are homeostatically stable during blood flow recording 4.3.1
TRPV1 KO mice, like WT mice, exhibited stable core temperature (Fig. 26d) and mesenteric 
blood flow (Fig. 26a–c) during blood flow recording, validating the use of these animals in 
studies of vasoactive responses to intervention that are not confounded by changes in 
temperature or haemodynamic status. In this series of experiments, 3 animals were 
excluded from the LPS group, and 2 from the naïve group, due to bleeding during dissection 
for blood flow recording.  
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Figure 26. Mesenteric blood flow and core temperature over time in naïve and septic TRPV1 KO 




 and (c) 3
rd
 order mesenteric vessels was stable over the recording 
period. Core temperature (d) was also sta ble over the recording period, suggesting that vasoactive 
responses recorded are not influenced by changes in temperature or haemodynamic status. Data are 
presented as mean ± SEM (n = 7–9). 
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 TRPV1 KO mice have exaggerated mesenteric flow impairment in LPS-4.3.2
induced sepsis 
Mesenteric blood flow was equivalent between TRPV1 WT and KO mice under naïve 
conditions, though there was a slight trend for decreased flow in 1st and 3rd order vessels in 
the latter. Following the induction of sepsis by intravenous injection of LPS, however, the 
flow impairment in KO animals was exaggerated relative to WT controls (Fig. 27), especially 
in smaller 3rd order vessels (Fig. 27c) that directly supply gut tissue, where flow was 







Figure 27. Mesenteric blood flow in TRPV1 WT and KO mice under naïve and septic conditions. 
Mesenteric blood flow is expressed as total area under the curve (AUC; x10
3
 flux units.time) over 5-




 and (c) 3
rd
 order vessels. AUC for each animal is represented 
as an individual symbol, with horizontal line denoting group mean. *p<0.05, 1-way ANOVA + 
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  Deletion of TRPV1 is associated with a worse clinical phenotype in LPS-4.3.3
induced sepsis 
TRPV1 KO mice exhibited an exaggerated phenotype in LPS-induced sepsis by a number of 
additional parameters. Arbitrary severity score (assigned in a blinded fashion based on 
voluntary mobility, gait, aversion to touch, facial expression and piloerection) was significantly 
increased in KO animals (Fig. 28a; p = 0.04, student’s unpaired two-tailed T-test). Hypothermia 
during sepsis was slightly exaggerated in KO animals (Fig. 28b), although weight loss over the 
24-h sepsis time course was equivalent between genotypes (Fig. 28c).  Initial body weight 
(prior to the induction of sepsis) was slightly lower in KO mice, however (Fig. 28d), despite a 
similar change over the sepsis period (mean Δg ± SEM: 2.75 ± 0.32 vs 2.78 ± 0.19 in WT and KO 
mice, respectively, ns). TRPV1 KO mice also had a slightly higher core temperature than WT 
mice under naïve conditions (37.03 ± 0.24°C vs 36.75 ± 0.22) though this was not statistically 
significant. Mice were age-matched between genotypes.  
Blood from LPS-treated TRPV1 KO mice was slightly more acidotic than WT controls, and urea 
was also slightly higher, though these changes were not statistically significant. PCO2 was also 
elevated in LPS-treated KOs relative to WTs, bicarbonate levels were slightly reduced, and base 
excess and anion gap were slightly exaggerated. Interestingly, naïve KO mice also exhibited 
trends towards basally pathological blood biochemistry. Urea was slightly elevated in these 
mice, and pH slightly decreased, relative to WT controls. Bicarbonate levels were also slightly 
decreased in KO mice, and basal glucose levels were higher. These data are summarised in 
Table 8.  
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Figure 28. Clinical parameters in TRPV1 WT and KO mice.  (a) Arbitrary severity score assigned in a 
blinded fashion based voluntary mobility, gait, aversion to touch, facial expression and piloerection. (b) 
Initial temperature taken immediately after induction of anaesthesia for blood flow recording. (c) 
Percentage weight loss over 24-h septic period (d) Initial body weight prior to the induction of sepsis, 
taken 24 h before blood flow recording. Values for each animal are presented as individual symbols, 
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 WT Naïve  KO Naïve WT LPS 24 h KO LPS 24 h 
Urea (mmol/L) 4.74 ± 0.63 5.91 ± 0.65 33.62 ± 5.56*** 39.61 ± 4.074*** 
pH 7.227 ± 0.04 7.186 ± 0.044 7.005 ± 0.07* 6.845 ± 0.05*** 
Base excess (mmol/L) -10.89 ± 0.99 -12.86 ± 2.19 -20.67 ± 2.35** -25.00 ± 1.50*** 
HCO3
- (mmol/L) 16.86 ± 0.73 10.42 ± 1.35## 15.41 ± 1.40  8.43 ± 0.95## 
PCO2 (mmHg) 41.62 ± 3.18 40.96 ± 3.92 40.10 ± 2.63 48.01 ± 5.09 
TCO2 (mmol/L) 18.25 ± 1.44 16.86 ± 1.37 11.67 ± 1.36* 10.00 ± 1.03**  
Glucose (mmol/L) 11.03 ± 0.66 14.89 ± 1.80 2.33 ± 0.31** 1.87 ± 0.19*** 
Na+ (mmol/L) 150.3 ± 0.25 148.8 ± 0.68 152.2 ± 0.79 155.3 ± 2.80 
K+ (mmol/L) 3.425 ± 0.43 4.133 ± 0.26 3.583 ± 0.29 4.089 ± 0.66 
Cl- (mmol/L) 109.0 ± 2.08 108.5 ± 1.13 117.3 ± 1.11* 115.8 ± 1.77** 
Anion gap (mmol/L) 27.33 ± 3.28 26.17 ± 2.01 28.25 ± 2.36 37.75 ± 8.79 
Haematocrit  (%PCV) 35.50 ± 2.18 35.00 ± 1.82 30.33 ± 1.99 28.11 ± 2.50 
Haemoglobin (g/dl) 12.39 ± 0.75 11.79 ± 0.80 10.17 ± 0.75 9.58 ± 0.85 
 
Table 8. Blood biochemistry in healthy and septic TRPV1 KO and WT mice. Blood gas and biochemistry were measured from venous blood samples by iSTAT point-of-care 
analyser in naïve septic mice at 24 h post-LPS. Data are presented as mean ± SEM. *p<0.05, **p<0.01 and ***p<0.001 relative to respective naïve controls; 
##
p<0.01 relative 
to respective WT controls, 1-way ANOVA and Bonferroni post-hoc test, n = 7–11.  
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; SO2, venous oxygen saturation; PCV, packed cell volume. 
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 Vasoactive responses to topical capsaicin administration may be altered 4.3.4
in endotoxaemic WT mice 
In order to assess changes in TRPV1 activity in vivo after the induction of sepsis, 10 µM 
capsaicin or vehicle (2% DMSO in pre-warmed saline) was applied onto the exposed mesentery 
of WT mice by aerosolised spray. In naïve mice, topical administration of capsaicin caused a 
decrease in blood flow in 1st order vessels (Figs. 29a & 30a). While vehicle also caused a small 
decrease in blood flow, this was significantly greater following stimulation with capsaicin 
(mean percentage change ± SEM: −2.19 ± 2.62% vs −13.95 ± 2.56%, p < 0.01, 1-way ANOVA + 
Bonferroni post-hoc test). In 2nd order vessels, vehicle and capsaicin caused a decrease in 
blood flow of a similar magnitude (mean percentage change ± SEM: −7.89 ± 1.78% vs −8.02 ± 
1.57%, respectively, ns; Figs. 29b & 30b), suggesting the effect was not mediated by TRPV1. In 
3rd order vessels, vehicle slightly decreased blood flow, whereas capsaicin caused a small 
increase (mean percentage decrease ± SEM: −2.65 ± 1.15% vs +3.69 ± 1.74, ns; Figs. 29c & 
30c).  
In LPS-treated mice, on the other hand, capsaicin caused a small increase in blood flow in all 
vessels, though vehicle produced a similar effect (albeit of a smaller magnitude). In 1st order 
vessels mean percentage change ± SEM was 2.70 ± 1.93% vs 14.52 ± 2.67% for vehicle and 
capsaicin, respectively (ns; Figs. 29d & 30d). In 2nd order vessels mean percentage change ± 
SEM was 7.40 ± 1.85% vs 20.37 ± 6.92% for vehicle and capsaicin, respectively (ns; Figs. 29e & 
30e). In 3rd order vessels mean percentage change ± SEM was −3.11 ± 1.48% vs 21.51 ± 5.89% 
for vehicle and capsaicin, respectively (p < 0.01, 1-way ANOVA + Bonferroni post-hoc test; Figs. 

















Figure 29. Vasoactive responses to capsaicin and vehicle in healthy and septic WT mice. Baseline mesenteric blood flow was recorded for 5 min in naïve (a–c) and septic 
(d–f) mice, 24 h after injections of LPS. Capsaicin (Cap; 10 µM) or vehicle (2% DMSO in saline) was then administered as an aerosolised spray, denoted by the dotted line, 
and blood flow was recorded for a further 5 min. In naïve mice, capsaicin caused a decrease in blood flow in (a) 1
st
 order and (b)  2
nd
 order vessels (though vehicle also 
decreased flow in the latter) but not in (c) 3
rd




 and (f) 3
rd
 order vessels. Data are 
presented as mean ± SEM, n = 6–14.  
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Figure 30. Mesenteric blood flow at baseline and following topical administration of capsaicin or vehicle in healthy and septic mice. Area under the curve (AUC; flux 
units.time) over 5-min baseline recording and 5-min response to topical administration of capsaicin (Cap; 10 µM) or vehicle (2% DMSO in saline) are denoted by closed 
black circles and open white squares respectively. In naïve mice, AUC decreased in (a) 1
st
 order and (b) 2
nd
 order vessels (though vehicle also decreased flow in the latter) 
but not in (c) 3
rd




, and (f) 3
rd
 order vessels. AUC for each animal is denoted by 
individual symbols connected by a black line (n = 6–14).  
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Figure 31. Representative flux images baseline and following topical administration of capsaicin in 
healthy and septic mice. Cold colours indicate low flow; warm colours, high flow. Topical administration 
of capsaicin (cap; 10 µM) by aerosolised spray caused a small decrease in flow in 1
st
  and 2
nd
 order 
vessels of naïve mice; and a small increase in blood flow in all vessels of septic mice (24 h LPS). White 
arrowheads indicate 1
st
 order vessels; black arrowheads indicate 2
nd
 order vessels.  
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 Summary 4.4
 
The key findings from this study are: 
1. TRPV1 KO mice, like WT mice, are homeothermically and haemodynamically stable 
under the conditions used for blood flow monitoring. 
2. Naïve TRPV1 KO mice exhibited a trend towards basal acidosis.  
3. TRPV1 KO mice exhibit exaggerated microvascular flow impairment and clinical 
pathology in LPS-induced sepsis.  
4. Vasoactive responses to topical administration of capsaicin may be altered in LPS-
induced sepsis.  
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 Discussion 4.5
Vascular dysfunction, and consequent perfusion impairment, is a major contributor to sepsis-
associated mortality. Numerous reports of a protective role for TRPV1 in sepsis have been 
published in recent years (Wang et al., 2008a, Clark et al., 2007, Fernandes et al., 2012); in light 
of the growing body of evidence establishing TRPV1 as a potential regulator of vascular 
function – particularly in small resistance arteries, where dysfunction correlates strongly with 
adverse outcome in sepsis –  we hypothesised that TRPV1 may mediate protective effects 
through its ability to regulate vascular function in inflammatory conditions. We aimed to 
compare the cardiovascular phenotype of TRPV1 WT and KO mice under naïve and septic 
conditions using our novel model of microcirculatory assessment, described in Chapter 3. We 
additionally aimed to relate any changes in blood flow to other measurements of disease 
severity, including blood markers of acidosis and organ dysfunction, as well as a variety of 
macroscopic clinical parameters. Finally we aimed to determine the impact of topical TRPV1 
agonism on mesenteric blood flow in healthy and septic wildtype mice. 
 TRPV1 KO mice exhibit a trend towards basal acidosis 4.5.1
Initially characterised by Caterina et al., TRPV1 KO mice are reported to be largely 
indistinguishable from WT littermates in terms of general appearance, gross anatomy, body 
weight, locomotion and overt behaviour (Caterina et al., 2000). Conversely, our TRPV1 KO mice 
were slightly but significantly leaner than their WT littermates, consistent with other reports 
that TRPV1 KO mice are leaner when young but have a greater tendency towards obesity with 
age (Moran et al., 2011). Furthermore, analysis of blood biochemistry in naïve KO mice 
revealed evidence of slight basal metabolic acidosis. Whereas naïve WT mice had a mean 
blood pH of 7.227 – normal for C57/BL6 mice (Tordoff et al., 2007) – naïve TRPV1 KO mice had 
a mean blood pH of 7.186 and significantly lower blood bicarbonate levels with normal PCO2, 
consistent with metabolic acidosis (Lien and Lai, 1998). These observations are consistent with 
reports that TRPV1 is the main nociceptive acid-sensor in mice (Leffler et al., 2006). 
Furthermore, while basal blood glucose levels in WT mice were consistent with previous 
reports (Berglund et al., 2008), they were slightly elevated in TRPV1 KO mice. The reason for 
this observation is not clear, though it may relate to recent reports of a hypermetabolic 
phenotype in TRPV1 KO mice (Riera et al., 2014), which could also explain the slightly lower 
body weight associated with TRPV1 deletion observed here. Hypermetabolism is also 
associated with hyperglycaemia (Buczkowska, 2002), which may account for the slightly 
elevated blood glucose levels recorded in TRPV1 KO mice. Since mice were not fasted prior to 
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the measurement of blood glucose, however, and since food intake was not monitored in this 
study, whether these differences are due to increased intake or metabolic factors is unclear.   
 TRPV1 KO mice exhibit exaggerated pathogenesis in LPS-induced sepsis 4.5.2
While microvascular blood flow in naïve mice was equivalent between genotypes, perfusion 
was reduced to a greater extent in septic TRPV1 KO mice, reaching statistical significance in the 
smallest 3rd order vessels. This may account for the accelerated organ dysfunction and 
increased mortality in septic mice lacking a functional TRPV1 receptor reported previously 
(Wang et al., 2008a, Clark et al., 2007, Fernandes et al., 2012), and is consistent with previous 
reports that TRPV1 KO mice have a greater tendency towards peripheral vasoconstriction 
(Garami et al., 2011).  
In line with reduced mesenteric perfusion, septic TRPV1 KO mice also exhibited enhanced 
pathogenesis by a number of other clinical parameters. Blood levels of urea and markers of 
metabolic acidosis were elevated in the KO mice relative to WT littermates, and LPS-induced 
hypothermia was exaggerated in the former. It is noteworthy that this cohort of WT mice did 
not exhibit significant hypothermia, however, whereas previous cohorts exhibited a significant 
drop in core temperature at 24 h post-LPS (Chapter 3; Fig. 5). Indeed in previous cohorts, 
mean temperature at 24 h post-LPS was 33.9 ± 0.71°C – markedly lower than the mean 
temperature (35.87 ± 0.44°C) recorded in this cohort. Whereas an initial period of hypothermia 
following intravenous administration of LPS is well-documented, numerous studies have 
reported a return to baseline temperatures by 24 h (Souza et al., 2014, Saia and Carnio, 2006), 
consistent with measurements for WT mice in this cohort. While the differences in 
hypothermic responses measured between cohorts in this study may be explained by 
fluctuations in ambient temperature (Rudaya et al., 2005), or by batch differences in LPS, WT 
and KO littermates in this study were studied under identical conditions, suggesting that the 
changes in hypothermic response are real.  
Overall the data recorded here are consistent with a protective role for TRPV1 in sepsis. There 
are numerous caveats to this conclusion, however. Firstly, given the propensity of genetic 
ablation to induce compensatory upregulation of similarly functioning genes during 
development, it would be necessary to repeat these studies using selective antagonists of 
TRPV1. Furthermore, the role of TRPV1 in inflammatory conditions appears to become more 
complicated with increasing age. Whereas selective antagonism of TRPV1 in 12-week old mice 
enhances LPS-induced mortality (consistent with the present data), both pharmacological 
antagonism and genetic deletion of TRPV1 delay and decrease mortality in 43-week old LPS-
treated mice (Wanner et al., 2012). While TRPV1 is suggested to suppress production of 
157  |  T H E  R O L E  O F  T R P V 1  I N  S E P S I S - A S S O C I A T E D  
M I C R O V A S C U L A R  D Y S F U N C T I O N  
tumour necrosis factor (TNF)α in young endotoxaemic mice, this anti-inflammatory effect 
appears to be reversed in older mice, where suppression of TRPV1 activity is associated with 
decreased serum TNFα levels (Wanner et al., 2012). On the other hand, deletion of TRPV1 in 
aged mice subjected to cecal ligation and puncture was associated with exaggerated pathology 
(Wanner et al., 2012), which may indicate suppression of anti-microbial defence systems, as 
suggested previously (Fernandes et al., 2012). A more extensive time-course, in which the 
effects of TRPV1 deletion on sepsis progression are monitored at different time points, and for 
longer periods, would also be useful in elucidating this further. 
Overall, research suggests that in the context of systemic inflammation, TRPV1 may evolve 
from an anti-inflammatory to a pro-inflammatory receptor with increasing age, whereas its 
role in the setting of infection may be more constant. Unfortunately, it was not possible to 
monitor changes in mesenteric blood flow in TRPV1 KO mice subjected to CLP in this study, 
owing to time constraints, though it would be interesting to see whether microvascular flow is 
similarly compromised in this model.  
 Vasoactive responses to topical capsaicin administration may be altered 4.5.3
in LPS-induced sepsis 
In situ investigation of vasoactive responses to TRPV1 activation was carried out in order to 
test the hypothesis that previously observed protective functions of TRPV1 in animal models of 
endotoxaemia (Wang et al., 2008a, Clark et al., 2007) may involve a vasoregulatory 
component. We hypothesised that changes to TRPV1 expression and/or activity under 
inflammatory conditions may underlie its protective effects.  
A topical method of application was chosen to assess vasoactivity directly, since systemic 
administration of capsaicin may be expected to cause reflex changes in blood pressure. 
Mesenteric vasoactivity has traditionally been studied by myographical methods, though this 
ex vivo approach is limited by a number of factors. Firstly, the relevance of an isolated 
perfused vessel to the complex physiological environment encountered in situ is uncertain, 
and furthermore, the mounting process itself can introduce mechanical disruption to the 
vessel, most notably endothelial damage and inappropriate tension. While other groups have 
established methods of monitoring mesenteric blood flow in situ in rodents, these techniques 
have typically required significant microdissection of perivascular fat and connective tissue, 
and are generally restricted to the measurement of blood flow in a single vessel (Pourageaud 
and De Mey, 1997, Rowland et al., 2012, Hinohara et al., 2010). The method employed here 
allows for simultaneous visualisation of blood flow in several different vessels, with no 
perivascular dissection, as well as in situ assessment of acute drug effects via an aerosolised 
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topical delivery method conferring minimal mechanical and refractory disturbance, as 
discussed more extensively in Chapter 3.  
A relatively high concentration of capsaicin [10 µM – approximately 10-fold higher than the 
EC50 in heterologous expression systems (Caterina et al., 1997)] was chosen for topical 
administration owing to the relatively diffuse delivery method. In naïve animals, capsaicin 
caused a small decrease in blood flow in 1st order vessels, consistent with vasoconstriction. 
While vehicle also caused a slight decrease in blood flow, this was of a smaller magnitude, 
indicative of at least a partially TRPV1-dependent effect. The reason for the vehicle-induced 
decrease in blood flow (particularly evident in 2nd order vessels) is unclear, and may be 
explained by evaporative cooling or a DMSO-mediated effect; DMSO has traditionally been 
associated with increased blood flow (Haller et al., 1987), however, though it has also been 
associated with cytoxicity, notably in endothelial cultures (Sperling and Larsen, 1979), which 
could contribute to vascular dysfunction and perfusion impairment. On the other hand, blood 
flow in 3rd order vessels was not reduced by either vehicle or capsaicin, suggesting that the 
constriction observed in 1st order vessels in particular, may have been due to a specific 
pharmacological action. 
Because TRPV1 activation on sensory nerves and in endothelial cells is generally associated 
with vasodilatation, it is conceivable that capsaicin-induced vasoconstriction could be 
attributed to TRPV1 expressed in smooth muscle cells, where its activation may lead to 
calcium-induced vasoconstriction, either directly or through local SP release, as suggested 
previously (Scotland et al., 2004). This is supported by observations that vasoconstriction 
occurs predominantly in 1st order vessels, likely to contain a substantial smooth muscle layer, 
rather than in 3rd order vessels, which directly supply the gut wall and are unlikely to contain a 
high proportion of smooth muscle tissue. The possibility of functional TRPV1 expression in 
smooth muscle cells is supported by a number of previous reports of capsaicin-induced 
vasoconstriction, as well as some direct evidence of smooth muscle TRPV1 expression (Kark et 
al., 2008, Bratz et al., 2008, Yang et al., 2010b, Scotland et al., 2004, Cavanaugh et al., 2011, 
Ma et al., 2011), as discussed in section 4.1.2.3.  
If indeed TRPV1 is expressed in the smooth muscle cells of these vessels, it is possible that it 
contributes to the myogenic response to increased blood pressure, as suggested previously 
(Scotland et al., 2004). It should be noted, however, that the concentration of capsaicin used 
here was relatively high. While previous reports that TRPV1 knockout mice show no aversion 
to water supplemented with 100 µM capsaicin (Caterina et al., 2000) suggest that higher 
concentrations of the compound remain specific for TRPV1, off-target effects cannot be ruled 
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out. Further investigation of vasoactive responses to capsaicin in TRPV1 KO mice would 
elucidate this further.  
In endotoxaemic mice capsaicin caused a subtle but consistent vasodilatation in all orders of 
mesenteric vessel. The switch from vasoconstriction to vasodilatation in response to capsaicin 
administration in sepsis is intriguing. It is possible that in the murine mesenteric bed, the pro-
dilatory drive mediated by perivascular nerves (and potentially endothelial TRPV1) competes 
with a pro-constrictive drive mediated by smooth muscle TRPV1, and that under basal 
conditions a net constriction occurs that is reversed in inflammation (Fig. 32). Increased 
production of anandamide, by circulating macrophages and endothelial cells themselves, for 
example, may contribute to greater TRPV1-mediated endothelium-dependent vasodilatation in 
sepsis. Experiments in which sensory nerves are ablated, or in which neurogenic vasodilatation 
is blocked by CGRP and SP antagonists, as well as in vitro assessment of smooth muscle cell 
responsiveness to increasing concentrations of capsaicin could shed further light on this 
hypothesis. It would also be useful to perform immunofluorescent analysis of mesenteric 
artery sections from naïve and septic mice, in order to determine the overlap of TRPV1 
expression with markers of sensory nerve terminals, endothelial cells and smooth muscle cells.  
Increasing levels of circulating NGF in the inflammatory milieu, as well as direct contact 
between endothelial cells and circulating cytokines and inflammatory mediators may lead to a 
selective upregulation of neuronal and/or endothelial TRPV1 in sepsis, sufficient to overcome 
the constrictive activity of smooth muscle TRPV1. Consistent with this hypothesis, increased 
plasma levels of SP and CGRP have been observed in both patients with sepsis and animal 
models of sepsis (Joyce et al., 1990, Beer et al., 2002), and increased TRPV1 and CGRP 
immunoreactivity has been observed in tongue tissue and mesenteric perivascular nerves, 
respectively, after 6 h of LPS treatment in rats (Orliac et al., 2007). It is possible therefore, that 
TRPV1-mediated vasodilatation is a protective mechanism in sepsis that helps to maintain 
tissue perfusion. Whether this is mediated through purely neuronal mechanisms, however, or 
whether endothelial TRPV1 is also involved, remains to be determined.  
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Figure 32. Proposed mechanisms of TRPV1-mediated vasoactive responses in the mesenteric bed 
under basal and septic conditions. Under basal conditions, smooth muscle-mediated constriction 
appears to dominate. Under inflammatory conditions, increased sensory nerve expression, previously 
shown to occur as early as 6 h after LPS administration in mice (Orliac et al., 2007), increased sensory 
nerve activation by protons, and increased endothelial activation through paracrine stimulation with 
anandamide may tip the balance in favour of TRPV1-mediated vasodilatation. 
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 Concluding remarks 4.5.4
Overall the data obtained in this study are consistent with a protective role for TRPV1 in sepsis 
that may relate to local vasodilatation and the maintenance of regional perfusion. Of particular 
note is the observation, consistent with previous reports, that visceral perfusion is more 
severely compromised in LPS-treated TRPV1 KO mice, despite previous reports of equivalent 
haemodynamic performance between septic WT and KO mice (Wang and Wang, 2013). These 
data strongly support the results outlined in Chapter 3, showing poor correlation between 
haemodynamic indices and both microvascular perfusion and markers of organ dysfunction. 
Whether the regional protective effects of TRPV1 are mediated through neuronal mechanisms, 
however, or whether TRPV1 contributes to vasoregulation directly, remains unclear. 
Irrespective of the mechanisms involved, the age-dependent effects of TRPV1 activity, as well 
as its divergent roles in different models of sepsis (Wanner et al., 2012), severely limit the 
potential for clinical translatability of this research. The pharmacological modulation of TRPV1 
activity as a therapeutic strategy is further complicated by its expression in sensory neurons, 
where channel activation is associated with significant pain. Consequently, while TPRV1 
appears to play a role in sepsis pathogenesis, it may not represent a viable clinical target.
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CHAPTER 5 | IN VITRO CHARACTERISATION 
OF VASCULAR TRPV1 AND TRPV4 
5.1 Introduction 
Numerous published reports (Clark et al., 2007, Wang et al., 2008a) and data presented in 
Chapter 4 suggest that TRPV1 may confer cardiovascular protection in sepsis. While the 
neurogenic effects of TRPV1 activation on vascular function are well established, however, the 
contribution of vascular TRPV1 expression to these responses is unknown. There has been 
much recent evidence suggesting that TRPV1 may also contribute to vascular function through 
non-neuronal mechanisms, though studies reporting its expression in endothelial and smooth 
muscle tissue have often raised contention. 
5.1.1 Functional expression of TRPV1 in the endothelium 
Functional expression of TRPV1 in the endothelium was initially inferred from recordings of 
capsaicin-induced Ca2+ influx in primary cultures of human cerebral artery endothelial cells 
(ECs) (Golech et al., 2004), although biochemical analysis of TRPV1 mRNA levels has produced 
conflicting results. TRPV1 has been detected in human pulmonary artery ECs (Fantozzi et al., 
2003) and murine aortic ECs (Yang et al., 2010b), as well as in the endothelium of intact murine 
mesenteric arteries (Yang et al., 2010b) and porcine coronary arteries (Bratz et al., 2008), 
though other investigators failed to detect TRPV1 mRNA in the endothelium of rat middle 
cerebral arteries (Marrelli et al., 2007). Whether discrepancies are due to changes in 
experimental conditions, or species or tissue differences, is unclear. 
The vascular endothelium produces a number of vasoactive substances, of which the main 
vasodilatory mediators are nitric oxide (NO), prostacyclin (PGI2) and endothelium-derived 
hyperpolarising factor (EDHF). The identity of the latter is debated and may vary between 
vascular beds, though K+ efflux through endothelial intermediate K+ channels and large 
conductance K+ channels is thought to be an important contributor. Activation of these 
vasodilatory mediators is highly dependent on Ca2+, and it is thought that influx of Ca2+ through 
endothelial TRPV1 is sufficient to stimulate each of these pathways (Baylie and Brayden, 2011). 
Correspondingly, activation of TRPV1 in the vascular endothelium has been reported to cause 
vasorelaxation in a number of studies (Baylie and Brayden, 2011, Bratz et al., 2008, Hoi et al., 
2007, Kark et al., 2008, Yang et al., 2010a). 
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Kark and colleagues studied this effect using a preparation of rat skeletal muscle arteries, in 
which perivascular innervation is absent, allowing delineation of functional vascular TRPV1 
expression without contamination from neuronal input (Kark et al., 2008). Administration of 
low-dose capsaicin (10 nM) produced an endothelium-dependent vasorelaxation that was 
abolished by the endothelial nitric oxide synthase (eNOS) inhibitor N ω-nitro-L-arginine methyl 
ester (L-NAME) as well as by removal of the endothelium itself, suggesting that activation of 
endothelial TRPV1 is capable of causing NO-dependent vasodilatation (Kark et al., 2008). 
Conversely, at higher concentrations (0.1–1 µM), capsaicin caused endothelium-independent 
vasoconstriction, that was attributed to functional expression of TRPV1 in vascular smooth 
muscle cells (VSMCs) (Kark et al., 2008). 
TRPV1-mediated endothelium-dependent vasodilatation was also demonstrated in porcine 
coronary arteries, where capsaicin caused a dose-dependent vasorelaxation, and at 100 µM 
induced cation influx in freshly isolated ECs (Bratz et al., 2008). This effect was abolished in 
endothelium-denuded rings and in the presence of the selective TRPV1 antagonist 
capsazepine. Furthermore, L-NAME, iberiotoxin (a blocker of large conductance K+ channels) 
and tetraethylammonium (TEA; a general K+ channel blocker) significantly reduced the 
vasodilatory response to capsaicin, though the effect was not completely abolished. Whether 
this was due to non-specific effects of capsaicin, or to endothelium-independent mechanisms 
was not investigated in this study, though it is clear that both NO and K+ channel activation 
contribute to capsaicin-induced vasorelaxation (Bratz et al., 2008).  
It should be noted, however, that at concentrations exceeding 10 µM, capsaicin can produce 
TRPV1-independent effects, and can alter the function of a number of structurally unrelated 
proteins; furthermore, many of these are also modulated by the antagonist capsazepine 
(Lundbaek et al., 2005). Moreover, high concentrations of capsaicin have been shown to cause 
membrane perturbations (Aranda et al., 1995, Meddings et al., 1991), which could induce Ca2+ 
influx independently of TRPV1.  
Other studies also support a role for TRPV1-mediated endothelial activation, however. VSN16, 
a synthetic cannabinoid-like compound, was shown to cause endothelium-dependent 
capsazepine-sensitive relaxation of rat mesenteric arteries (Hoi et al., 2007). Furthermore, in a 
chronically denervated mesenteric vascular bed, perfusion of nanomolar concentrations of 
capsaicin and anandamide led to an increase in perfusate NO levels, which was abolished by 
capsazepine and L-NAME (Poblete et al., 2005). The selective TRPV1 antagonist SB366791 also 
inhibited endothelium-dependent NO release by capsaicin and anandamide in non-denervated 
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arteries, indicating a specific role for TRPV1 in this response. Although anandamide has also 
been shown to activate TRPV4, (Watanabe et al., 2003b) this pathway was ruled out as a 
mechanism for anandamide-induced vasodilatation in this bed, following the observation that 
an alternative TRPV4 agonist, 4α-PDD, failed to elicit significant NO production (Poblete et al., 
2005). 
A more recent investigation by Yang and colleagues, using a combination of in vitro and in vivo 
techniques, has provided further evidence of functional TRPV1 expression in the vascular 
endothelium. The authors demonstrated a capsaicin-induced Ca2+ influx in primary cultures of 
mouse aortic ECs, which increased phosphorylation and activation of protein kinase A (PKA) 
and eNOS (Yang et al., 2010b). In addition to causing vasodilatation directly, through 
phosphorylation and inhibition of myosin light chain kinase (Conti and Adelstein, 1980), PKA 
also promotes increased NO production through phosphorylation of eNOS, enhancing smooth 
muscle relaxation (Michell et al., 2001). Capsaicin-induced endothelium-dependent NO 
production and vasodilatation in isolated mouse mesenteric arteries were significantly 
attenuated in TRPV1 knockout (KO) animals. Furthermore, this study demonstrated for the 
first time that chronic dietary administration of capsaicin can attenuate the haemodynamic 
phenotype of spontaneously hypertensive rats (SHRs), and improve their endothelial function, 
evidenced by increased vasodilatory responses to acetylcholine (ACh) (Yang et al., 2010b). 
Improved ACh-mediated vasorelaxation was not observed in capsaicin-fed TRPV1 KO mice and 
was similarly inhibited by L-NAME. Moreover, increased levels of phosphorylated PKA, 
phosphorylated eNOS and NO, observed in wildtype (WT) mice, were not found in KO 
counterparts.  
Given that TRPV1 shows broad tissue distribution, it is unclear whether endothelial TRPV1 is 
truly responsible for the anti-hypertensive effects of capsaicin in vivo. Furthermore, given that 
chronic exposure of the channel to capsaicin can both desensitise and downregulate the 
channel, and defunctionalise sensory nerve terminals, it is not clear whether dietary 
administration of capsaicin would induce chronic channel activation or inhibition of channel 
function. However, the in vitro data published by Yang and colleagues. from isolated ECs and 
mesenteric arteries provide strong evidence that TRPV1 is present and functional within the 
endothelium, and that activation leads to Ca2+ influx, PKA activation, NO production and 
smooth muscle relaxation (Yang et al., 2010b). These results, coupled with the separate 
observation that neonatal sensory denervation does not inhibit capsaicin-induced NO release 
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(Rocha and Bendhack, 2009), are strongly indicative of a non-neuronal mechanism of TRPV1-
mediated vasodilatation.  
In addition to stimulating increased NO production, TRPV1 may also elicit vasorelaxation 
through alternative pathways. A TRPV1-mediated increase in endothelium-derived CGRP 
expression and secretion has been shown to occur in human umbilical vein ECs (HUVECs) (Luo 
et al., 2008), as well as in rat mesenteric and aortic ECs (Ye et al., 2007), though whether this 
pathway represents a physiological mechanism for arterial tone regulation is not clear. 
Alternatively, activation of TRPV1 in human cerebral artery ECs by 2-arachidonoyl-glycerol (2-
AG) has been shown to cause vasorelaxation through the phosphorylation of vasodilator-
stimulated phosphoprotein (VASP) (Golech et al., 2004). It is possible that activation of 
endothelial TRPV1 stimulates a Ca2+-dependent phosphorylation of PKA and/or PKG [consistent 
with previous observations (Yang et al., 2010b)], which mediate vasodilatation through 
phosphorylation of VASP, a known substrate of PKA and PKG (Golech et al., 2004). 
5.1.2 Functional expression of TRPV1 in vascular smooth muscle 
While activation of endothelial TRPV1 has been associated with vascular relaxation, there have 
been several reports of capsaicin-induced vasoconstriction that may represent functional 
expression of TRPV1 in VSMCs. Investigations of this hypothesis, however, have produced 
somewhat conflicting results. Yang and colleagues have demonstrated the presence of TRPV1 
mRNA in endothelium-denuded rat aorta and intralobal arteries (Yang et al., 2010b), which the 
authors interpreted as an indication of VSMC expression, though contamination by 
perivascular nerves or residual ECs was not ruled out. Furthermore, although other 
investigators have inferred protein expression of TRPV1 in vascular smooth muscle from 
functional assays, these studies have been limited by a lack of biochemical data (Kark et al., 
2008, Bratz et al., 2008) or by the use of cultured and immortalised cell lines (Wang et al., 
2008b). One group failed to detect any TRPV1 expression in rat cerebral artery smooth muscle 
(Marrelli et al., 2007). 
To date, four groups have published robust evidence of functional TRPV1 expression in VSMCs. 
Using an isolated rat hind limb preparation, Kark and colleagues demonstrated increased 
vascular resistance and decreased skeletal muscle perfusion in response to capsaicin, that was 
unaffected by sensory denervation (Kark et al., 2008). Furthermore, in isolated rat skeletal 
muscle arterioles, which are devoid of sensory innervation, higher doses of capsaicin (0.1–1 
µM) elicited endothelium-independent vasoconstriction (Kark et al., 2008). This 
vasoconstriction was later found to be absent in arterioles treated with the selective TRPV1 
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antagonist AMG-9810 or isolated from TRPV1 KO mice, and was additionally shown to occur in 
parallel with Ca2+ influx into the arteriolar wall through simultaneous measurement of vessel 
diameter and intracellular Ca2+ levels (Czikora et al., 2012). Correspondingly, expression of 
TRPV1 in rat aortic smooth muscle was detected both by qRT-PCR and immunohistochemical 
analysis (Kark et al., 2008), and was inferred from observations of significant capsaicin-induced 
Ca2+ influx in isolated canine coronary artery SMCs (Czikora et al., 2012).  
Cavanaugh et al. used gene targeting to modify the TRPV1 genetic locus, generating reporter 
mice that produce a highly sensitive read-out of TRPV1 expression (Cavanaugh et al., 2011). In 
contrast to the observations of Kark and colleagues, this group failed to detect any TRPV1 
protein in the murine aorta, though TRPV1 was detected in VSMCs of a number of 
thermoregulatory tissues, including the cremaster muscle, the dura, the tongue, the trachea, 
the ear and the skin (Cavanaugh et al., 2011). In these tissues, VSMC TRPV1 expression was 
restricted to small- to medium-diameter vessels, postulated to represent small resistance 
arteries and arterioles, and was substantially reduced after RTX-induced degradation of TRPV1-
positive cells. Confirmation of functional TRPV1 expression was achieved by live-cell calcium 
imaging of isolated and denervated ear arterioles. Importantly, capsaicin failed to produce 
either Ca2+ influx or vasoconstriction in isolated arterioles from TRPV1 KO mice (Cavanaugh et 
al., 2011). 
In 2011, Ma and colleagues reported TRPV1 mRNA and protein expression in murine aorta and 
freshly isolated aortic VSMCs by a variety of biochemical techniques, confirming functional 
expression by Fura-2-based calcium imaging (Ma et al., 2011). More recently, Martin et al. 
demonstrated TRPV1 mRNA and protein expression in rat intrapulmonary arteries, as well as 
Ca2+ influx in isolated pulmonary artery SMC, in response to 10 µM capsaicin (Martin et al., 
2012). In this study, both TRPV1 and TRPV4 were suggested to contribute directly to SMC 
migration (Martin et al., 2012). 
Despite discrepancies between different studies, that may represent species differences or 
insufficiently selective antibodies or agonist concentrations, collectively these reports provide 
compelling evidence that TRPV1 is present and functional in VSMCs, though perhaps in a 
regionally restricted fashion. It is possible that activation of TRPV1 on VSMCs could 
counterbalance the effects of neuronal TRPV1 activation by physiological agonists, such as 
heat and protons, which supports the observations of capsaicin-induced vasoconstriction, 
reported previously (Scotland et al., 2004). 
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5.1.3 A role for TRPV4 in vascular regulation 
While this study was originally designed to investigate the role of TRPV1 in vascular regulation, 
we were also aware of an increasing research interest in other members of the TRP vanilloid 
subfamily, most notably TRPV4. TRPV4 expression in both endothelial and smooth muscle 
tissues is well established (Baylie and Brayden, 2011), and recent reports linking excessive 
activation of TRPV4 to profound hypotension, endothelial failure and circulatory collapse 
(Willette et al., 2008, Sonkusare et al., 2012) suggest that it may play a role in the 
haemodynamic dysfunction that characterises septic shock. In light of this evidence, we have 
additionally characterised endothelial TRPV4 activity in basal and inflammatory conditions in 
vitro, with a view to extending this research in vivo, as described in Chapter 6. The molecular 
basis of TRPV4-mediated vasoactivity is also described more extensively in Chapter 6. 
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5.1.4 Hypotheses 
Based on previous reports, as well as our own data supporting a vasculo-protective role for 
TRPV1 in sepsis, it was hypothesised that TRPV1 may mediate this protection through activity 
in the vascular system. Since peripheral vasodilatation may confer protection against perfusion 
impairment in sepsis, we hypothesised that TRPV1 may be expressed in vascular tissue, and 
that alterations in its expression and/or activity in sepsis may contribute to the maintenance of 
perfusion in regional beds.  
In light of recent reports linking excessive TRPV4 activation to profound hypotension and 
circulatory collapse (key features of sepsis) we additionally hypothesised that vascular TRPV4 
activity may be altered under inflammatory conditions.  
5.1.5 Aims 
Based on the hypotheses outlined above, and the limitations of previous studies of vascular 
TRPV1 expression, our aims were as follows: 
1) To address the controversy regarding vascular TRPV1 expression in published 
literature, and to determine whether TRPV1 is expressed in vascular tissues and cells 
from different species  
2) To confirm the expression of TRPV4 in vascular cells and tissues 
3) To characterise TRPV1 and TRPV4 activity in isolated vascular cell types under basal 
and inflammatory conditions using fluorometric calcium imaging techniques 
4) To characterise TRPV1 and TRPV4 activity in macrophages, based on previous reports 
of TRPV1- and TRPV4-induced macrophage-mediated inflammatory function 
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5.2 Methods 
5.2.1 Materials 
A list of materials used in this study, and details of their origin, are provided in Table 9. 
Material Manufacturer Catalogue No. 
Capsaicin Sigma-Aldrich M2028 
GSK1016790A Sigma-Aldrich G0798 




DMEM (4.5 g/L glucose) PAA Laboratories E15-009 
DMEM (1 g/L glucose) PAA Laboratories E15-005 
Endothelial cell medium PAA Laboratories U15-002 
HBSS (with Ca2+ and Mg2+) Sigma-Aldrich 55037C 
Ionomycin Sigma-Aldrich I9657 
Adenosine triphosphate Sigma-Aldrich A2383 
Thiozolyl blue tetrazolium 
bromide 
Sigma-Aldrich M5655 
Table 9. Materials used in study. DMEM: Dulbecco’s modified Eagle’s medium, HBSS: Hank’s balanced 
salt solution 
 
170  |  I N  V I T R O  C H A R A C T E R I S A T I O N  O F  V A S C U L A R  T R P V 1  
A N D  T R P V 4  
5.2.2 Cell isolation and culture 
Primary bovine aortic endothelial cells, murine pulmonary endothelial cells and murine aortic 
smooth muscle cells, immortalised murine skin endothelioma cells and murine bone marrow-
derived macrophages were cultured as described in section 2.8.  
5.2.3 Measurement of vascular TRPV1 and TRPV4 expression 
Non-quantitative assessment of TRPV1 and TRPV4 mRNA expression in vascular cells and 
isolated murine aortae was performed as described in section 2.9. Vascular TRPV1 expression 
was also evaluated by Western immunoblotting, as described in section 2.7. A list of antibodies 
used in provided in Table 10.  
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Antibody Manufacturer Catalogue 
No 
Species Vehicle Working 
dilution 
Primary antibodies 
Anti-TRPV1 Alomone Labs ACC-030 Rabbit 
1% BSA, 0.05% 
NaN3 in PBS 
1 : 200 
Anti-TRPV1 Abcam Ab45759 Mouse 
1% BSA, 0.05% 
NaN3 in PBS 
1 : 200 
Anti-TRPV1 





1% BSA, 0.05% 
NaN3 in PBS 
1 : 500 
Anti-TRPV1 Sigma V2764 Rabbit 
1% BSA, 0.05% 
NaN3 in PBS 
1 : 500 
Anti-β-
actin 
Sigma A2228 Mouse 
1% non-fat milk in 
TBS-T 
1 : 2000 
Secondary antibodies 
Anti-rabbit Cell Signaling 7074  
1% non-fat milk in 
TBS-T 
1 : 2000 
Anti-
mouse 
Sigma A4416  
1% non-fat milk in 
TBS-T 
1 : 5000 
 
Table 10. Antibodies used in Western blot analysis. Ab45759 (Abcam), A2228 (Sigma) and the anti-
TRPV1 antibody donated by Prof Caterina were monoclonal; all others were polyclonal. TBS-T: Tris-
buffered saline containing 0.1% Tween-20.  
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5.2.4 Measurement of vascular TRPV1 and TRPV4 activity 
5.2.4.1 Calcium fluorometry 
As both TRPV1 and TRPV4 are cation channels highly permeable to Ca2+, a fluorescent Ca2+ 
indicator was used to investigate the functional expression of these two receptors in 
endothelial cells. In the wake of pioneering work by Nobel laureate Professor Roger Tsien in 
the 1980s, the development of highly accurate fluorescent calcium indicator dyes has 
progressed steadily. These dyes are generally based on a Ca2+-sensitive construct coupled to 
fluorophore, which upon binding to Ca2+ ions undergoes a conformational change, eliciting a 
fluorescent signal.  
More recently, Ca2+ dyes have been engineered as acetoxymethyl (AM) esters, which allow 
loading of relatively hydrophilic dyes across hydrophobic cellular membranes by passive 
diffusion, negating the need for microinjection or electroporation previously required (Paredes 
et al., 2008). Following diffusion across the plasma membrane, AM groups are cleaved by 
intracellular esterases, effectively trapping the indicator inside the cell.  
Vascular TRPV1 and TRPV4 activity was assessed by Fura-2/AM either in a microscope-based 
single cell imaging set-up, or by a microplate-based method, as described in section 2.11. Fura-
2/AM is one of the ratiometric indicators, which shift the peak wavelength of their excitation 
or emission curve upon binding Ca2+ ions. Specifically, Fura-2 is a dual-excitation dye: peak 
absorbance shifts from 380 nm in the Ca2+-free state, to 340 nm following Ca2+ binding (Fig. 
33). Peak emission occurs at 510 nm for both excitation wavelengths (Paredes et al., 2008). A 
significant advantage of using ratiometric dyes is that they correct for artefacts associated with 
photobleaching, changes in culture volume, uneven dye loading, leakage or extrusion.  
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Figure 33. Excitation spectra for Fura-2 fluorescence recorded along the 510 nm emission wavelength 
in high [Ca2+] and zero [Ca2+] solutions. Peak fluorescence was recorded at 376 nm and 339 nm, 
respectively. Figure adapted from Palmer and Moore (Palmer and Moore, 2000). 
 
5.2.4.2 Experimental set-up 
All Ca2+-fluorometry was conducted using either a high-throughput microplate-based imaging 
system, or a microscope-based technique adapted for live imaging of single cells, as described 
in section 2.11. Briefly, cells were plated either into 96-well plates or onto glass coverslips, and 
allowed to reach approximately 80% confluence. Culture medium was then replaced with 
Hank’s balanced salt solution (HBSS; with 10 mM glucose, 10 mM HEPES, pH 7.4) containing 
2.5 µM Fura-2/AM and 2 mM probenecid, and cells were incubated at 37°C for 1 h.  
Fluorescence was then recorded over a baseline, and following the addition of agonists.  
5.2.4.3 Assay validation 
We aimed to probe TRPV1 and TRPV4 channel activity in endothelial cells using the selective 
agonists, capsaicin and GSK1016790A, respectively. While the latter is consistently 
administered in a vehicle of 1-2% DMSO (Alexander et al., 2013, Willette et al., 2008, Pankey et 
al., 2014), capsaicin preparations were found to vary between previous studies. In order to 
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determine the optimal preparation for in vitro capsaicin delivery in this study, a range of 
capsaicin concentrations was dissolved in three different commonly used vehicles, and applied 
to HEK cells stably expressing TRPV1 (HEK-TRPV1; kindly donated by Dr Andy Grant). 
Fluorescence was read on a microplate imaging system, as described in section 2.11.1, and 
capsaicin was added, after 20-s baseline recording, by an automated pipettor system. 
Capsaicin in both 2% DMSO and 2% ethanol/2% Tween-80 caused a concentration-dependent 
increase in relative fluorescence (Fig. 34a and 34c, respectively). Capsaicin in 2% ethanol, on 
the other hand, did not appear to induce concentration-dependent calcium influx in HEK-
TRPV1 cells, suggesting insufficient drug solubility (Fig. 34b). Unfortunately, maximum 
response and EC50 values for the different treatments were not calculated, as some curves 
were not considered to have reached maximum response.  
We additionally sought to assess drug selectivity at higher concentrations using untransfected 
HEK cells and an identical microplate-based system. Neither capsaicin in 2% DMSO nor 
capsaicin in 2% ethanol produced any response in untransfected cells at concentrations of 10 
µM and below (Fig. 35a and 35b, respectively). Similarly, the TRPV4 agonist GSK1016790A 
produced no response in HEK cells at 10 µM and below (Fig. 35d). Capsaicin dissolved in 2% 
ethanol/2% Tween-80, on the other hand, produced a small and relatively consistent calcium 
influx at all concentrations, suggesting a non-specific vehicle-mediated effect (Fig. 35c). In light 
of these results, 2% DMSO was considered the optimal vehicle for in vitro capsaicin 
administration, and was used in all further experiments.  
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Figure 34. Assessment of capsaicin solubility in three different vehicles. Concentration-response curves 
were generated in HEK cells stably transfected with rat TRPV1, treated with increasing doses of capsaicin 
(0.1 – 2 µM) dissolved in 3 different vehicles: (a) 2% DMSO, (b), 2% ethanol or (c) 2% ethanol + 2% 
Tween-80. Left hand panel: representative traces of ratiometric emission intensity over time. Drugs 
were added after 20 s, denoted by the dotted line. Right hand panel: corresponding non-linear 
regression curves generated for each treatment. Data are presented as mean response over 3 wells for 
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Figure 35. Assessment of drug selectivity in untransfected HEK cells. Concentration-response curves 
were generated in untransfected HEK cells treated with increasing doses of capsaicin (1–10 µM; Cap) 
dissolved in 3 different vehicles: (a) 2% DMSO; (b) 2% ethanol; or (c) 2% ethanol + 2% Tween-80, or with 
GSK1016790A  (1–10 µM; GSK) in 2% DMSO (d). Left hand panel: representative traces of ratiometric 
emission intensity over time. Drugs were added after 20 s, as denoted by the dotted line. Right hand 
panel: corresponding non-linear regression curves. Data are presented as mean response over 3 wells 
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5.2.5 Sequencing of TRPV1 KO cDNA 
RNA was extracted from lungs of TRPV1 KO mice and reverse-transcribed into cDNA, as 
described in section 2.9.1. PCR amplification of cDNA was performed using the TRPV1 KO 
forward primer and TRPV1 common reverse primer, as described in section 2.1.3. PCR 
products were separated on a 1% agarose gel by electrophoresis (80 V, 50 min). Bands were 
excised using a sterile scalpel, and DNA was extracted using QIAquick gel extraction kit 
(Qiagen, 28704), as per manufacturer’s instructions. DNA was eluted in elution buffer (10 mM 
Tris-Cl, pH 8.5), and sequenced using the following primers:  
a. Neomycin forward: 5’-TGG ATG TGG AAT GTG TGC GAG-3 
b. TRPV1 C-terminus reverse: 5’-TCC TCA TGC ACT TCA GGA AA-3’ 
Sequencing was performed at the Wolfson Institute for Biomedical Research, University 
College London.  
5.2.6 Assessment of cell viability by MTT assay 
Viability of bovine aortic endothelial cells (bAEC) following exposure to increasing 
concentrations of LPS over 24 h was assessed by MTT assay. This colorimetric assay was 
developed in 1983 and is based on the tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide], which is reduced to dark blue formazan by the mitochondria of 
living cells, but not of dead cells or erythrocytes (Mosmann, 1983). Dissolution of this coloured 
crystalline product produces a homogenous solution that is suitable for spectrophotometric 
analysis.  
bAEC were plated in 96-well plates and allowed to reach 80% confluency. They were then 
treated with increasing concentrations of LPS (1–100 ng/mL) in the presence of either TRPV4 
antagonist HC-067047 (10 µM) or vehicle (2% DMSO in DMEM). After 24 h, 10 µL MTT (in 
saline) was then added to each well (final concentration: 5 mg/mL), and cells were incubated 
at 37°C for 4 h. The formazan product was solubilised in DMSO, and absorbance was read at 
560 nm in a FlexStation® 3 Microplate Reader (Molecular Devices, Sunnydale, CA). 
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5.2.7 Measurement of macrophage TRPV1 and TRPV4 activity 
Bone marrow-derived macrophages (BMDM) were isolated from the femur bone of TRPV4 WT 
and KO mice, and were plated at a density of 6 x 105/well in eight-chamber culture slides (BD 
Falcon, 354118). 1-µm fluorescent latex beads (1:1000; 5 µl/well; Sigma-Aldrich, L2778) were 
added to cells in the presence or absence of LPS (100 ng/ml) with either GSK1016790A (100 
nM) or vehicle (2% DMSO). After 1 h incubation at 37°C, extracellular beads were removed by 
washing (3 x phosphate buffered saline; PBS), and cells were fixed in 4% paraformaldehyde for 
10 min at RT. Wells were then washed again (3 x PBS), the chamber walls were removed, and 
10 µL PBS was pipetted into the centre of each chamber. A glass coverslip was placed over the 
slide and sealed with varnish. A fluorescent microscope was then used to capture an image 
from the centre of each well, and fluorescence was quantified using ImageJ software (National 
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5.3 Results 
5.3.1 TRPV1 and TRPV4 mRNA is expressed in vascular endothelium 
Total RNA was isolated from murine aortae and endothelial cells from three different species 
and was reverse-transcribed to cDNA. TRPV1 and TRPV4 cDNA was then amplified by PCR 
thermocycling with specific primers. TRPV1 and TRPV4 mRNA was detected in murine aortic 
tissue (Fig. 36a) and all three endothelial cell types: immortalised murine skin endothelioma 
cells (sEnd1), primary human umbilical vein endothelial cells (HUVEC) and bovine aortic 
endothelial cells (bAEC; Fig. 36b). In bAEC, expression of both genes was still preserved at 
passage 7, consistent with a previous report demonstrating a persistent endothelial phenotype 
for up to 35 population doublings (Augustin-Voss et al., 1993). 
 
Figure 36. Agarose gels visualised under UV illumination showing products of PCR amplification of 
TRPV1 and TRPV4 cDNA. (a) Expression of murine TRPV1 (mTRPV1) and TRPV4 (mTRPV4) mRNA in 
aortic lysates from 4 TRPV1 WT mice and one TRPV1 KO mouse. (b) Expression of murine, human (h) 
and bovine (b) TRPV1 and TRPV4 in mouse skin endothelioma cells (sEnd1), human umbillical vein 
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5.3.2 TRPV1 protein expression is not detectable with commercially available 
antibodies 
Whereas functional endothelial expression of TRPV4 is now well established (Sonkusare et al., 
2012), the role and indeed the presence of TRPV1 in these cells remains contentious. Although 
numerous reports of endothelial TRPV1 expression have been published to date, studies have 
typically relied on inferences based on mRNA data or on unvalidated antibodies, often used in 
the absence of appropriate positive and negative controls. Despite observing clear TRPV1 
mRNA expression in aortic and endothelial lysates, we were unable to demonstrate TRPV1 
protein expression by traditional antibody-recognition methods. Protein samples from TRPV1 
WT and KO mice were size-separated by SDS-PAGE, and transferred to PVDF membranes for 
incubation with an anti-TRPV1 antibody (Alomone, ACC-030), previously suggested to bind 
selectively to TRPV1 WT protein (Yang et al., 2010b). In this instance, however, a single band of 
approximately 80 kDa was observed in aortic and dorsal root ganglia (DRG) samples from both 
WT and KO mice (Fig. 37). This was repeated using samples from further WT and KO mice (n = 
12) and in each case an identical positive band was observed in both WT and KO samples, 
indicative of non-specific binding.  
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Figure 37. Representative immunoblots of TRPV1 protein expression in murine tissues. (a) and (b) 
Immunopositive bands in aortic and DRG lysates, respectively, from TRPV1 WT and KO mice, probed 
with ACC-030 anti-TRPV1 antibody (Alomone; predicted molecular weight 95 kDa). β-actin expression 
was used as loading control (predicted molecular weight 42 kDa). The presence of immunoreactive 
bands in TRPV1 KO samples indicates that these bands are likely false positives, and suggests that this 
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5.3.2.1 Sequencing of TRPV1 KO cDNA 
The ACC-030 anti-TRPV1 antibody used for immunoblotting was raised against the extreme C-
terminus of TRPV1. Given that generation of the mutant TRPV1 construct involves replacement 
of transmembrane domains 5 and 6 with a neomycin cassette, rather than deletion of the 
entire C-terminus (Caterina et al., 2000), cDNA isolated from the lungs of TRPV1 KO mice was 
sequenced, in order to determine whether the C-terminus of the mutant protein is still 
translated. TRPV1 KO lung cDNA was isolated, and a region spanning the neomycin cassette 
and the C-terminus of TRPV1 was amplified by PCR and sequenced. The C-terminal end of the 
neomycin cassette was found to contain a TAG stop codon, precluding the possibility of C-
terminal translation in mutant TRPV1 (Fig. 38), and invalidating the use of the ACC-030 
antibody for specific identification of TRPV1.  
 
Figure 38. Sequencing data from mutant TRPV1 lung cDNA. The sequence obtained from PCR 
amplification of mutant cDNA using a forward primer binding in the inserted neomycin cassette and a 
reverse primer binding in the C-terminus of TRPV1 is shown in the box. Nucleotides highlighted in blue 
represent the neomycin cassette; those in red correspond to WT TRPV1 sequence. Alignment of this 
sequence with that of WT TRPV1, shown on the left, demonstrates transcription of WT DNA 
downstream of the inserted neomycin cassette (NEO). Overlapping sequence is highlighted in red, and 
the binding site of the C-terminal reverse primer in exon 13 is underlined. The TAG stop codon 
(highlighted in yellow) in the C-terminus of the neomycin cassette suggests that TRPV1 C-terminus 
mRNA is not translated.  
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5.3.2.2  Characterisation of other TRPV1 antibodies 
In addition to ACC-030 (Alomone Labs), a number of other antibodies were tested, each also 
producing an immunoreactive band in TRPV1 KO tissue, and often non-specific bands of 
incorrect molecular weight. Representative immunoblots of TRPV1 WT and KO tissue using 
various commercially available and donated anti-TRPV1 antibodies are shown in Fig. 39. A 
second batch of the original ACC-030 antibody was also tested. The details of all antibodies 
used are provided in Table 10. 
 
 
Figure 39. Representative immunoblots of dorsal root ganglia (DRG) lysates from TRPV1 WT and KO 
mice, using a number of different anti-TRPV1 antibodies. (a) ab4579, Abcam, Cambridge, UK. (b) ACC-
030 Batch 2, Alomone Labs, Israel. (c) V2764, Sigma-Aldrich, UK. (d) anti-TRPV1 antibody synthesised in-
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5.3.3 TRPV4, but not TRPV1, is active in vascular cells under basal conditions 
Despite a lack of sufficiently selective antibodies for TRPV1, selective agonists for both TRPV1 
and TRPV4 are commercially available. Consequently, we aimed to characterise TRPV1 and 
TRPV4 protein activity in cultured vascular cells, using selective agonists and the fluorescent 
Ca2+ dye Fura-2/AM to quantify changes in intracellular Ca2+ levels in response to channel 
activation. Given that microplate-based fluorometry provides an average reading across the 
entire surface of a well, a signal may remain undetected if only a small number of cells respond 
to a particular stimulus. In order to gain the most detailed picture of TRPV1 and TRPV4 activity 
in isolated vascular cells, therefore, we opted initially to conduct single-cell live imaging, using 
a fluorescent microscope-based system.  
Freshly isolated murine pulmonary arterial endothelial cells (mPAEC) and murine aortic 
smooth muscle cells (mASMC) loaded with Fura-2/AM were perfused with HBSS for 30 sec in 
order to record basal intracellular calcium levels. Cells were then sequentially perfused with 
capsaicin (1 µM), GSK1016790A (GSK; 1 µM) and positive control (either 1 µM ionomycin or 
100 µM adenosine triphosphate; ATP), with intermittent washing stages. A fluorescence ratio 
change of 0.1 or greater was deemed responsive to agonist stimulation (Alexander et al., 2013) 
and any cells non-responsive to positive control were excluded from analysis. Capsaicin did not 
appear to elicit any response in mPAEC (Fig. 40a & c), or mASMC (Fig. 40b & d), though cells 
responded robustly to TRPV4 activation, with approximately 60% response rate to GSK in both 
cell types (Fig. 40). The mean ratio change following TRPV4 activation in mPAEC was 0.2974 ± 
0.053 (Fig. 40g & h). 
Similarly, no evidence of capsaicin responsiveness was observed in primary endothelial cells 
isolated from bovine aortae: 2.65% of cells responded to capsaicin application, compared with 
71.73% of cells responding to GSK (Fig. 41).  
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Figure 40. Basal TRPV1 and TRPV4 activity in murine vascular cells. (a) and (b) Representative 
fluorescent images of mPAEC and mASMC, respectively, at baseline [B], and after stimulation with 1 µM 
capsaicin [C], 1 µM GSK1016790A [G] and 1 µM ionomycin [I]. (c) and (d) Representative traces of 
ratiometric emission intensity following different treatments in mPAEC and mASMC, respectively (C = 1 
µM capsaicin; W = wash; G = 1 µM GSK1016790A; I = 1 µM ionomycin). (e) and (f) Percentage of mPAEC 
and mASMC, respectively, responding to 1 µM capsaicin (Cap) and 1 µM GSK1016790A (GSK). Data 
represent mean percentage of responders over 6 and 5 coverslips, respectively, ± SEM (5 – 60 cells per 
coverslip). (g) and (h) Mean ratio change of responding mPAEC and mASMC ± SEM across 6 and 5 
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Figure 41. Basal TRPV1 and TRPV4 activity in bovine endothelial cells. (a) Percentage of bAEC 
responding to 1 µM capsaicin (Cap) and 1 µM GSK1016790A (GSK). Data represent mean percentage of 
responders ± SEM over 4 coverslips (5 – 60 cells per coverslip). (b) Mean ratio change ± SEM of 
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5.3.4 GSK1016790A responses are TRPV4-specific, and are optimal in low-
glucose culture conditions 
This study subsequently aimed to determine that the response to GSK1016790A was indeed 
mediated by TRPV4 channels, using the selective TRPV4 antagonist HC-067047 (Sigma-Aldrich, 
SML0143). Given that a response to GSK1016790A was observed in a large proportion of cells 
(approximately 60% in mPAEC and 70% in bAEC) a high-throughput microplate-based imaging 
system was used for further investigation.  
For previous experiments, cells had been maintained in Dulbecco’s modified Eagle’s medium 
containing 4.5 g/L glucose (equivalent to approximately 25 mM). In 2012, a report was 
published demonstrating significant downregulation of TRPV4 in high-glucose (25 mM) 
conditions (Hills et al., 2012). Consequently, we used the microplate-based imaging system to 
characterise TRPV4 activity in bAEC maintained under three different culture conditions: high-
glucose DMEM (4.5 g/L), low-glucose DMEM (1 g/L), or specialised Endothelial Cell Medium (1 
g/L glucose). 
A concentration-dependent response to GSK1016790A was observed on non-linear regression 
analysis, and the concentration-response curve for each culture condition was shifted towards 
the right following pre-treatment for 10 min with 1 µM HC-067047, indicating competitive 
antagonism (Fig. 42). Maximum response (Emax) to GSK1016790A was roughly equivalent 
across culture conditions, though EC50 was lowest in low-glucose DMEM (Table 11). 
Consequently, low-glucose DMEM was used in all subsequent experiments.   
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Figure 42. TRPV4 activity in bovine aortic endothelial cells under different culture conditions. 
Concentration-response curves were constructed for the TRPV4 agonist GSK1016790A (GSK) in the 
presence or absence of 1 µM HC-067047 (HC; 10 min pre-treatment) in (a) low-glucose DMEM, (b) high-
glucose DMEM and (c) specialised endothelial cell medium (n = 4). (d) Basal Ca
2+
 levels under different 















































































































189  |  I N  V I T R O  C H A R A C T E R I S A T I O N  O F  V A S C U L A R  T R P V 1  A N D  T R P V 4  
 
Table 11. TRPV4 activity in bovine aortic endothelial cells under different culture conditions. Data are presented as mean (95% CI).  
 
 Low-glucose (1 g/mL) High-glucose (4.5 g/mL) Endothelial medium (1 g/mL) 
 Control HC-067047 (1 µM) Control HC-067047 (1 µM) Control HC-067047 (1 µM) 




52.12 nM  
(18.15–149.97 nM) 
1.15 µM 
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5.3.5 LPS may sensitise TRPV4 in endothelial cells 
In order to characterise the changes in TRPV4 activity under inflammatory conditions more 
extensively, we used a high-throughput microplate-based system to monitor the time-and 
concentration-dependent effects of LPS on TRPV4-induced Ca2+ release. Cells were stimulated 
with 100 nM GSK1016790A, as this concentration was found to produce a reliable Ca2+ signal in 
this system. While responses to GSK1016790A were not altered with increasing concentrations 
of LPS, or with increasing exposure time (1–24 h), responses to ATP declined in a 
concentration- and time-dependent manner, indicative of cytotoxicity (Fig. 43a–c). When 
responses to GSK1016790A were normalised to positive control, activity appeared to increase 
with increasing concentrations of LPS, following 24-h exposure (Fig. 43d–f). 24-h exposure to 
LPS was correspondingly found by MTT assay to decrease cell viability in a concentration-
dependent manner, though increased TRPV4 activity did not appear to be involved in this 
cytopathic response: co-incubation of bAEC with 10 µM HC-067047 and LPS did not improve 





















Figure 43. TRPV4 activity in bovine aortic endothelial cells pre-treated with LPS. (a–c) Responses to 100 nM GSK1016790A (GSK) or positive control (100 µM ATP) 
following exposure to increasing concentrations of LPS for 1 h, 6 h or 24 h, respectively. (d–f) Responses to 100 nM GSK1016790A normalised to ATP responses following 
exposure to increasing concentrations of LPS for 1 h, 6 h or 24 h, respectively. Data are presented as mean ± SEM (n = 7). **p<0.01, ***p<0.001 relative to untreated 
controls, 1-way ANOVA + Bonferroni post-hoc test.  
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Figure 44. Bovine aortic endothelial cell viability following 24-h exposure to increasing concentrations 
of LPS. Cell viability was assessed by MTT assay: decreased formazan production, and corresponding 
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5.3.6 TRPV4, but not TRPV1, is expressed in murine bone marrow-derived 
macrophages 
Based on previous reports that TRPV1 expressed in peritoneal macrophages could influence 
sepsis pathogenesis (Fernandes et al., 2012), and that alveolar macrophage-derived TRPV4 
may contribute to lung dysfunction (Alvarez et al., 2006, Hamanaka et al., 2010), we aimed to 
determine whether TRPV1 and TRPV4 were expressed in bone marrow-derived macrophages 
(BMDM) isolated from the femur bones of TRPV4 KO and WT mice. GSK1016790A caused a 
concentration-dependent increase in intracellular Ca2+ levels in WT, but not in TRPV4 KO mice 
(Fig. 45). Capsaicin, on the other hand, did not cause a significant rise in intracellular Ca2+, 
suggesting that TRPV1 is not present in this cell type.  
We also aimed to determine the functional significance of TRPV4 expression in BMDM, by 
measuring phagocytosis of fluorescent latex beads in the presence and absence of LPS and 
GSK1016790A. While LPS increased bead uptake my BMDM, this was not affected by TRPV4 
stimulation (Fig. 46). 
 













Figure 45. Basal TRPV1 and TRPV4 activity in murine BMDM. (a) and (b) Representative fluorescent images of BMDM from TRPV4 WT and KO mice, respectively, at baseline 
[B], and after stimulation with 20 nM GSK1016790A [G20], 100 nM GSK1016790A [G100], 1 µM GSK1016790A [G1000], 1 µM capsaicin [C1000] and 100 µM ATP [ATP]. (c) 
Representative traces of ratiometric emission intensity following different treatments in BMDM. (d) Percentage of BMDM responding to increasing concentrations of 
GSK1016790A (GSK) and 1 µM capsaicin (Cap). Data represent mean percentage of responders over 7 coverslips ± SEM (80–100 cells per coverslip). (e) and (f) Mean ratio 
change of responding BMDM ± SEM across 7 coverslips. The threshold for response was 0.1. *p<0.05, **p<0.001 relative to 20 nM GSK, 
###
p<0.001 relative to KO 
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Figure 46. Phagocytosis of fluorescent latex beads by murine BMDM. (a) Representative fluorescent 
images of BMDM either untreated or following stimulation with LPS (100 ng/ml, 24 h) in the presence of 
either GSK1016790A (100 nM; GSK) or vehicle (2% DMSO in DMEM). (b) Percentage of total area with 
fluorescence, as quantified by ImageJ software. Data are presented as mean ± SEM (n = 8 chambers 
from 2 mice).  
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5.4 Summary 
The key findings from this study are as follows: 
1. TRPV1 is expressed at an mRNA level in vascular endothelial cells, but does not appear 
to be expressed as an active protein in the cell lines tested, either under basal or 
inflammatory conditions 
2. Commercially available anti-TRPV1 antibodies do not appear to be selective for TRPV1 
3. TRPV4 is expressed and functional in endothelial cells, and may be sensitised under 
inflammatory conditions 
4. TRPV4 does not appear to contribute to LPS-induced cytotoxicity in endothelial cells 
5. TRPV4, but not TRPV1, is expressed in murine BMDM, but its activation does not 
appear to influence phagocytic function 
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5.5 Discussion 
Following numerous reports suggesting that TRPV1 and TRPV4 may be important endothelial 
regulators, we aimed to characterise their expression and activity in a number of different 
endothelial cell lines. Functional expression of TRPV4 in the vascular endothelium is widely 
accepted (Baylie and Brayden, 2011), and data obtained in this study is consistent with 
published literature. While endothelial expression of TRPV4 has been demonstrated 
convincingly in a number of physiological settings, however, its role in pathological contexts 
has not yet been explored.  
The role – and indeed the very presence – of TRPV1 in endothelial cells, on the other hand, 
remains highly contentious. While several groups have reported evidence of endothelial TRPV1 
expression (Fantozzi et al., 2003, Yang et al., 2010a, Bratz et al., 2008), others have failed to 
reproduce these findings (Marrelli et al., 2007, Cavanaugh et al., 2011). Many studies have 
relied on mRNA expression alone, and protein quantification has often been conducted in the 
absence of appropriate controls, or using antibodies that have not been validated in TRPV1 KO 
tissue. We aimed to clarify these discrepancies using a combination of biochemical and 
functional analysis in a number of different endothelial cell lines.  
5.5.1 TRPV1 is expressed at an mRNA but not a protein level in cultured 
endothelial cells 
Initial experiments were aimed at determining expression levels of TRPV1 in vascular cells and 
tissues. Using reverse transcription and PCR amplification of vascular cDNA, we found evidence 
of TRPV1 mRNA expression in aortic lysates of WT, but not KO mice, as well as in freshly 
isolated and immortalised endothelial cells from three different species. Although we initially 
intended to compare tissue protein levels of TRPV1 between naïve and septic animals, we 
were unfortunately unable to do this by traditional antibody-recognition methods, since the 
commercially available antibodies tested were found to be insufficiently selective for TRPV1.  
ACC-030 (Alomone Labs) is a widely used anti-TRPV1 antibody, that in previous reports showed 
no immunoreactivity in samples from TRPV1 KO mice (albeit in the absence of a protein 
loading control) (Yang et al., 2010b). We observed clear and distinct bands in aortic and DRG 
lysates from KO mice of identical origins, suggesting that this antibody is an unsuitable 
indicator of TRPV1 protein expression. Furthermore, these bands were observed at 
approximately 75 kDa – 20kDa smaller than the predicted molecular weight of TRPV1 (Caterina 
et al., 1997): further evidence of non-selective immunoreactivity. While the other antibodies 
tested are similarly widely used, they do not appear to have been validated in TRPV1 KO 
samples, and according to our results are likewise insufficiently selective for TRPV1 protein. 
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Although TRPV1 KO mice are functional knockouts, retaining the C-terminus of the TRPV1 gene 
against which most TRPV1 antibodies are raised, our sequencing data demonstrate the 
presence of a TAG stop codon inside the inserted neomycin cassette, precluding the possibility 
of residual C-terminal translation. These observations call into question much of the data on 
TRPV1 expression that has been published to date, and suggest that numerous reports of 
TRPV1 protein expression will require considerable further validation. 
In the absence of a biochemical method for determining TRPV1 protein levels, we attempted 
to assess TRPV1 expression and activity by functional assay, using the highly selective agonist 
capsaicin. Freshly isolated murine and bovine endothelial cells were perfused with 1 µM 
capsaicin, roughly equivalent to the EC50 of rat TRPV1 in heterologous expression systems 
(Caterina et al., 1997, Welch et al., 2000). Neither cell type exhibited any calcium influx in 
response to capsaicin treatment, despite responding robustly to TRPV4 activation and positive 
controls. 
Although cellular yield was insufficient to perform molecular analysis of primary murine 
endothelial cells, TRPV1 mRNA was detected in other vascular tissues and cells, including 
immortalised murine endothelial cells, and we were surprised, therefore, that no evidence of 
functional TRPV1 expression was observed here, particularly given that a previous group 
reported significant Ca2+ influx in murine aortic endothelial cells in response to 1 µM capsaicin 
(Yang et al., 2010b). It is possible that regionally restricted expression or species differences 
could account for this discrepancy, or that the culture conditions used could have contributed 
to downregulation of the channel. Furthermore, despite finding no evidence of functional 
TRPV1 expression in the endothelium of two different vascular beds (aorta and lung) from two 
different species (cow and mouse, respectively), it is possible that a specific stimulus (perhaps 
inflammatory) is required in order for TRPV1 translation or membrane insertion to occur. It is 
notable, however, that TRPV1 mRNA expression has also been observed in odontoblasts, 
which similarly do not appear to respond to capsaicin (Egbuniwe et al., 2014).  
Given that TRPV1 KO mice appear to have a normal haemodynamic profile under basal 
conditions (Pacher et al., 2004, Marshall et al., 2013), it is possible that protein translation and 
activity in vascular tissue are minimal in a physiological setting, and that under pathological 
conditions the receptor is upregulated, as observed previously in other cell types (Stander et 
al., 2004). A scenario in which endothelial cells retain pools of TRPV1 mRNA that is translated 
under conditions of stress and inflammation, may explain our observations of clear TRPV1 
mRNA expression with despite no evidence of receptor activity. Alternatively, TRPV1 protein 
may be retained in intracellular pools, either in the endoplasmic reticulum or in cytoplasmic 
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vesicles, in endothelial cells, as described previously (Guo et al., 1999, Morenilla-Palao et al., 
2004) 
While pre-treatment of bovine endothelial cells with the bacterial endotoxin LPS did not 
induce responsiveness to capsaicin in this study, it is possible that a different inflammatory 
stimulus would have increased activity. Alternatively, while TRPV1 may be expressed at an 
mRNA level in all endothelial tissue, it may only be functional in microvascular beds. Previous 
studies have demonstrated TRPV1 mRNA in human pulmonary capillary endothelial cells, 
which respond to the capsaicin analogue nonivamide and are sensitised by LPS (Thomas et al., 
2012). Given that TRPV1 KO mice exhibit microvascular dysfunction (Chapter 4), we 
acknowledge that bovine aortic endothelial cells do not represent the most relevant model for 
in vitro assessment of vascular TRPV1 activity. Numerous proteins, including selectins and cell 
adhesion molecules, for eample, show widely divergent expression patterns across the 
vascular system (Aird, 2012); it is conceivable therefore, that expression of TRPV1 in different 
endothelial layers may be similarly heterogeneous. While it was not possible to isolate 
microvascular cells in this study (isolates from murine lungs would have contained a mix of 
macrovascular and microvascular endothelial cells, and yield was furthermore prohibitively 
low), further research using pure populations of microvascular cells could shed further light on 
the endothelial expression of TRPV1 under basal and inflammatory conditions. 
5.5.2 Cultured endothelial cells response robustly to TRPV4 activation, and may 
become sensitised to TRPV4 stimuli under inflammatory conditions 
Consistent with previous reports (Baylie and Brayden, 2011), functional endothelial TRPV4 
expression was demonstrated in this study in a number of different cell types. The robust 
response to the TRPV4 agonist GSK1016790A was antagonised by HC-067047, suggesting 
selective TRPV4 activation. The cellular response to GSK1016790A was found to be relatively 
delayed with a slow wash-off rate. This may be indicative of an intracellular binding site for the 
agonist. Previous studies using phorbol esters, such as 4α-phorbol 12,13-didecanoate (4α-
PDD), to activate TRPV4 in transfected HEK cells and isolated murine aortic ECs showed 
similarly slow kinetics of activation and dissociation (Watanabe et al., 2002a). It is possible that 
the synthetic agonist GSK1016790A, like 4α-PDD, must first diffuse across the cellular 
membrane in order to access an intracellular binding site, accounting for the notable lag 
between administration of the GSK1016790A compound and an increase in intracellular [Ca2+].  
While the role of TRPV4 in endothelial function has been studied widely, its activity under 
pathological conditions has not been characterised. Recent reports have suggested that 
excessive TRPV4 activation causes endothelial failure and circulatory collapse (Willette et al., 
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2008). Given that numerous modulators of TRPV4 – arachidonic acid metabolites (Watanabe et 
al., 2003b), shear stress (Kohler et al., 2006, Hartmannsgruber et al., 2007), osmolality 
(Strotmann et al., 2000, Liedtke et al., 2000) – are altered in sepsis, we aimed to characterise 
TRPV4 activity under inflammatory conditions.  
Using a high-throughput microplate-based system, intracellular [Ca2+] in response to 
GSK1016790A was quantified following pre-incubation with increasing concentrations of LPS. 
While the overall response to 100 nM GSK1016790A was relatively consistent with increasing 
LPS concentrations and exposure time, responsiveness to ATP – the positive control – was 
markedly reduced in a concentration-dependent manner after 24-h exposure to LPS. While it is 
possible that purinergic 2X (P2X) receptors – thought to be chiefly responsible for mediating 
ATP-induced effects in the endothelium (Harrington et al., 2007) – are simply downregulated 
following LPS exposure, we were unable to find any previous reports of LPS-induced 
desensitisation of ATP responsiveness. On the contrary, responsiveness to ATP appears to be 
increased in other cell types under inflammatory conditions (Xu and Huang, 2002), and several 
receptor subtypes are upregulated in cultured human umbilical vein endothelial cells 
stimulated with LPS, tumour necrosis factor (TNF)-α, interferon-γ (IFN-γ) or interleukin-1β (IL-
1β) (Wilson et al., 2007). We therefore considered the reduced responsiveness to ATP in our 
system to be representative of increased cell death, and consequently normalised 
GSK1016790A responses to ATP responses. Following normalisation, a concentration-
dependent sensitisation of endothelial cells to GSK1016790A was observed, suggesting that 
endothelial TRPV4 activity could be increased in sepsis. Further experiments using a receptor-
independent positive control, such as ionomycin, would be required to confirm these 
observations, however. 
Consistent with this interpretation of decreased ATP responsiveness, 24-h exposure to LPS was 
found to cause a concentration-dependent decrease in endothelial cell viability. This likely 
contributes to the vascular dysfunction that characterises sepsis. While a previous study has 
shown that excessive TRPV4 activation causes endothelial detachment and necrosis (Willette 
et al., 2008), incubation of bAEC with HC-067047 did not attenuate LPS-induced loss of cell 
viability. This suggests that tonic activation of TRPV4 in the presence of LPS does not 
contribute to cytotoxicity in this system, and that exogenous or more potent agonism is 
required to induce endothelial death. Further experiments, in which endothelial viability is 
assessed in the presence of both LPS and GSK1016790A may be informative. While endothelial 
synthesis of endogenous agonists of TRPV4, such as anandamide (Watanabe et al., 2003b), 
may be increased under inflammatory conditions (Opitz et al., 2007), this did not appear to 
play a role in cell death in our culture conditions; if any endogenous autocrine TRPV4 
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activation was present in this system, it was likely substantially lower than the level of 
GSK1016790A-induced TRPV4 activation that caused endothelial cell death in previous studies 
(Willette et al., 2008). 
5.5.3 TRPV4, but not TRPV1, is present in bone marrow-derived macrophages, 
but does not appear to regulate phagocytosis 
Previous reports have suggested that TRPV1 (Fernandes et al., 2012) and TRPV4 (Alvarez et al., 
2006, Hamanaka et al., 2010) are expressed in macrophages; given the known link between 
Ca2+ influx and phagocytosis (Diler et al., 2014), expression of these two Ca2+-permeable 
channels in this cell type may indicate a potential role in phagocytosis.  In view of the central 
role of macrophages in sepsis (Warren, 2011), we aimed to  characterise TRPV1 and TRPV4 
expression in murine bone marrow-derived macrophages. While GSK1016790A caused a 
robust and concentration-dependent increase in intracellular [Ca2+] in BMDM from WT but not 
TRPV4 KO mice, only very few cells responded to capsaicin, and with a comparatively low 
response size. Owing to the very slow wash-off rate of GSK1016790A, it is possible that any 
responses recorded after stimulation with capsaicin were actually the result of residual TRPV4 
activity. While the perfusion sequence was not randomised in this study – a limitation that 
should be addressed in future experiments – the very small number of responding cells, and 
the very low response size following capsaicin stimulation, suggest that significant expression 
of TRPV1 is not present in this cell type under the culture conditions used.   
These data are inconsistent with a previous report that TRPV1 plays a key role in macrophage 
phagocytosis (Fernandes et al., 2012). There are numerous potential explanations for this 
discrepancy. Firstly, the role of TRPV1 may differ between different macrophage populations: 
only quiescent bone marrow-derived macrophages were used in this study, whereas 
Fernandes and colleagues characterised TRPV1 activity in peripheral macrophages isolated 
from the peritoneal cavity of TRPV1 WT and KO mice, which may have had a different 
activation state. Secondly, while macrophages from TRPV1 WT and KO mice appeared to 
function differently (Fernandes et al., 2012), the expression of TRPV1 in WT macrophages was 
only established at the mRNA level; indirect regulation of macrophage function by TRPV1-
dependent mechanisms may also have accounted for the divergent behaviour of WT and KO 
cells. Finally, it is of note that in the study by Fernandes and colleagues, LPS stimulation did not 
increase phagocytosis of latex beads; somewhat confusingly, however, the phagocytic capacity 
of macrophages isolated from TRPV1 KO mice appeared to be reduced below baseline levels in 
the presence of LPS, suggesting that LPS inhibits phagocytosis in the absence of TRPV1. While 
this observation was not explained by the authors, it is inconsistent with previous reports that 
the phagocytic activity of both bone marrow-derived macrophages (Cooper et al., 1984) and 
202  |  I N  V I T R O  C H A R A C T E R I S A T I O N  O F  V A S C U L A R  T R P V 1  
A N D  T R P V 4  
peritoneal macrophages (Anand et al., 2007) is potentiated by LPS. The relatively high 
concentration of latex beads used by Fernandes and colleagues, combined with the long 
incubation time of 24-h, may have induced maximum bead uptake that could not be further 
potentiated by LPS. 
Using a 10-fold lower concentration of beads, and an incubation time of 1 h, we observed 
increased bead uptake by BMDM in the presence of LPS, consistent with previous reports 
(Cooper et al., 1984, Anand et al., 2007). Co-incubation with GSK1016790A, however, did not 
influence bead uptake, suggesting that TRPV4 does not contribute to phagocytic function in 
the culture conditions used.  
While prior reports have suggested that TRPV4 regulates alveolar macrophage activation 
(Alvarez et al., 2006, Hamanaka et al., 2010), neither previous study evaluated phagocytic 
function. In addition to phagocytosis, macrophages also participate in the production of 
cytokines, chemokines and reactive oxygen species; it is possible that expression of TRPV4 in 
this cell type is related to one of these latter functions, rather than to phagocytosis. While we 
observed no change in phagocytic function in the presence of a TRPV4 agonist, however, our 
data do not preclude completely the potential involvement of the channel in this process. 
Further investigation using a larger sample size, a wide range of agonist concentrations, and 
selective antagonism to investigate any tonic activity in this cell type will elucidate the role of 
TRPV4 in phagocytosis further. Furthermore, we used a relatively crude measure of uptake by 
counting fluorescent pixels. Fluorescent staining and analysis of overlap between TRPV4 
expression, macrophage markers and phagocytosed beads would help to elucidate whether 
subsets of TRPV4-expressing macrophages do have a specific role in pathogen phagocytosis.  
5.5.4 Concluding remarks 
Despite demonstrating robust TRPV1 mRNA expression in aortic lysates and isolated 
endothelial cells, we have found no evidence of functional TRPV1 protein expression in these 
tissues, in spite of numerous previous reports to the contrary. On the other hand, these data 
do not preclude the possibility of induced endothelial TRPV1 expression under certain 
pathological conditions, or indeed of functional expression in specific subpopulations of 
endothelial cells (from the microvasculature, for example).  
We have observed convincing evidence of functional TRPV4 expression in the vascular 
endothelium of three separate species, and in murine macrophages, consistent with previous 
reports and indicative of an important role for TRPV4 in these cells. We have observed a 
sensitisation of the channel under inflammatory conditions, and given recent reports linking 
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excessive TRPV4 activation to profound hypotension and circulatory collapse (Willette et al., 
2008), we hypothesise that TRPV4 may be an important vascular regulator in sepsis.
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Transient receptor potential vanilloid 4 (TRPV4) was discovered by two different groups 
simultaneously (Liedtke et al., 2000, Strotmann et al., 2000), following a database screen for 
sequences with similarity to TRPV1, TRPV2, and the C. elegans TRPV isoform OSM-9. Due to an 
initial lack of consensus nomenclature, TRPV4 was variously called OTRPC4 (Strotmann et al., 
2000), VR-OAC (Liedtke et al., 2000), TRP12 (Wissenbach et al., 2000) and VRL-2 (Delany et al., 
2001) by the different groups to clone the receptor. Originally identified as an osmosensor in 
the kidney (Strotmann et al., 2000, Liedtke et al., 2000), TRPV4 is expressed in numerous 
tissues, and has been implicated in a wide variety of physiological processes, including vascular 
regulation.  
 TRPV4 structure 6.1.1
TRPV4 is an 871-amino-acid protein that shares numerous structural features with TRPV1: the 
channel has large intracellular N- and C-termini, six transmembrane domains with a re-entrant 
pore-forming loop between domains 5 and 6, and at least three ankyrin repeat domains in the 
cystosolic N-terminus (Plant and Strotmann, 2007). Despite sharing a high degree of sequence 
homology with TRPV1 (among other TRPV channels), TRPV4 was originally thought to exist 
exclusively as a homotetramer (Hellwig et al., 2005), though there have been recent reports of 
heterotetramerisation with TRPC1 and TRPP2 in vascular endothelial cells and renal cortical 
collecting duct cells (Du et al., 2012, Ma et al., 2010). The structure of the TRPV4 subunit is 
shown schematically in Fig. 47.  
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Figure 47. Structural features of the TRPV4 subunit. TRPV4 subunits comprise 6 transmembrane 
domains with a re-entrant pore-forming loop between domains 5 and 6, and cytosolic N- and C-termini. 
Residues important for channel function and regulation are indicated in black shaded areas. Three 
ankyrin repeat domains and a SRC family kinase (SFK) phosphorylation site are present in the N-
terminus. Serine and tyrosine residues in transmembrane domain 3 are essential for channel activation 





-mediated channel inhibition, and inhibition by ruthenium red (RR). The C-terminus 
contains a putative binding site for Ca
2+
-calmodulin, as well as a residue essential for spontaneous 
channel activity. The mechanism of activation by epoxyeicosatreinoic acids (EETs) is unknown. Figure 
adapted from TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades, 
Chapter 9 (Plant and Strotmann, 2007). 
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 Tissue expression 6.1.3
TRPV4 was originally identified in the kidney, and orthologues for numerous other species, 
including mice and humans, have been cloned from this tissue (Strotmann et al., 2000, Liedtke 
et al., 2000, Wissenbach et al., 2000, Delany et al., 2001). It is additionally expressed in a wide 
variety of other tissues, including the vascular endothelium and smooth muscle, heart, lung, 
spleen, cochlea, liver, testes, placenta, trachea, salivary glands, adipose tissue and numerous 
brain regions (Filosa et al., 2013).   
 Channel activation 6.1.4
TRPV4 channels often exhibit spontaneous activity in heterologous expression systems, leading 
to elevated basal intracellular Ca2+ levels (Plant and Strotmann, 2007). This spontaneous 
activity is likely supported by as yet unidentified cellular factors, since currents disappear in 
ruptured patch recordings (Strotmann et al., 2000). Numerous endogenous and exogenous 
agonists have been identified for TRPV4, however. 
 Extracellular osmolarity 6.1.4.1
Originally identified as an osmosensor in the kidney (Strotmann et al., 2000, Liedtke et al., 
2000), TRPV4 is highly sensitive to changes in extracellular osmolarity, responding to 
fluctuations as small as 1%; decreases in osmolarity result in membrane currents and a rise in 
intracellular [Ca2+], whereas increases above 300 mosmol/L inhibit membrane currents and 
decrease intracellular [Ca2+] in spontaneously active cells (Strotmann et al., 2000).  
Responses to changes in osmolarity are temperature-dependent, and require a relatively intact 
intracellular environment: current responses to hypotonic solutions are significantly greater in 
perforated patch recordings than in ruptured patch recordings (Strotmann et al., 2000). The 
observation that TRPV4 still responds to other agonists – such as phorbol esters – in ruptured 
patch recordings (Watanabe et al., 2002a), suggests that channel activation by hypotonic 
stimuli relies on the generation of second messengers. Consistent with in vitro data 
demonstrating the osmosensitivity of heterologously expressed TRPV4, TRPV4 knockout (KO) 
mice exhibit osmoregulatory defects (Liedtke and Friedman, 2003, Mizuno et al., 2003). 
 TRPV4 as a mechanosensor 6.1.4.2
Because changes in extracellular osmolarity are associated with cell swelling and membrane 
stretch, numerous studies have investigated the possibility that TRPV4 is a mechanosensor. 
This notion is supported by the expression profile of TRPV4 in mechanosensory tissues, 
including the inner ear, vascular endothelium and sensory neurons. These investigations have 
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produced conflicting results, however. While initial experiments provided no evidence of 
TRPV4 activation in response to membrane stretch (Strotmann et al., 2000), a subsequent 
study recorded TRPV4 responses to cell inflation (Suzuki et al., 2003). Gao and colleagues also 
described an increase in intracellular [Ca2+] in TRPV4-expressing HEK293 cells exposed to shear 
stress that was sensitive to ruthenium red (a non-selective blocker of TRPV channels). This 
response was abolished when the temperature was reduced from 37°C to RT (Gao et al., 
2003), suggesting that TRPV4 responses to mechanical stimuli, like hypotonic stimuli, are 
temperature-dependent. Two more recent studies also support the notion of direct TRPV4 
activation by mechanical stimulation (Loukin et al., 2010, Matthews et al., 2010) 
Whether a conserved mechanism underlies TRPV4 activation by hypotonic and mechanical 
stimulation is unclear. The observation of a markedly delayed response (≥20 s) to changes in 
osmolarity suggests that TRPV4 is not directly activated by this stimulus, and that cell swelling 
or initiation of downstream signalling pathways is required for activity. Whether mechanical 
stimulation of TRPV4 activates the channel directly, as proposed previously (O'Neil and Heller, 
2005) is also not clear: while 3 ankyrin repeats in the N-terminus appear to anchor the 
receptor to the cytoskeleton (Xu et al., 2003), deletion of these ankyrin repeats does not 
abolish TRPV4 responses to hypotonicity (Liedtke et al., 2000).  
 Arachidonic acid metabolites 6.1.4.3
One potential pathway through which mechanical stimuli may activate TRPV4 involves the 
generation of arachidonic acid metabolites. Both the endocannabinoid anandamide and its 
downstream metabolite arachidonic acid have been shown to activate TRPV4 in vascular 
endothelial cells in a manner that is strongly inhibited by blockers of Cytochrome P450 
(CYP450) epoxygenase (Watanabe et al., 2003b). CYP450 epoxygenase-mediated metabolism 
of arachidonic acid generates epoxyeicosatrienoic acids (EETs), which have been shown to be 
responsible for channel activation (Watanabe et al., 2003b, Vriens et al., 2004).  
Responses to hypotonic stimuli are similarly blocked by structurally unrelated inhibitors of 
phospholipase A2 (PLA2; the enzyme responsible for release of arachidonic acid from 
phospholipid bilayers) and CYP450 epoxygenase (Vriens et al., 2004, Vriens et al., 2005). 
Correspondingly, activation of TRPV4 by hypotonic stimuli is potentiated by upregulation of 
CYP450 epoxygenase (Vriens et al., 2005). These data suggest that activation of TRPV4 by 
changes in extracellular osmolarity involves initiation of an intracellular signalling cascade, as 
described in Fig. 48. Constitutive activation of PLA2 under isotonic conditions was originally 
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postulated to underlie spontaneous TRPV4 activity, though experiments using inhibitors of 
PLA2 do not support this hypothesis (Vriens et al., 2004). 
 
 
Figure 48. Putative signalling mechanisms for TRPV4 activation by changes in extracellular osmolarity. 
Decreases in extracellular osmolarity cause cell swelling and activation of phospholipase A2 (PLA2). PLA2 
catalyses the release of arachidonic acid (AA) from membrane phospholipids, which in turn is 
metabolised to epoxyeicostrienoic acids (EETs) by cytochrome P450 (CYP450) epoxygenase. EETs may 
activate TRPV4 directly, or through the generation of further second messengers.   
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 Phorbol ester derivatives 6.1.4.5
Watanabe and colleagues were the first to report activation of TRPV4 by phorbol ester 
derivatives (Watanabe et al., 2002a). The compound 4α-phorbol 12,13 didecanoate (4αPDD), 
in particular, was thought to activate TRPV4 exclusively, though recent studies have challenged 
its selectivity  (Alexander et al., 2013). Responsiveness of TRPV4 to 4αPDD is unaffected by 
PLA2 inhibitors, though mutation of Tyr555 abolishes responses to both 4αPDD and heat, 
suggesting a common pathway of activation for these two stimuli (Vriens et al., 2004). The 
divergent pathways of activation by cell swelling/arachidonic acid and by phorbol ester 
derivatives was subsequently confirmed in endothelial cells (Vriens et al., 2005). The response 
of TRPV4 to phorbol ester derivatives also appears to be temperature-dependent, however: 
higher temperatures potentiate responses, which are relatively diminished at RT (Gao et al., 
2003).  
 Temperature gating 6.1.4.6
Like many other members of the TRPV subfamily, TRPV4 is gated by temperature. Whereas 
TRPV1 is activated by relatively hot temperatures (≥ 42°C), the temperature threshold of 
TRPV4 is between 25 and 33°C (Guler et al., 2002, Watanabe et al., 2002b); heat activates only 
a fraction of the number of channels responsive to 4αPDD, suggesting less efficient channel 
recruitment (Watanabe et al., 2002b). Responses to warming exhibit a degree of 
desensitisation, though some spontaneous activity remains at 37°C (Plant and Strotmann, 
2007). TRPV4 responses to heat are observed in cell-attached but not cell-free patches 
(Watanabe et al., 2002b), indicative of an indirect activation that involves intracellular 
signalling components. The ankyrin repeat domains present in the N-terminus of the channel 
are thought to be essential for heat activation (Watanabe et al., 2002b). 
Consistent with TRPV4 expression in sensory neurons, keratinocytes and the hypothalamus, 
TRPV4 KO mice exhibit altered physiological and behavioural responses to thermal stimuli 
(Todaka et al., 2004), particularly in the context of thermal hyperalgesia (Suzuki et al., 2003, 
Liedtke and Friedman, 2003, Todaka et al., 2004). Despite its expression in the hypothalamus, 
the centre of thermoregulation (Boulant, 1981), no difference in core temperature, or in the 
thermodynamic response to cold stress have been recorded in TRPV4 KO mice, however, 
indicating intact thermoregulatory function (Liedtke and Friedman, 2003). 
 Ca2+-dependent regulation of TRPV4 activity 6.1.4.7
Consistent with the cytotoxicity associated with excessive Ca2+ entry, negative-feedback 
regulatory mechanisms exist for most Ca2+-permeable channels. Ca2+ is involved in both the 
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activation phase and the decay phase of TRPV4 responses to hypotonicity, phorbol ester 
derivatives and heat (Plant and Strotmann, 2007). Removal of extracellular Ca2+ abolishes 
spontaneous TRPV4 activity and lowers intracellular [Ca2+]. Replacement of extracellular Ca2+ 
with Ba2+ or Sr2+ − which also permeate the channel well – delay and blunt agonist-induced 
responses, highlighting the dependence of activation on Ca2+ (Strotmann et al., 2003). 
Like TRPV1, TRPV4 contains a putative calmodulin binding site in its cytosolic C-terminus, 
through which Ca2+-dependent regulation may be achieved (Strotmann et al., 2003). While 
mutations to this motif were found to alter Ca2+-induced potentiation of channel activation by 
a variety of agonists, however, current inactivation was unaffected (Strotmann et al., 2003). 
Large currents through TRPV4 decay below baseline levels, even with persistent exposure to 
agonists, in a manner that is dependent upon Ca2+: Watanabe and colleagues have shown that 
increasing extracellular [Ca2+] not only potentiates TRPV4 activation, but also accelerates and 
enhances current decay; furthermore, raising intracellular [Ca2+] with a patch pipette also 
reduces current amplitudes (Watanabe et al., 2003a). The mechanism by which Ca2+ 
inactivates TRPV4 remains unclear, however. 
 TRPV4 in vasoregulation 6.1.5
Consistent with its role as a Ca2+ channel, TRPV4 has been implicated in a variety of 
physiological processes, including nociception (Alessandri-Haber et al., 2003), bone 
development (Rock et al., 2008, Krakow et al., 2009) and osmoregulation (Liedtke and 
Friedman, 2003, Mizuno et al., 2003). This thesis will focus on its role in the cardiovascular 
system, where it is emerging as an important regulator of vascular function.  
 The role of TRPV4 in vascular endothelial cells  6.1.5.1
The first evidence of functional TRPV4 expression in the murine aortic endothelium was 
provided by Bernd Nilius’ group (Watanabe et al., 2002b). Since then, its endothelial 
expression has been characterised throughout the vascular system, from large conductance 
vessels to the microvasculature (Filosa et al., 2013).  Aortic expression of TRPV4 was confirmed 
by Vriens and colleagues using RT-PCR, Western blot analysis and functional Ca2+ imaging in 
isolated murine aortic endothelial cells (Vriens et al., 2005); similarly endothelial TRPV4 activity 
has been demonstrated in the rat carotid artery and arteria gracilis by in situ patch-clamping, 
single-cell RT-PCR and pressure myography (Kohler et al., 2006), and in the pulmonary artery 
and microvascular endothelium (Alvarez et al., 2006). More recently, a systemic study of rat 
tissues by Willette and colleagues has revealed a ubiquitous pattern of TRPV4-positive staining 
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in endothelial and epithelial tissues (Willette et al., 2008). Data outlined in Chapter 5 of this 
thesis further support a functional role for TRPV4 in the vascular endothelium.  
The function of TRPV4 in endothelial tissue has been the subject of intense investigation in 
recent years, and the generation of TRPV4 KO mice (Liedtke and Friedman, 2003) has helped to 
elucidate the channel’s role in vascular regulation. Many studies have implicated TRPV4 in 
flow- and agonist-induced vasodilation in a variety of rodent vascular beds (Kohler et al., 2006, 
Hartmannsgruber et al., 2007, Loot et al., 2008, Zhang et al., 2009, Mendoza et al., 2010, 
Adapala et al., 2011, Zhang and Gutterman, 2011) 
Zhang and colleagues were among the first to demonstrate a role for TRPV4 in acetylcholine 
(ACh)-mediated vasorelaxation. ACh-induced nitric oxide (NO) production was found to be 
significantly reduced in carotid artery endothelial cells from TRPV4 KO mice; in TRPV4 KO small 
mesenteric arteries, the NO-mediated component of ACh-induced vasodilatation was 
attenuated and the endothelium derived hyperpolarising factor (EDHF)-mediated component 
abolished (Zhang et al., 2009). The haemodynamic depressor response to ACh was similarly 
attenuated in TRPV4 KO mice (Zhang et al., 2009). These data suggest that TRPV4 is involved in 
ACh-mediated vasorelaxation, in a manner that is consistent with the relative contribution of 
endothelium-derived relaxing factors in different vascular beds: in larger conduit vessels, NO 
and prostanoids are the principal mediators, whereas in smaller resistance beds, EDHF 
predominates (Hwa et al., 1994). The results of Zhang and colleagues are furthermore 
consistent with a previous report showing that in larger vessels, inhibition of endothelial nitric 
oxide synthase (eNOS) almost completely abolished 4αPDD-induced vasodilatation, whereas in 
smaller vessels, selective blockade of small- and intermediate-conductance Ca2+-sensitive SKCa 
and IKCa channels inhibited TRPV4-mediated vasodilatation (Kohler and Hoyer, 2007). 
Numerous studies have indicated that TRPV4 activation may represent the hyperpolarising 
mechanism by which ACh induces endothelium-dependent vasodilatation. 
In addition to vasoactive responses to agonist stimulation, TRPV4 has also been implicated in 
the vasodilatory response to fluid shear stress (Hartmannsgruber et al., 2007, Mendoza et al., 
2010, Loot et al., 2008). Mendoza and colleagues showed that TRPV4-mediated Ca2+ influx is 
essential for flow-mediated dilatation of human coronary arteries and involves CYP450 
epoxygenase activity and PLA2 (Mendoza et al., 2010); this has also been demonstrated in 
murine carotid arteries (Loot et al., 2008, Hartmannsgruber et al., 2007). Pre-constricted 
murine carotid arteries exhibit a predominantly NO-independent and entirely prostacyclin-
independent vasodilatory response to increases in fluid shear stress. This response is abolished 
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in conditions of high extracellular [K+] and following inhibition of CYP450 epoxygenase activity 
(Loot et al., 2008).  
In 2012, Sonkusare and colleagues used a very elegant approach to investigate the role of 
TRPV4 in the endothelium of small resistance arteries. Using transgenic mice expressing a Ca2+ 
biosensor exclusively in the endothelium, the authors recorded basal endothelial Ca2+ pulses in 
isolated mesenteric arteries, that were dramatically increased in frequency by the 
administration of 10 nM GSK1016790A, a selective TRPV4 agonist (Sonkusare et al., 2012). In 
contrast to Ca2+ pulsars, which tend to be localised to holes in the internal elastic lamina 
(representing sites of endothelial projections into the smooth muscle), the Ca2+ sparklets 
described by Sonkusare and colleagues were evenly distributed between myoendothelial holes 
and the ends of cells. Rapid removal of extracellular Ca2+ abolished the responses to 
GSK1016790A.  
Stimulation with 10 nM GSK1016790A was found to activate approximately three sparklets per 
cell, though this was sufficient to hyperpolarise the underlying smooth muscle and cause 
maximal relaxation of the pressurised arteries. This dilatory response was unaffected by 
inhibitors of eNOS and cyclo-oxygenase, though charybdotoxin – an inhibitor of intermediate-
conductance IKCa channels – abolished dilatation in response to 3 nM GSK1016790A, and 
greatly reduced the dilatory response to 10 nM GSK1016790A. Perforated patch clamping 
revealed an outward current in response to 10 nM GSK1016790A that was substantially 
reduced by charybdotoxin and further reduced by subsequent addition of apamin – a blocker 
of small-conductance SKCa channels. In fact, 10 nM GSK1016790A was found to increase the 
density of IK+ and SK+ currents by a similar magnitude to dialysis with 3 µM Ca2+. Together, 
these results demonstrate a specific link between TRPV4 activation and endothelium-
dependent hyperpolarisation of vascular smooth muscle: a hyperpolarising current generated 
in endothelial cells may spread to the underlying smooth muscle via myoendothelial gap 
junctions, leading to vascular relaxation.  
Zheng and colleagues provided the first evidence of TRPV4-dependent endothelial regulation 
in human vessels. The authors demonstrated that arachidonic acid-induced dilatation of 
isolated human coronary arterioles depends on endothelial TRPV4-mediated Ca2+ entry and 
endothelial hyperpolarisation via activation of IKCa and SKCa channels (Zheng et al., 2013). They 
demonstrated in isolated human coronary artery endothelial cells that arachidonic acid causes 
TRPV4-dependent Ca2+ entry that is markedly decreased following inhibition of protein kinase 
A (PKA). The PKA activator forskolin had no effect on Ca2+ entry, suggesting that protein 
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phosphorylation facilitates activation of TRPV4 by stimuli such as arachidonic acid, without 
directly opening the channel.  
 The role of TRPV4 in vascular smooth muscle cells 6.1.5.2
In addition to mediating endothelium-dependent smooth muscle hyperpolarisation, TRPV4 
may contribute to smooth muscle hyperpolarisation directly. TRPV4 expression has been 
localised to the smooth muscle cells of rat cerebral arteries (Marrelli et al., 2007, Earley et al., 
2005), human and rat lung extra-alveolar vessels (Alvarez et al., 2006), endothelium-denuded 
rat intralobar pulmonary arteries (Martin et al., 2012, Yang et al., 2012), rat and mouse 
mesenteric arteries (Gao and Wang, 2010, Earley et al., 2009), and rat and mouse aortae 
(Watanabe et al., 2008). Despite representing a Ca2+ entry pathway, activation of TRPV4 in 
smooth muscle cells is associated with smooth muscle hyperpolarisation and vascular 
relaxation. 
Under high-speed laser-scanning confocal microscopy, both 4αPDD and 11,12-EET have been 
shown to elicit Ca2+ sparks via sarcoplasmic ryanodine receptors in the smooth muscle cells of 
isolated rat cerebral arteries (Earley et al., 2005). These sparks were found to activate 
sarcolemmal large-conductance BKCa channels, leading to smooth muscle hyperpolarisation 
and relaxation. These responses were abolished following anti-sense knockdown of TRPV4 
expression (Earley et al., 2005), suggesting that TRPV4 may form a Ca2+ signalling complex with 
ryanodine receptors and BKCa channels to mediate smooth muscle relaxation; endogenous 
activation of this complex may involve endothelium-derived relaxing factors, such as EETs.  
Further studies of TRPV4 function have been conducted in murine small mesenteric arteries: 
11,12-EET-induced ion currents and vasorelaxation were abolished in arteries isolated from 
TRPV4 KO mice  (Earley et al., 2009). Endothelial denudation reduced 11,12-EET-induced 
smooth muscle hyperpolarisation and relaxation by approximately 50%, implicating smooth 
muscle-derived TRPV4 in the remaining response.  Correspondingly, the authors found that 
inhibition of endothelial IKCa and SKCa channels, or smooth muscle BKCa channels similarly 
attenuated 11,12-EET-induced responses to an equivalent degree. 
EETs can be produced by endothelial cells in response to numerous physiological stimuli, 
including bradykinin, ACh, pulsatile or shear stress (Filosa et al., 2013). Thus EET-induced 
activation of endothelial and smooth muscle TRPV4 channels, via coupling to KCa channels, may 
play a major role in the control of vascular tone under various physiological conditions. 
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Consistent with this view, TRPV4 KO mice exhibit exaggerated hypertension in response to 
chronic eNOS inhibition, relative to WT controls (Earley et al., 2009). 
Until now, a functional role for TRPV4 in vascular smooth muscle has only been shown 
definitively in rat cerebral arteries (Earley et al., 2005) and murine mesenteric arteries (Earley 
et al., 2009). It seems likely, however, that this mechanism is conserved throughout a variety 
of vascular beds: indirect stimulation of hyperpolarising smooth muscle BKCa channels by EETs 
has been demonstrated in numerous artery types (Campbell and Fleming, 2010), supporting a 
widespread role for the EET-TRPV4-BKCa axis in smooth muscle regulation throughout the 
vascular system.  
 Other mechanisms of vasoregulation 6.1.5.3
In addition to its expression in vascular tissue, TRPV4 is also thought to be present in 
perivascular nerves, where it co-localises with vasoactive peptides CGRP and SP (Grant et al., 
2007, Koltzenburg, 2004). Both sensory denervation and CGRP antagonism have been shown 
to attenuate the hypotensive response to 4αPDD (Gao and Wang, 2010), implicating neuronal 
TRPV4 expression in haemodynamic regulation.  Other studies have suggested that TRPV4 
expressed in DRG neurons may initiate a sympathetic pressor response after sensing changes 
in osmolarity in the portal vascular bed (McHugh et al., 2010).  
 A potential role for TRPV4 in sepsis 6.1.6
Systemic activation of TRPV4 is known to cause profound hypotension and circulatory collapse 
(Pankey et al., 2014, Willette et al., 2008) – key features of septic shock. In addition to its 
potential involvement in the regulation of vascular tone, TRPV4 has also been implicated in the 
endothelial retraction and barrier failure (Willette et al., 2008); it is known to contribute to 
pulmonary oedema in response to raised pulmonary venous pressure (Alvarez et al., 2006, Wu 
et al., 2009, Hamanaka et al., 2010) – as encountered in sepsis (Parker and Brigham, 1987, 
D'Orio et al., 1986). An elevation in lung microvascular pressure has been shown to elicit Ca2+ 
influx via TRPV4; this, in addition to activating myosin light chain kinase (MLCK) to initiate 
endothelial retraction (increasing endothelial permeability and oedema formation), also 
induces NO formation which acts as a negative feedback mediator to switch off TRPV4 activity 
through a cGMP-dependent mechanism (Yin et al., 2008). In cases of low NO bioavailability (as 
encountered in sepsis, where elevated ROS production can lead to peroxynitrite formation), 
this negative-feedback loop may become compromised, leading to elevated pulmonary 
oedema formation.  
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Low NO bioavailability may also alter vasoactive responses to TRPV4 activation. In the 
presence of L-NAME, pulmonary arteries pre-constricted with U-46619 have been shown to 
respond to TRPV4 activation in a biphasic manner, with a potent isradipine-sensitive 
vasoconstrictor component (Pankey et al., 2014). Thus, in sepsis, where excessive ROS 
production and insufficient L-arginine production can lead to low NO bioavailability (Luiking et 
al., 2009), TRPV4-mediated Ca2+ entry may elicit vasoconstriction, exacerbating impaired 
perfusion in microvascular beds.  
Numerous endogenous agonists and regulators of TRPV4, including anandamide (Varga et al., 
1998), arachidonic acid and its metabolites (Bruegel et al., 2012), and PKA (Yang et al., 1997), 
have been shown to be upregulated in sepsis. It is conceivable therefore, that inflammation-
induced upregulation of endogenous factors could contribute to sepsis-associated circulatory 
failure via inappropriate TRPV4 activation. Alternatively, because TRPV4 is thought to be 
constitutively active at body temperature (Strotmann et al., 2000), it is possible that 
inflammatory mediators may sensitise the channel and increase tonic activity. 
 Hypotheses 6.1.7
Given that TRPV4 may be sensitised in inflammation (as demonstrated in Chapter 5) and that 
excessive TRPV4 activation is associated with profound hypotension, endothelial failure and 
circulatory collapse (Willette et al., 2008), it was hypothesised that deletion or blockade of 
TRPV4 will be protective against cardiovascular dysfunction in sepsis.  
 Aims 6.1.8
The aims of this study were as follows: 
1. To compare haemodynamic performance using radiotelemetry in TRPV4 KO and WT 
mice, treated with either vehicle or TRPV4 antagonist, both at baseline and during 
endotoxaemia 
2. To use the novel model of microcirculatory assessment described in Chapter 3 to 
determine the impact of TRPV4 deletion or antagonism on microcirculatory blood flow 
under basal and endotoxaemic conditions 
3. To relate any changes in haemodynamic performance and blood flow to other 
measurements of disease severity, including blood markers of acidosis and organ 
dysfunction, and other macroscopic clinical parameters 
4. To determine the impact of topical pharmacological TRPV4 activation on mesenteric 
blood flow in healthy and endotoxaemic WT mice 
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 Methods 6.2
 Materials 6.2.1
A list of materials used in this study, and details of their origin, are provided in Table 12. 
Material Manufacturer Catalogue No 
GSK1016790A Sigma-Aldrich G0798 




Table 12. Materials used in study.  
 
 Animals 6.2.2
Male wildtype (WT) and TRPV4 knockout (KO) mice were bred in house from heterozygous 
crosses of breeding pairs kindly donated by Dr Andrew Grant (Wolfson Centre for Age-Related 
Diseases, King’s College London), as described in section 2.1. Mice were used between 10 and 
14 weeks of age (approx. 25–30g). 
 Haemodynamic recording in the transition from health to disease 6.2.3
Radiotelemetry catheters were introduced into the carotid artery of 10-week old mice, as 
described in section 2.4. Animals were allowed to recover over 10 days before baseline 
haemodynamic parameters were recorded over a 48-h weekend period. Food and water 
intake was measured continuously, and mice were closely monitored for adverse signs. The 
following weekend, HC-067047 (10 mg/kg in 500 µL, i.p.) or vehicle (10% DMSO in 500 µL, i.p.) 
was administered to WT mice by Dr Anna Starr or Dr Manasi Nandi for blinding purposes, 
based on doses characterised previously (Everaerts et al., 2010). TRPV4 KO mice were left 
untreated. Haemodynamic parameters were then recorded over a second 48-h weekend 
period. On the following Monday, WT mice were re-injected with either HC-067047 or vehicle 
(consistent with the first treatment) and lipopolysaccharide (LPS; 12.5mg/kg) from Salmonella 
typhimurium (Sigma, L7261) was administered intravenously to all mice, as described in 
section 2.3.3.1. Haemodynamic parameters were recorded for 24 h, and mice were then 
terminally anaesthetised for blood flow assessment, as described in Chapter 3.  
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 In situ monitoring of mesenteric blood flow 6.2.4
Mesenteric blood flow was measured in naïve and septic mice 24 h post-LPS, as described in 
Chapter 3. After 5 min baseline recording, the mesenteric bed was gently sprayed (2 pump 
compressions from a distance of approximately 10 cm) with 1 µM GSK1016790A dissolved in 
saline containing 1% DMSO, and pre-warmed to 37°C. Responsiveness to GSK1016790A was 
measured over a further 5 min; a venous blood sample was subsequently drawn from the 
inferior vena cava, and animals were terminated by cervical dislocation. Blood biochemistry 
was assessed immediately from 100 µl venous blood using a hand-held iSTAT® point-of-care 
analyser (Abbott Laboratories, IL, USA), with CG8+ cartridges (Abbott Laboratories). Results 
were analysed in moorFLPI Review software (V4.0) and GraphPad Prism, as described in 
section 3.2.7.1. Results are expressed as mean area under the curve (AUC) over time ± SEM. 
 Assessment of organ oedema 6.2.5
Oedema formation was measured by comparing wet and dry weights of lungs, hearts, upper 
liver lobes, right kidneys, 1-cm sections of small intestine and whole spleens. Tissues were 
excised immediately after blood flow recording and wet weights were recorded. Samples were 
then placed in an oven at 50°C until a constant dry weight was reached (approximately 3 days). 
The ratio of wet weight:dry weight was used as an indication of oedema formation.  
A timeline summarising the sequence of experimental procedures is provided in Figure 49. 
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Figure 49. Timeline of experimental procedures. Mice were implanted with telemetry probes on Day 1, and were left to recover for 10 days. Basal haemodynamic data 
were then recorded over a 48-h weekend period (BL1). The following weekend, WT mice were injected with either vehicle (10% DMSO in saline) or TRPV4 antagonist HC-
067047 (10 mg/kg, i.p.) and a second 48-h baseline recording (BL2) was taken for all mice. TRPV4 KO mice were left untreated. Injections in WT mice were performed in a 
randomised fashion by Dr Anna Starr or Dr Manasi Nandi to ensure investigator blinding. Following the second weekend baseline recording, WT mice received a second 
injection of either HC-067047 or vehicle (consistent with initial treatment) and LPS (12.5 mg/kg, i.v.) was administered to all mice. Haemodynamic data were recorded over 
24-h of sepsis progression. Mice were then terminally anaesthetised for blood flow recording and ex vivo analysis. A separate cohort of naïve mice were included in blood 
flow and ex vivo studies. 
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 Results 6.3
 TRPV4 heterozygous mice did not breed according to expected Mendelian 6.3.1
ratios 
C57/BL6 mice heterozygous for a non-functional TRPV4 receptor gene (TRPV4 KO) were re-
derived from frozen embryos generously donated by Dr Andy Grant, Wolfson Centre for Age-
Related Disease, and were originally derived from a colony generated by Liedtke & Friedman at 
the Rockefeller Institute in New York (Liedtke and Friedman, 2003). While mice in Dr Grant’s 
colony were found to breed normally, heterozygous crosses set up in our animal unit did not 
yield expected Mendelian ratios: only 5 male TRPV4 KOs were born following multiple rounds 






Figure 50. Typical genotyping results from heterozygous cross. Crosses of TRPV4 heterozygotes 
generated predominantly WT (single upper band) and heterozygous (upper and lower bands) pups. Only 
one KO (marker by the asterisk) was born in this litter. 
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 Loss of TRPV4 activity is associated with modest alterations in water but 6.3.2
not food intake 
TRPV4 WT and KO mice were singly-housed from the time of radiotelemeter implantation 
throughout the duration of the study. Food and water intake were monitored throughout. 
Recovery from telemetry surgery (measured as recovery in body weight and food and water 
intake) was equivalent across all animals. Following recovery, TRPV4 KO mice were found to 
consume marginally less water than WT counterparts, though this difference was not 
statistically significant (Fig. 51a). Systemic administration of both HC-067047 and vehicle 
reduced water intake, though the magnitude of change was significantly greater in antagonist-
treated animals (Fig. 51b). Water intake was reduced in all animals over the 24 h following the 
induction of sepsis (Fig. 51c). No difference in food intake was observed between different 
genotypes (Fig. 51d). Systemic administration of both vehicle and HC-067047 slightly reduced 
food intake, though to a similar degree across treatment groups (Fig. 51e). LPS markedly 
reduced food intake to a similar degree in all groups (Fig. 51f). 












Figure 51. Water and food intake in TRPV4 WT and KO mice before and after induction of sepsis. (a) Mean basal water intake in TRPV4 WT and KO mice over 
approximately 1 week (not including 7-day recovery period from telemetry surgery). (b) Change in water intake over 24-h period following i.p. administration of either 
vehicle (10% DMSO) or HC-067047. (c) Water intake over 24-h period following administration of LPS (12.5 mg/kg i.v.). (d) Mean basal food intake in TRPV4 WT and KO 
mice over approximately 1 week (not including 7-day recovery period from telemetry surgery). (e) Change in food intake over 24-h period following i.p. administration of 
either vehicle (10% DMSO) or HC-067047. (f) Food intake over 24-h period following administration of LPS (12.5 mg/kg i.v.). Data for individual animals are represented as 
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 Loss of TRPV4 activity is associated with modest haemodynamic 6.3.3
alterations 
Male TRPV4 WT and KO littermates were implanted with radiotelemetry devices for remote 
haemodynamic monitoring. Two WT mice were excluded from the study due to loss of 
transmitter signal. Under basal conditions, all animals exhibited diurnal variation in blood 
pressure, heart rate and ambulatory activity, within the expected physiological range for mice 
(Curtis et al., 2007) (Fig. 52). No significant difference in basal haemodynamic parameters was 
observed between genotypes, although TRPV4 KO mice exhibited a trend towards slightly 
lower blood pressure (both daytime and night-time) and daytime ambulatory activity than WT 
counterparts [mean MAP over 24 h: 93.71 ± 2.83 mmHg vs. 99.89 ± 1.87 mmHg, respectively, 
ns; mean daytime activity over 12 h: 3.25 ± 0.43 counts/min vs. 4.31 ± 0.33 counts/min, 
respectively, ns (n = 5–10)] (Fig. 52a,c,d,f).  
Systemic administration of the TRPV4 antagonist HC-067047 caused an increase in mean 
daytime blood pressure of approximately 5 mmHg, though this was reversed after 12 h, 
leading to small but consistent decrease in night-time pressure (Table 13). Systemic 
administration of vehicle (10% DMSO in saline) also caused an increase in blood pressure, 
however, though this was more transient (Fig. 52). Administration of neither HC-067047 nor 
vehicle significantly altered any other haemodynamic parameters under basal conditions, 
though heart rate was transiently increased in both groups, and subsequently declined during 
night-time hours, relative to time-matched pre-treatment values (Table 13). In both cases 
(daytime tachycardia and night-time bradycardia) the magnitude of the change was slightly 
greater in HC-067047-treated mice than in vehicle-treated controls, though this was not 
statistically significant. Mice treated with HC-067047 did exhibit significantly greater daytime 
ambulatory activity, relative to time-matched pre-treatment values (Table 13); this change was 
not observed in vehicle-treated animals, and was no longer evident during night-time hours. 
Since TRPV4 KO mice were not treated with pharmacological stimuli, baseline parameters 
were simply re-recorded in the same mice. Values were relatively consistent across separate 
baseline recording periods (Table 13), confirming the robustness of the monitoring system.  
Systemic administration of LPS caused a significant decline in blood pressure in all animals (Fig. 
52a, c, d & Table 13), that began to stabilise after approximately 12 h. No significant difference 
between genotypes was observed, though both TRPV4 KOs and antagonist-treated mice 
exhibited a trend towards more severe hypotension, particularly in terms of systolic pressure 
(Fig. 52a & c and Table 13). Pulse pressure also appeared more severely compromised in 
TRPV4 KO and HC-067047-treated mice, relative to vehicle-treated controls, a potential sign of 
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left ventricular dysfunction and low stroke volume and/or excessive aortic compliance (Fig. 
52e and Table 13).  
An immediate increase in heart rate was observed in both HC-067047- and vehicle-treated WT 
animals following the induction of sepsis; this tachycardia was sustained during daylight hours, 
consistent with a baroreceptor reflex to low blood pressure. TRPV4 KO mice exhibited a very 
transient increase in heart rate immediately after LPS administration, but became markedly 
bradycardic thereafter, indicating failure of the baroreceptor reflex (Fig. 52b and Table 13). All 
mice exhibited marked bradycardia during night-time hours, relative to time-matched pre-LPS 
values, though the magnitude of the decrease was greatest in TRPV4 KO mice (Table 13) 
Ambulatory activity was almost entirely abolished in all mice following the induction of sepsis 
(Fig. 52f).  
 













Figure 52. Haemodynamic monitoring in TRPV4 WT and KO mice under basal and septic conditions. (a) Mean arterial pressure, (b) heart rate, (c) systolic pressure, (d) 
diastolic pressure, (e) pulse pressure and (f) locomotor activity at baseline (BL1), following systemic treatment (WT mice only) with HC-067047 (HC) or vehicle (10% DMSO) 
(BL2) and after induction of sepsis (at time 48h: LPS, 12.5mg/kg, i.v.). Boxed regions denote periods of darkness. Data were acquired by radiotelemetry in conscious, 
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Mean arterial pressure, mean diff (95% CI), mm Hg 
 Day Night 
Comparison 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 +4.835 
(-10.99 to +20.66) 
+5.297 
(-7.62 to +18.21) 
-0.406 
(-14.56 to +13.74) 
-1.532 
(-13.82 to +10.75) 
-4.956 
(-14.99 to +5.08) 
-2.327 
(-13.32 to +8.66) 
BL1 – LPS -2.838 
(-18.66 to +12.98) 
-2.124 
(-15.04 to +10.79) 
-4.326 
(-18.48 to +9.825) 
-14.480** 
(-29.77 to +2.19) 
-19.020*** 
(-29.05 to -8.99) 
-15.410*** 
(-26.4 to -4.418) 
BL2 – LPS -7.674 
(-23.49 to +8.147) 
-7.421 
(-20.34 to +5.50) 
-3.920 
(-18.07 to +10.23) 
-12.95* 
(-25.23 to +0.66) 
-14.060 
(-24.09 to -4.03) 
-13.080** 
(-24.07 to -2.09) 
Systolic pressure, mean diff (95% CI), mm Hg 
 Day Night 
Comparison 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 +4.523 
(-14.82 to +23.87) 
+5.443 
(-10.35 to +21.24) 
-1.898 
(-19.20 to +15.41) 
-0.935 
(-19.33 to +17.46) 
-3.393 
(-18.41 to +11.62) 
-2.923 
(-19.37 to +13.53) 
BL1 – LPS -7.558 
(-26.90 to +11.79) 
-6.681 
(-22.48 to +9.12) 
-9.699 
(-27.00 to +7.61) 
-14.64 
(-33.03 to +3.75) 
-22.590*** 
(-37.61 to -7.58) 
-19.870** 
(-36.32 to -3.42) 
BL2 – LPS -12.08 
(-31.43 to +7.27) 
-12.12 
(-27.92 to +3.67) 
-7.801 
(-25.10 to +9.50) 
-13.70  
(-32.10 to +4.69) 
-19.20** 
(-34.22 to -4.19) 
-16.94* 
(-33.39 to -0.49) 
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Diastolic pressure, mean diff (95% CI), mm Hg 
 Day Night 
Comparison WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 
+4.175 
(-12.49 to +20.84) 
+3.614 
(-10.00 to +17.22) 
-0.3836 
(-15.29 to +14.53) 
-1.603 
(-13.95 to +10.75) 
-6.103 
(-16.19 to +3.98) 
-0.263 
(-11.31 to +10.78) 
BL1 – LPS 
-0.366 
(-17.04 to +16.30) 
+1.581 
(-12.03 to +15.19) 
+2.953 
(-11.96 to +17.86) 
-13.410* 
(-25.76 to -1.06) 
-15.940*** 
(-26.03 to -5.86) 
-9.740 
(-20.79 to +1.307) 
BL2 – LPS 
-4.541 
(-21.21 to +12.13) 
-2.033 
(-15.64 to +11.58) 
+3.337 
(-11.57 to +18.25) 
-11.810 
(-24.16 to +0.54) 
-9.841 
(-19.93 to +0.24) 
-9.476 
(-20.52 to +1.57) 
Heart rate, mean diff (95% CI), bpm 
 Day Night 
Comparison 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 
+18.45 
(-80.45 to +117.40) 
+22.51 
(-58.25 to +103.30) 
-0.96 
(-89.43 to +87.50) 
-19.20 
(-126.00 to +87.55) 
-34.53 
(-121.70 to +52.63) 
-10.50 
(-106 to +84.98) 
BL1 – LPS 
+23.19 
(-75.75 to +122.10) 
+56.30 
(-24.46 to +137.10) 
-2.04 
(-90.50 to +86.42) 
-57.22 
(-164.00 to +49.54) 
-42.61 
(-129.80 to +44.55) 
-86.79 
(-182.30 to +8.69) 
BL2 – LPS 
+4.74 
(-94.17 to 103.60) 
+33.79 
(-46.97 to +114.50) 
-1.08 
(-89.54 to +87.39) 
-38.01 
(-144.80 to +68.74) 
-8.076 
(-95.24 to +79.09) 
-76.29 
(-171.80 to +19.20) 
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Pulse pressure, mean diff (95% CI), mm Hg 
 Day Night 
Comparison 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 
+1.049 
(-13.99 to +16.08) 
+1.941 
(-10.33 to +14.22) 
-0.475 
(-13.92 to +12.97) 
+1.003 
(-17.85 to +19.86) 
+1.149 
(-14.24 to +16.54) 
-2.314 
(-19.18 to +14.55) 
BL1 – LPS 
-6.405 
(-21.44 to +8.63) 
-9.437 
(-21.71 to +2.84) 
-11.62 
(-25.06 to +1.83) 
-0.939 
(-19.79 to +17.91) 
-6.659 
(-22.05 to +8.74) 
-9.965 
(-26.83 to +6.90) 
BL2 – LPS 
-7.454 
(-22.49 to +7.58) 
-11.38 
(-23.65 to +0.90) 
-11.14 
(-24.59 to +2.31) 
-1.943 
(-20.80 to +16.91) 
-7.808 
(-23.20 to +7.59) 
-7.651 
(-24.51 to +9.21) 
Activity, mean diff (95% CI), counts/min 
 Day Night 
Comparison 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
WT + Vehicle 
(n = 4) 
WT + HC-067047 
(n = 6) 
TRPV4 KO 
(n = 5) 
BL1 – BL2 
+1.548 
(-1.97 to +5.07) 
+3.260* 
(+0.39 to +6.14) 
+0.880 
(-2.27 to +4.03) 
-0.114 
(-4.20 to -397) 
-0.360 
(-3.69 to +2.97) 
-2.169 
(-3.30 to +3.69) 
BL1 – LPS 
-3.764 
(-7.29 to +0.24) 
-2.762 
(-5.64 to +0.11) 
-1.568 
(-4.72 to +1.58) 
-8.932*** 
(-13.02 to -4.85) 
-5.788*** 
(-9.12 to -2.45) 
-7.105*** 
(-10.76 to -3.45) 
BL2 – LPS 
-5.311*** 
(-8.83 to +1.79) 
-6.023*** 
(-8.90 to -3.15) 
-2.448 
(-5.60 to +0.70) 
-8.818*** 
(-12.90 to -4.74) 
-5.428*** 
(-8.76 to -2.09)  
-4.936** 
(-8.59 to -1.28) 
 
Table 13. Statistical comparison of haemodynamic parameters in TRPV4 WT and KO mice under basal and septic conditions. Data are presented as mean difference (95% 
CI), and are divided into daytime and night-time phases. BL1 represents mean baseline values in untreated mice over 48-h weekend recording. BL2 represents mean 
baseline values following i.p. treatment (WT mice only) with vehicle (10% DMSO) or HC-067047; BL2 in KO mice represents a separate untreated 48-h baseline recording. 
LPS represents mean values following systemic treatment with LPS (12.5 mg/kg, i.v.) over 24-h recording period. *p<0.05, **p<0.01, ***p<0.001, 1-way ANOVA + 
Bonferroni post-hoc test.  
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 Loss of TRPV4 activity does not significantly alter mesenteric blood flow 6.3.4
All mice telemetered for haemodynamic recording were subjected to mesenteric blood flow 
analysis. A group of naïve animals were included for comparison, and additional vehicle- and 
HC-067047-treated WT mice were used to increase statistical power. Owing to the low yield of 
TRPV4 KO mice, an additional 4 LPS-treated age-matched mice were included from the colony 
of Dr Andy Grant at the Wolfson Centre for Age-Related Diseases, King’s College London; 6 
naïve KO mice were also generously supplied by Dr Grant, though these were not age-
matched. Blood flow recording in the 10 additional KO mice was performed on-site at the 
Wolfson Centre, as transfer to our unit was not possible.  
Blood flow was significantly reduced in all groups 24 h after the induction of sepsis (Fig. 53a–
c). No significant differences were observed between genotypes or treatment groups, though 
septic mice pre-treated with HC-067047 exhibited a slight trend towards improved flow. In 
order to determine whether blockade of TRPV4 may play a role earlier in sepsis pathogenesis, 
mesenteric flow was recorded in a separate cohort of WT mice treated for 6 h with HC-067047 
and LPS. At this time-point, blood flow in HC-067047-treated mice was slightly decreased 
relative to vehicle-treated controls, though these changes were not statistically significant (Fig. 
53e–f). 





























Figure 53. Mesenteric blood flow in healthy and septic TRPV4 WT and KO mice. (a–c) Mesenteric blood flow in TRPV4 KO mice and WT mice treated i.p. with vehicle (10% 
DMSO) or HC-067047 (HC) for 24 h, either under naïve or septic (LPS 12.5 mg/kg, i.v., 24 h). Data are expressed as total area under the curve (AUC; x10
3
 flux units.time) 






 order vessels, respectively. **p<0.01, ***p<0.001, relative to naïve counterparts, 1-way ANOVA + Bonferroni post-hoc test. 
(d–f) Mesenteric blood flow in WT mice treated i.p. with vehicle (10% DMSO) or HC-067047, either under naïve (24-h treatment) or septic conditions (6 h or 24 h; drugs 






 order vessels, respectively. AUC for each animal is represented as an individual symbol, with horizontal line 
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 Neither antagonism nor gene ablation of TRPV4 significantly alters the 6.3.5
sepsis phenotype 
Antagonism and gene ablation of TRPV4 had only minor effects on clinical phenotype, though 
in opposing directions. In line with marginally improved mesenteric perfusion, antagonist-
treated mice exhibited a slightly lower severity score after 24-h treatment with LPS, relative to 
vehicle-treated controls. On the other hand, the severity score in TRPV4 KO mice was 
significantly greater than in antagonist-treated counterparts (Fig. 54a).  The percentage weight 
loss over 24 h of sepsis was roughly equivalent between groups, but was lower in antagonist-
treated and TRPV4 KO mice, than in vehicle-treated controls (Fig. 54b). Core temperature 
decreased significantly in all LPS-treated mice, though remained stable in all animals 
throughout the recording period (Fig. 54c). Although no statistically significant differences in 
core temperature were observed between groups, there were trends towards attenuated 
hypothermia in HC-067047-treated mice, and exaggerated hypothermia in TRPV4 KO mice, 
relative to vehicle-treated counterparts.  
TRPV4 antagonism and gene ablation appeared to have divergent effects on blood 
biochemistry (Table 14). Whereas urea was elevated in all groups 24 h post-LPS, the increase 
in TRPV4 KO mice was greatest, whereas that in antagonist-treated mice did not reach 
statistical significance. Blood pH was also lowest in LPS-treated TRPV4 KO mice, whereas 
acidosis was slightly attenuated in antagonist-treated mice, relative to vehicle-treated 
controls. PCO2 was slightly increased by LPS treatment, and bicarbonate slightly decreased, 
indicative of respiratory and metabolic acidosis, respectively, though no significant differences 
were observed across treatment groups. All mice also became significantly hypoglycaemic 
following the induction of sepsis. While both vehicle- and antagonist-treated animals became 
significantly hypernatraemic and hyperchloraemic over the course of sepsis, consistent with 
dehydration and loss of bicarbonate, respectively, no change in plasma Na+ or Cl- levels was 
observed in TRPV4 KO mice. Correspondingly, bicarbonate levels decreased in both vehicle- 
and antagonist-treated mice, but not in TRPV4 KO mice. Both haemoglobin and haematocrit 
decreased slightly with sepsis, though to an equivalent extent across groups.  
Interestingly, like naïve TRPV1 KO animals, naïve TRPV4 KO mice also exhibited trends towards 
pathological blood biochemistry. Urea was slightly elevated in these mice, and blood pH 
significantly decreased, relative to vehicle-treated WT controls. Basal haemoglobin and 
231  |  T H E  R O L E  O F  T R P V 4  I N  S E P S I S - A S S O C I A T E D  
C A R D I O V A S C U L A R  D Y S F U N C T I O N  
haematocrit levels were also slightly decreased in these animals, relative to WT controls, 
indicative of basal anaemia (Table 14).  
The effect of TRPV4 antagonism was also assessed at an earlier time-point in sepsis 
pathogenesis. In contrast with the 24-h time-point, no significant difference in severity score, 
percentage weight loss, or core temperature was observed between vehicle- and antagonist-
treated mice at 6 h post-LPS (Fig. 55). Blood biochemistry was similarly equivalent between 
treatment groups at the 6-h time-point (Table 15).  
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Figure 54. Clinical parameters in TRPV4 WT and KO mice. (a) Arbitrary severity score assigned in a 
blinded fashion after 24-h treatment with LPS (12.5 mg/kg, i.v.) based voluntary mobility, gait, aversion 
to touch, facial expression and piloerection. WT mice were treated i.p. with vehicle (10% DMSO) or HC-
067047 (HC) at the time of LPS administration. TRPV4 KO mice did not receive any pharmacological 
treatment. (b) Percentage weight loss over 24-h septic period. Values for each animal are presented as 
individual symbols, with horizontal line denoting group mean. 
#
p<0.05, relative to HC-treated animals, 1-
wayANOVA + Bonferroni post-hoc test (n = 8–9). (c) Core temperature measured by rectal probe 
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Vehicle Naïve  HC Naïve KO Naïve  Vehicle LPS HC LPS KO LPS 
Urea (mmol/L) 5.100 ± 0.51 4.938 ± 0.44 5.417 ± 0.39 22.45 ± 5.55* 18.53 ± 3.81 30.30 ± 4.85*** 
pH 7.314 ± 0.01 7.291 ± 0.01 7.189 ± 0.03
#
 7.095 ± 0.03*** 7.156 ± 0.02** 7.090 ± 0.04 
Base excess (mmol/L) -12.38 ± 0.80 -11.38 ± 1.03 -14.83 ± 0.79 -17.75 ± 1.05 -16.11 ± 1.23 -16.78 ± 2.05 
HCO3
-
 (mmol/L) 13.73 ± 0.88 15.41 ± 1.09 13.55 ± 0.94 11.90 ± 0.73 12.88 ± 1.26 13.14 ± 1.74 
PCO2 (mmHg) 27.25 ± 2.18 32.06 ± 2.40 36.65 ± 5.20 39.08 ± 3.15 36.90 ± 4.02 42.11 ± 4.99 
TCO2 (mmol/L) 14.63 ± 0.92 16.50 ± 1.15 14.67 ± 1.02 13.13 ± 0.74 14.00 ± 1.36 14.33 ± 1.85 
Glucose (mmol/L) 11.70 ± 1.03 12.36 ± 0.90 10.77 ± 1.10 1.08 ± 0.04*** 1.34 ± 0.12*** 1.76 ± 0.50*** 
Na
+





 (mmol/L) 4.088 ± 0.15 4.250 ± 0.19 4.150 ± 0.24 3.950 ± 0.30 3.589 ± 0.32 3.625 ± 0.23 
Cl
-
 (mmol/L) 121.8 ± 1.3 119.5 ± 0.8 124.0 ± 0.6 130.0 ± 1.6* 128.6 ± 1.0*** 124.3 ± 1.6
# 
Anion gap (mmol/L) 18.50 ± 0.53 17.25 ± 0.94 16.67 ± 0.92 18.50 ± 0.87 16.11 ± 1.11 16.25 ± 1.03 
Haemoglobin (g/dl) 10.41 ± 0.54 10.93 ± 0.59 8.60 ± 0.25 9.43 ± 0.71 8.96 ± 7.33  9.53 ± 0.59 
Haematocrit  (%PCV) 30.63 ± 1.60 32.13 ± 1.74 25.25 ± 0.75 29.57 ± 1.17 27.88 ± 1.36 28.00 ± 1.72 
 
Table 14. Blood biochemistry in healthy and septic TRPV4 WT and KO mice. Blood gas and biochemistry were measured from venous blood samples by iSTAT point-of-
care analyser in either TRPV4 KO mice, or WT mice treated i.p. with vehicle (10% DMSO) or HC-067047 (HC) for 24 h, either under naïve or septic (LPS 12.5 mg/kg, i.v., 24 h) 
conditions. Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, relative to naïve controls; 
#
p<0.05, relative to vehicle-treated controls, 1-way ANOVA + 
Bonferroni post-hoc test (n = 6–9). 
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; PCV, packed cell volume; HC, HC-067047; KO, TRPV4 knockout; LPS, lipopolysaccharide
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Figure 55. Clinical parameters in WT mice treated with TRPV4 antagonist or vehicle. (a) Arbitrary 
severity score assigned in a blinded fashion after 6- or 24-h treatment with LPS (12.5 mg/kg, i.v.) based 
voluntary mobility, gait, aversion to touch, facial expression and piloerection. WT mice were treated i.p. 
with vehicle (10% DMSO) or HC-067047 (HC) at the time of LPS administration (b) Percentage weight 
loss over 6- or 24-h septic period. (c) Mean core temperature measured by rectal probe over blood flow 
recording period. Values for each animal are presented as individual symbols, with horizontal line 
denoting group mean. **p<0.01, ***p<0.001, relative to naïve controls, 1-wayANOVA + Bonferroni post-
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a b 
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Vehicle Naïve  HC Naïve Vehicle LPS 6 h  HC LPS 6 h Vehicle LPS 24 h HC LPS 24 h 
Urea (mmol/L) 5.100 ± 0.51 4.938 ± 0.44 7.888 ± 0.51 7.838 ± 0.76 22.45 ± 5.55* 18.53 ± 3.81 
pH 7.314 ± 0.01 7.291 ± 0.01 7.073  ± 0.03*** 7.090 ± 0.02***  7.095 ± 0.03*** 7.156 ± 0.02** 
Base excess (mmol/L) -12.38 ± 0.80 -11.38 ± 1.03 -19.00 ± 1.18* -18.63 ± 1.16** -17.75 ± 1.05 -16.11 ± 1.23 
HCO3
-
 (mmol/L) 13.73 ± 0.88 15.41 ± 1.09 11.09 ± 0.89 11.30 ± 1.13 11.90 ± 0.73 12.88 ± 1.26 
PCO2 (mmHg) 27.25 ± 2.18 32.06 ± 2.40 38.25 ± 3.28 37.46 ± 4.41 39.08 ± 3.15 36.90 ± 4.02 
TCO2 (mmol/L) 14.63 ± 0.92 16.50 ± 1.15 12.13 ± 0.97  12.38 ± 1.22 13.13 ± 0.74 14.00 ± 1.36 
Glucose (mmol/L) 11.70 ± 1.03 12.36 ± 0.90 2.063 ± 0.52*** 1.838 ± 0.42*** 1.08 ± 0.04*** 1.34 ± 0.12*** 
Na
+
 (mmol/L) 150.3 ± 1.7 147.9 ± 1.0 156.8 ± 0.4** 156.6 ± 0.5*** 155.9 ± 0.9* 154.0 ± 1.1** 
K
+
 (mmol/L) 4.088 ± 0.15 4.250 ± 0.19 3.788 ± 0.20 3.788 ± 0.33 3.950 ± 0.30 3.589 ± 0.32 
Cl
-
 (mmol/L) 121.8 ± 1.3 119.5 ± 0.8 131.3 ± 1.0*** 131.4 ± 0.9*** 130.0 ± 1.6* 128.6 ± 1.0*** 
Anion gap (mmol/L) 18.50 ± 0.53 17.25 ± 0.94 18.13 ± 1.11 17.50 ± 0.50 18.50 ± 0.87 16.11 ± 1.11 
Haemoglobin (g/dl) 10.41 ± 0.54 10.93 ± 0.59 9.44 ± 0.64 9.23 ± 0.85 9.43 ± 0.71 8.96 ± 7.33  
Haematocrit  (%PCV) 30.63 ± 1.60 32.13 ± 1.74 27.75 ± 1.92 29.14 ± 1.71 29.57 ± 1.17 27.88 ± 1.36 
 
Table 15. Blood biochemistry in healthy and septic WT mice treated with TRPV4 antagonist or vehicle. Blood gas and biochemistry were measured from venous blood 
samples by iSTAT point-of-care analyser in WT mice treated i.p. with vehicle (10% DMSO) or HC-067047 (HC), either under naïve (24-h treatment) or septic (LPS 12.5 mg/kg, 
i.v., 6 h or 24 h) conditions. Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, relative to naïve controls, 1-way ANOVA + Bonferroni post-hoc test (n = 8–
9). 
Abbreviations: PCO2, partial pressure of CO2; TCO2, total carbon dioxide; PCV, packed cell volume; HC, HC-067047; KO, TRPV4 knockout; LPS, lipopolysaccharide
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 TRPV4 KO mice exhibit exaggerated kidney, liver and spleen oedema in 6.3.6
LPS-induced sepsis 
Oedema formation was measured by comparing wet and dry weights of various tissues. 
Surprisingly, treatment with LPS for 24 h did not cause any appreciable oedema formation in 
WT mice (Fig. 56). Septic TRPV4 KO mice exhibited marginally elevated oedema formation in 
the liver and spleen, and significantly increased oedema in the kidney. No difference was 
observed between vehicle and antagonist-treated mice.  
The effect of TRPV4 antagonism on oedema formation was also assessed at an earlier time-
point in sepsis pathogenesis. In contrast with the 24-h time-point, significant liver oedema was 
observed in both vehicle- and HC-067047-treated mice after 6 h, though this had returned to 
baseline levels by 24 h post-LPS (Fig. 57). No significant difference in oedema formation was 
observed in any other tissues, however. No changes in the ratio of heart weight to body weight 
were observed following the induction of sepsis in any of the animal groups.   
 












Figure 56. Oedema formation in TRPV4 WT and KO mice. Oedema formation was measured by comparing wet and dry weights of (a) lungs, (b) hearts, (c) upper liver 
lobes, (d) right kidneys, (e) 1-cm sections of small intestine and (f) whole spleens. WT mice treated i.p. with vehicle (10% DMSO) or HC-067047 (HC) for 24 h, either under 
naïve or septic (LPS 12.5 mg/kg, i.v., 24 h) conditions. Values for each animal are presented as individual symbols, with horizontal line denoting group mean. ***p<0.001, 
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Figure 57. Oedema formation in WT mice treated with TRPV4 antagonist or vehicle. Oedema formation was measured by comparing wet and dry weights of (a) lungs, (b) 
hearts, (c) upper liver lobes, (d) right kidneys, (e) 1-cm sections of small intestine and (f) whole spleens. WT mice were treated i.p. with vehicle (10% DMSO) or HC-067047 
(HC) at the time of LPS (12.5 mg/kg, i.v., 6 or 24 h). Values for each animal are presented as individual symbols, with horizontal line denoting group mean. **p<0.01, 
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 Vasoactive responses to topical TRPV4 activation are enhanced in sepsis 6.3.7
In order to assess changes in TRPV4 activity in vivo after the induction of sepsis, 1 µM 
GSK1016790A and vehicle (2% DMSO in pre-warmed saline) were sequentially applied to the 
exposed mesenteric bed by aerosolised spray. No significant responses to GSK1016790A were 
observed in the mesenteric beds of naive mice: both vehicle and GSK1016790A caused a slight 
non-significant decrease in blood flow, likely to reflect evaporative cooling (Fig. 58a−c and 
Table 16). In LPS-treated mice, on the other hand, GSK1016790A caused a modest increase in 


















Figure 58. Vasoactive responses to GSK1016790A and vehicle in healthy and septic WT mice. Baseline mesenteric blood flow was recorded for 5 min in naïve (a–c) and 
septic (d–f) mice, 24 h after injections of LPS. Vehicle (V; 2% DMSO in saline) was then administered as an aerosolised spray, followed by administration of GSK1016790A 
(G; 1 µM) 5 min later. Blood flow was recorded in (a & d) 1
st
 order, (b & e) 2
nd
 order and (c & f) 3
rd
 order mesenteric vessels. Data are presented as mean ± SEM. *p<0.05, 
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 Naive LPS 24 h 
 1st order 2nd order 3rd order 1st order 2nd order 3rd order 
BL−Veh -7.33 ± 3.10% -8.39 ± 1.73% -1.10 ± 0.32% -3.00 ± 2.77% -1.18 ± 1.51% -2.22 ± 3.87% 
Veh−GSK -7.61 ± 1.30% -8.46 ± 3.27% -3.42 ± 2.05% +12.11 ± 6.19% +14.71 ± 6.70% *,# +11.73 ± 8.72%** 
 
Table 16. Change in mesenteric blood flow following topical TRPV4 activation in naïve and septic mice. Baselines (BL), and responses to aerosolised vehicle (Veh; 10% 
DMSO in pre-warmed saline) and GSK1016790A (GSK; 1 µM) were recorded over sequential 5-min periods. Data are presented as mean percentage change in area under 
the curve over 5-min recording period. *p<0.05, **p<0.01, relative to vehicle response in the same mouse, paired 2-tailed Student’s T-test; 
#
p<0.05 relative to 
corresponding response in naïve controls, 1-way ANOVA + Bonferroni post-hoc test (n = 5).  
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 Summary 6.4
The key findings from this study are: 
1. Loss of TRPV4 activity is associated with slightly reduced water intake 
2. TRPV4 KO mice have normal basal haemodynamic function, but exhibit a trend 
towards lower blood pressure and reduced ambulatory activity 
3. Systemic TRPV4 antagonism caused a modest and transient increase in blood pressure, 
followed by a subsequent decrease in night-time blood pressure, though systemic 
administration of vehicle produced similar effects, albeit of lower magnitude 
4. Loss of TRPV4 activity may be associated with marginally exaggerated hypotension in 
sepsis, though a larger sample size would be needed to confirm this observation 
5. TRPV4 does not appear to play a significant role in the regulation of mesenteric blood 
flow, either under basal or septic conditions 
6. TRPV4 antagonism slightly attenuates the clinical phenotype of sepsis, whereas TRPV4 
gene ablation is associated with a slightly exaggerated phenotype  
7. Topical TRPV4 activation in the mesenteric bed does not cause significant changes in 
blood flow under naïve conditions, but slightly increases blood flow in septic mice 
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 Discussion 6.5
Based on our own observations of LPS-induced sensitisation of endothelial TRPV4 (Chapter 5), 
and in light of previous studies demonstrating that excessive TRPV4 activation can cause 
profound hypotension, endothelial failure and circulatory collapse (Willette et al., 2008), we 
hypothesised that TRPV4 may contribute to haemodynamic and vascular dysfunction during 
sepsis. Numerous endogenous agonists and regulators of TRPV4, including anandamide (Varga 
et al., 1998), arachidonic acid and its metabolites (Bruegel et al., 2012), and PKA (Yang et al., 
1997), have been shown to be upregulated in sepsis. It is conceivable therefore, that 
inflammation-induced upregulation of endogenous factors could contribute to sepsis-
associated circulatory failure via excessive TRPV4 activation. By extension, blockade of TRPV4 
activity may be expected to attenuate the circulatory dysfunction that underlies sepsis 
pathogenesis.  To test this hypothesis we used both TRPV4 KO mice and a selective TRPV4 
antagonist.  
 Basal phenotype of mice lacking TRPV4 6.5.1
In contrast to the parent colony housed at the Wolfson Centre for Age-Related Diseases, King’s 
College London, heterozygous mice re-derived from frozen embryos in our animal unit did not 
produce TRPV4 KO mice in the expected Mendelian ratios: only 5 male TRPV4 KOs were born 
following multiple rounds of breeding by 8 heterozygous pairs. Mice lacking TRPV4 have been 
shown to be fully viable (Liedtke and Friedman, 2003), and the fact that some KOs were 
generated in this study demonstrate that the mutation is not developmentally lethal. It is 
unclear, therefore, why the yield of TRPV4 KO mice was so low. It is possible that epigenetic 
changes acquired during embryo isolation, freezing, transport or implantation could have 
contributed to in utero selection against mutant zygotes, and that homozygous crosses of 
TRPV4 KO mice would be required to generate sufficient numbers of mutant mice.  This was 
unfortunately not possible for this study, due to time constraints, and experiments were thus 
limited by the small sample size. Therefore meaningful statistical comparison was only possible 
for antagonist-treated mice, though trends in KO mice support further investigation.  
Consistent with a role for TRPV4 in osmoregulation, and with previous reports (Liedtke and 
Friedman, 2003), we observed a modest decrease in water intake in TRPV4 KO mice. 
Meaningful comparison was limited by the low mouse number, although it is supported by the 
observation that systemic treatment with a TRPV4 antagonist also reduced water intake over 
the following 24 h. Previous reports suggest that differences in water intake between mutant 
and WT mice are only evident when mice are singly housed, as they were in this study: 
mutually-stimulating group drinking patterns and free access to food both increase water 
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intake and mask genotype differences (Liedtke and Friedman, 2003). The decrease in water 
intake observed in this study is in contrast with a previous report which recorded no 
differences in water intake between HC-067047- and vehicle-treated mice (Everaerts et al., 
2010). Differences in the composition of the vehicle (1% DMSO versus 10% in this study) could 
account for this discrepancy; it is also possible the differences observed here would have been 
further enhanced in the absence of food. The observation that food intake is unaffected by 
loss of TRPV4 activity suggests that the decrease in water intake represents a reduced desire 
to drink, rather than a non-specific physiological effect that indirectly alters consumption 
behaviour.  
 The role of TRPV4 in basal haemodynamic regulation 6.5.2
Consistent with previous reports (Zhang et al., 2009, Nishijima et al., 2014), TRPV4 KO mice 
exhibited a trend towards lower basal arterial pressure during both daytime and night-time 
periods. This is surprising given that TRPV4 has been implicated in both NO- and EDHF-
mediated vasodilatory responses to physical and chemical stimuli in both conduit and 
resistance arteries (Kohler et al., 2006, Hartmannsgruber et al., 2007, Loot et al., 2008, Zhang 
et al., 2009, Mendoza et al., 2010, Adapala et al., 2011, Rath et al., 2012, Sonkusare et al., 
2012, Ma et al., 2013a). A possible explanation is that loss of TRPV4 leads to compensatory 
upregulation of alternative vasodilatory pathways during development; although studies of 
isolated vessels from TRPV4 KO mice have shown impaired vasodilatation in response to a 
range of physiological stimuli (Zhang et al., 2009, Earley et al., 2009), the effects of isolation 
and ex vivo culture are unknown. Alternatively, it is possible that loss of TRPV4 expression in 
vascular smooth muscle may represent loss of a vasoconstrictor mechanism. While numerous 
studies have suggested that TRPV4 in vascular smooth muscle couples with hyperpolarising K+ 
channels to induce vasodilatation (Earley et al., 2005, Earley et al., 2009), global activation of 
TRPV4 (as opposed to very localised activation) may trigger Ca2+-dependent vasoconstriction 
that may contribute to the maintenance of vascular tone. Indeed, TRPV4-mediated 
vasoconstriction has previously been demonstrated in the lung, where TRPV4 gene ablation 
suppresses the development of chronic hypoxic pulmonary hypertension (Xia et al., 2013).  
Given that TRPV4 exhibits tonic activity both in heterologous expression systems (Strotmann et 
al., 2000) and in primary endothelial cells (Sonkusare et al., 2012), its blockade may be 
expected to cause acute hypertension. While systemic administration of HC-067047 did induce 
a small transient increase in blood pressure under basal conditions, a similar effect was 
observed in vehicle-treated animals, suggesting that the transient hypertension may have 
been a stress response to manual handling. In accordance with these data, administration of a 
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different TRPV4 antagonist – GSK 2193874 – did not significantly alter blood pressure after 
either acute intravenous administration or repeated oral gavage (Thorneloe et al., 2012) 
The lack of any dramatic effect on blood pressure is consistent with a previous ex vivo report 
that blockade of the TRPV4-CYP450 epoxygenase axis only inhibits flow-induced vasodilatation 
in the presence of eNOS and prostacyclin antagonists (Loot et al., 2008). In other words, 
blockade of one endothelium-dependent vasodilatory pathway can lead to acute upregulation 
of a compensatory pathway. Upregulation of alternative (and perhaps slightly more potent) 
endothelial vasodilatory pathways following loss of TRPV4 activity may also explain the 
subsequent night-time decreases in blood pressure following HC-067047 administration, which 
were not evident in vehicle-treated mice (as well as the trend towards hypotension in TRPV4 
KO mice). A compensatory increase in eNOS activity and PGI2 production could also account for 
the night-time decreases in heart rate following TRPV4 antagonism, since both are known to 
confer negative chronotropy (Feron et al., 1998, Chiba and Malik, 1980).  
 Haemodynamic consequences of TRPV4 deletion during sepsis 6.5.3
While the haemodynamic role of TRPV4 has been studied under physiological conditions 
(Willette et al., 2008, Gao et al., 2009, Zhang et al., 2009, Gao and Wang, 2010, Thorneloe et 
al., 2012), its function in pathological and inflammatory settings has not been well 
characterised. Based on our own observations of LPS-induced sensitisation of endothelial 
TRPV4 (Chapter 5), and in light of previous studies demonstrating that excessive TRPV4 
activation can cause profound hypotension, endothelial failure and circulatory collapse 
(Willette et al., 2008), we hypothesised that TRPV4 may contribute to haemodynamic and 
vascular dysfunction during sepsis. Numerous endogenous agonists and regulators of TRPV4, 
including anandamide (Varga et al., 1998), arachidonic acid and its metabolites (Bruegel et al., 
2012), and PKA (Yang et al., 1997), have been shown to be upregulated in sepsis. It is 
conceivable therefore, that inflammation-induced upregulation of endogenous factors could 
contribute to sepsis-associated circulatory failure via excessive TRPV4 activation. We 
hypothesised that blockade of TRPV4 activity would attenuate the circulatory dysfunction that 
occurs in sepsis.  
Surprisingly, neither TRPV4 gene deletion nor pharmacological antagonism attenuated the LPS-
induced haemodynamic dysfunction. In fact, both HC-067047-treated TRPV4 KO mice exhibited 
a trend towards exaggerated hypotension that was most evident in measurements of systolic 
pressure. The exaggerated systolic hypotension and greater decrease in pulse pressure 
observed in both antagonist-treated and KO mice may be indicative of reduced cardiac output 
and left ventricular dysfunction, though these parameters were not measured in this study. 
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Whether reduced water intake prior to the induction of sepsis may have contributed to 
exaggerated hypovolaemia is unclear. Alternatively, it is possible that elevated NO production 
(as a response to TRPV4 loss) could have increased aortic compliance in these animals, leading 
to greater systolic hypotension and a narrower pulse pressure.  
Overall, the haemodynamic phenotype of sepsis appeared to be worse in mice lacking TRPV4: 
hypotension was slightly exaggerated, and the baroreceptor reflex was almost entirely absent 
in TRPV4 KO mice. Given that NO is thought to antagonise the positive chronotropic effects of 
increased sympathetic drive (Feron et al., 1998), it is possible that excessive NO production in 
TRPV4 KO mice could account for the pronounced bradycardia following LPS administration. It 
will be interesting, in the future, to compare tissue levels of eNOS and iNOS, and plasma levels 
of NO and PGI2 in mice with and without functional TRPV4, both under basal and septic 
conditions. 
 TRPV4 in microvascular regulation 6.5.4
Despite numerous reports of an important role for TRPV4 in mediating agonist- and flow-
induced vasoactive responses in small resistance vessels (Kohler et al., 2006, Earley et al., 
2009, Zhang et al., 2009, Mendoza et al., 2010, Adapala et al., 2011, Sonkusare et al., 2012, Ma 
et al., 2013a), we did not observe any marked changes in mesenteric blood flow in antagonist-
treated or TRPV4 KO mice. While there was a trend towards slightly improved flow in 1st and 
2nd order vessels in septic HC-067047-treated mice, this is unlikely to represent a true 
biological phenomenon at it was not evident in TRPV4 KO mice. Of note, perhaps, is the 
observation that antagonist-treated mice exhibited trends towards exaggerated hypotension 
following LPS administration, but marginally better mesenteric perfusion; these results are 
consistent with our hypothesis put forward in Chapter 3, that stabilisation of arterial pressure 
during sepsis may occur at the expense of the microcirculation. 
Because the exact half-life of HC-067047 has not been reported, though plasma levels are 
known to exceed the IC50 for some hours after i.p. administration (Everaerts et al., 2010), we 
also investigated the effect of TRPV4 antagonism on mesenteric blood flow at an earlier time-
point. At 6-h post-LPS, there was a trend towards lower blood flow in antagonist-treated mice, 
consistent with a vasodilatory role for TRPV4, though this was not significant.  
While TRPV4 is known to dilate small resistance vessels (such that its blockade may be 
expected to decrease mesenteric blood flow) its activation has also been associated with 
increased endothelial permeability and oedema formation, which would impair perfusion 
(Willette et al., 2008). These divergent effects on microvascular blood flow may account for 
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the reverse in trends between 6-h and 24-h treatment with LPS. Nonetheless, our data do not 
support a prominent role for TRPV4 in regulating mesenteric blood flow in this model, either 
under basal or septic conditions. It is likely that compensatory pathways are upregulated both 
acutely and chronically to compensate for its loss.  
In contrast to numerous studies demonstrating TRPV4-mediated dilatation of mesenteric 
arteries (Kohler et al., 2006, Earley et al., 2009, Zhang et al., 2009, Mendoza et al., 2010, 
Adapala et al., 2011, Sonkusare et al., 2012, Ma et al., 2013a) topical activation of TRPV4 with 
GSK1016790A did not induce any marked changes in blood flow in naïve mice. Despite the 
relatively high concentration used (1 µM), it is possible that owing to the aerosolised delivery 
method, which may be prone to evaporation, insufficient concentrations of the agonist were 
able to come into contact with vascular receptors. While TRPV4 is known to be expressed in 
vascular smooth muscle (Earley et al., 2005), the compound may not have been able to reach 
the luminal side of the vessel to induce endothelium-dependent vasodilatation. Further 
experiments using higher concentrations or a different delivery method are required to 
elucidate this further. The observation that GSK1016790A caused a small increase in blood 
flow under in LPS-treated mice support our hypothesis that TRPV4 may become sensitised 
under inflammatory conditions.  
 TRPV4 in blood biochemistry 6.5.5
Like TRPV1 KO animals, TRPV4 KO mice exhibited trends towards basal pathology. Blood pH 
was significantly lower in these animals compared with WT counterparts; base excess was 
correspondingly reduced, and partial pressure of CO2 elevated, indicative of respiratory 
acidosis. These data are consistent with a potential acid-sensing role for TRPV4 reported 
previously (Suzuki et al., 2003). However, because the naïve TRPV4 KO mice used in this study 
were derived from a separate colony, were measured in a different animal unit, and 
furthermore were not age-matched, results should be interpreted with caution. Future 
research comparing the basal phenotype of WT and TRPV4 KO littermates would be required 
to establish whether loss of TRPV4 is truly associated with basal acidosis. Nonetheless, the 
observation that blood pH was also slightly reduced in naive HC-067047-treated mice relative 
to vehicle-treated controls, suggests that TRPV4 may be involved in maintaining acid-base 
homeostasis.  
Following the induction of sepsis, TRPV4 KO mice exhibited a more dramatic increase in 
plasma urea concentration than WT mice, consistent with a role for TRPV4 in regulating renal 
function. Although not measured in this study, it is possible that loss of TRPV4 activity may 
result in impaired renal circulation. While TRPV4 KO mice also exhibited the lowest blood pH of 
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all groups in sepsis, however, this was not significantly different from basal pH in these animals 
(which was mildly acidotic). Both antagonist- and vehicle-treated WT mice, in contrast, 
exhibited a significant decline in pH between basal and septic conditions, though the 
magnitude of the decrease was less pronounced in HC-067047-treated animals. This suggests 
that blockade of TRPV4 activity may attenuate the development of metabolic acidosis. 
Consistent with this notion, base excess was slightly lower and bicarbonate levels slightly 
higher in both antagonist-treated and TRPV4 KO mice, relative to vehicle-treated controls.  
Both vehicle- and antagonist-treated WT animals became severely hyperchloraemic over the 
course of sepsis. Fluid loss, and perhaps the administration of saline resuscitation at the time 
of sepsis, could have contributed to this finding. Hyperchloraemic metabolic acidosis (in which 
serum Cl- levels are elevated, bicarbonate reduced and blood pH is low) is also indicative of 
kidney dysfunction (Walker, 1990). Surprisingly, given the elevated plasma urea levels, TRPV4 
KO mice did not exhibit LPS-induced hyperchloraemia or hypernatraemia. Because naïve 
controls were not properly matched it is difficult to say whether ion concentrations change 
between physiological and pathological settings, however. 
 Measurement of oedema formation 6.5.6
 Following reports linking excessive TRPV4 activation to endothelial failure and oedema 
formation (Alvarez et al., 2006, Willette et al., 2008) we aimed to establish the role of TRPV4 in 
oedema formation during sepsis – a condition characterised by increased endothelial 
permeability (Bridges and Dukes, 2005). No marked changes in the ratio of tissue wet-to-dry 
weight were observed in WT mice following 24-h treatment with LPS: only the lung and the 
kidney exhibited trends towards increased plasma extravasation, and values were not different 
between vehicle- and antagonist-treated mice. Whether these data indicate that oedema 
formation is not significant at this time-point in sepsis pathogenesis is not clear; it is possible 
that the method used is insufficiently sensitive to detect small changes in tissue water volume, 
and that assessment of Evan’s Blue extravasation would have yielded more information.  
We did observe evidence of exaggerated oedema formation in the kidneys of LPS-treated 
TRPV4 KO mice (there were also trends towards increased wet-to-dry weight ratios in the 
livers and spleens of these animals). This was surprising given that these mice did not exhibit 
an altered ionic balance, and furthermore, because activation of TRPV4 has been associated 
with increased permeability (Alvarez et al., 2006, Willette et al., 2008). Nonetheless, it appears 
that in our hands deletion of the TRPV4 gene is associated with slightly exaggerated oedema 
formation in the kidney, liver and spleen following LPS administration, though it is not clear 
what mechanism may be involved. 
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 In vivo administration of HC-067047 6.5.7
One possible explanation for the lack of any dramatic effect following treatment with HC-
067047 in either naïve or septic animals is inadequate dosing. The dose of HC-067047 used in 
this study (10 mg/kg) was chosen based on the only two previous reports of its administration 
in vivo (Everaerts et al., 2010, Materazzi et al., 2012). While both previous studies used vehicle 
concentrations of DMSO significantly lower than the one used here (1% and 2.5%, 
respectively), in this study, 10% DMSO was found to represent the lowest concentration in 
which HC-067047 was completely soluble: at lower concentrations white particulate matter 
was clearly visible in the solution. Whether lower solubility may account for the lack of 
differences in water intake in HC-067047-treated mice reported previously (Everaerts et al., 
2010) is unclear. It is equally possible that certain unknown environmental factors (ambient 
temperature, purity of DMSO) could have affected the solubility of HC-067047 in this study.  
While the effects of systemic TRPV4 antagonism were not dramatic in this study, use of higher 
concentrations was not possible: intraperitoneal injection of 100 mg/kg HC-067047 has been 
shown to cause obvious adverse effects, including hunching and piloerection (Everaerts et al., 
2010), and higher concentrations of DMSO could potentially induce cellular toxicity. Repeated 
dosing may represent a more viable option for blood flow recording or biochemical analysis, 
though repeated manual handling and intraperitoneal injections would certainly preclude 
meaningful haemodynamic recording. Supplementation of drinking water with orally available 
TRPV4 antagonists (Thorneloe et al., 2012) would be required to elucidate further the effects 
of TRPV4 blockade on cardiovascular function in sepsis.  
Nonetheless, plasma levels of the compound have been shown to remain above the IC50 for 
more than 2 hours after intraperitoneal administration of 10 mg/kg HC-067047 (Everaerts et 
al., 2010), suggesting that any prominent role for TRPV4 in sepsis-associated cardiovascular 
dysfunction would at least have been evident in the early phase of sepsis. The fact that no 
major changes in haemodynamics, mesenteric blood flow, blood biochemistry or tissue 
oedema were observed at 6 h post-LPS, suggests either that TRPV4 does not play a major role 
in cardiovascular regulation during sepsis or that other pathways can be upregulated acutely 
to compensate for its loss. However, as the TRPV4 KO study was underpowered, and the 
antagonist was only administered as a single dose, further studies in which research conditions 
are optimised may yet uncover evidence of a vasoregulatory role for TRPV4 in sepsis.  
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 Concluding remarks 6.5.8
Overall, our data do not support a major role for TRPV4 in sepsis-associated cardiovascular 
dysfunction. It is possible that upregulation of alternative endothelium-dependent 
vasodilatory pathways may compensate for its loss both acutely and chronically, and that 
changes would only be evident on blockade of NO- and PGI2-dependent pathways. 
Alternatively, since plasma osmolality is known to increase in sepsis (Jochberger et al., 2009), 
and hypertonicity inhibits TRPV4 activity (Strotmann et al., 2000), it is possible that under 
septic conditions, TRPV4 activity is inhibited such that gene deletion or pharmacological 
antagonism will produce no further effect. Regardless of underlying mechanisms, based on 
data obtained in this study, TRPV4 does not appear to be a viable target in the treatment of 
sepsis-associated cardiovascular dysfunction. 
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CHAPTER 7 | GENERAL DISCUSSION 
 Overview  7.1
Sepsis is an overwhelming inflammatory response to infection that can progress to septic 
shock, characterised by refractory hypotension and insufficient organ perfusion. It is 
associated with significant global morbidity and mortality, accounting for almost 40,000 deaths 
per annum in the UK alone (Daniels, 2011), and global incidence has continued to increase 
over several decades (Melamed and Sorvillo, 2009); septic shock is now the leading cause of 
death  in intensive care units, claiming an estimated 20,000 lives per day worldwide (Daniels, 
2011).  
Following the withdrawal of Xigris® – the only approved anti-sepsis drug – in 2011, aggressive 
fluid resuscitation and antibiotic therapy remain the only strictly causal treatments available to 
septic patients. With the growing threat of widespread antibiotic resistance, the need for new 
and effective drugs becomes ever more urgent. While research activity has been intensive in 
recent years, however, translation of pre-clinical results into clinical treatments has been 
extremely poor. The complexity of the syndrome – compounded by heterogeneous patient 
populations and the confounding influence of clinical interventions – makes sepsis very 
difficult to model in pre-clinical systems. Issues in trial design – inappropriate dosing, altered 
endpoints, lack of patient stratification – have undoubtedly also limited translation of research 
into the clinic. It is clear that refinement of pre-clinical models, with a strong focus on clinically 
relevant endpoints, and better communication between research scientists, trial 
administrators and clinicians will be required to address this tremendous healthcare burden.  
Cardiovascular collapse plays a key role in mortality, and correspondingly, pre-clinical and 
clinical assessment of the impact of interventions on disease progression has been based upon 
systemic haemodynamics and achieving target blood pressures. In recent years, however, it 
has become increasingly clear that systemic stabilisation does not necessarily prevent the 
onset of organ failure, and may actually be achieved at the expense of visceral perfusion 
(Spronk et al., 2004, Sakr et al., 2004). Sepsis is now increasingly understood to be a ‘disease of 
the microcirculation’ (Spronk et al., 2004), though pre-clinical models rarely assess this 
parameter – a further possible explanation for the lack of research translatability. Indeed, any 
negative impact of interventions on the microcirculation may have been overlooked through 
excessive focus on the stabilisation of systemic haemodynamics.  
In light of growing clinical appreciation of the importance of microvascular perfusion in sepsis, 
the principal aim of this study was to investigate the changes in microcirculatory function 
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following the onset of sepsis in a murine model, and to characterise these changes in relation 
to standard measures of outcome, including haemodynamic function and blood biochemistry. 
We additionally aimed to use a novel approach to microcirculatory flow assessment, in 
combination with in vitro investigation, to evaluate the roles of two ion channels – TRPV1 and 
TRPV4 – in sepsis-associated vascular dysfunction.  
 Summary of results 7.2
The salient findings of this thesis are as follows: 
1. Laser speckle contrast imaging can be used in concert with other standard 
hemodynamic monitoring techniques to robustly assess microcirculatory perfusion in 
healthy and septic mice. 
2. Blood flow in the gut declines significantly in a time-dependent manner, despite 
systemic stabilisation in both LPS- and CLP-induced murine sepsis. 
3. Microcirculatory flow, as quantified in the mesenteric vascular bed, correlates with 
end organ dysfunction and metabolic disturbance in both sepsis models. 
4. Stabilisation of global haemodynamics is likely to occur at the expense of 
microcirculatory perfusion, and is therefore insufficiently predictive of outcome. By 
extension, strategies aimed at elevating MAP pharmacologically may adversely affect 
microcirculatory perfusion. 
5. Aggressive fluid resuscitation and topical administration of vasodilatory agents 
measurably improve microcirculatory perfusion and end organ function, consistent 
with clinical observations. 
6. TRPV1 appears to be protective against cardiovascular dysfunction in sepsis, though 
this protection is likely to be neuronal in origin, since we found no evidence of TRPV1 
expression in vascular cells or macrophages.   
7. TRPV4 is expressed in both vascular cells and bone marrow-derived macrophages, and 
may be sensitised under inflammatory conditions; its blockade, under the conditions 
of this study, does not markedly affect either haemodynamic or microcirculatory 
function, either under basal or inflammatory conditions, however.  
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 Discussion 7.3
 Optimisation of pre-clinical sepsis models 7.3.1.1
In light of numerous clinical reports of the prognostic value of microcirculatory perfusion (De 
Backer et al., 2002, Spronk et al., 2004, Sakr et al., 2004, Trzeciak et al., 2007b, Trzeciak et al., 
2008, Spanos et al., 2010, Davis et al., 2009), we aimed to establish a robust model for 
assessing microvascular function in mice. The mesenteric bed was chosen on the strength of 
several important factors, not least its accessibility and its significant contribution to peripheral 
vascular resistance. Importantly, low mesenteric flow is known to correlate strongly with 
multiple organ failure and mortality, both in animal models (Baykal et al., 2000) and in human 
patients  (Takala, 1997). Clinically, gut ischaemia is known as the ‘motor of multiple organ 
failure’ (Carrico et al., 1986); impaired mesenteric blood flow is associated with intestinal 
hyperpermeability, and breakdown in barrier function facilitates the leakage of endotoxins and 
microorganisms into the lymphatic and cardiovascular circulation, which can exacerbate the 
inflammatory response (Sautner et al., 1998). Furthermore, gastric perfusion is known to 
correlate well with sublingual perfusion (Marik, 2001) – a robust indicator of outcome in 
patients (De Backer et al., 2010).  
Consistent with original aims, this thesis has demonstrated successful development of a robust 
and reproducible system for monitoring mesenteric blood flow in healthy and septic mice. 
Blood flow was found to decline significantly over the course of sepsis in line with the 
development of metabolic acidosis and organ dysfunction, and in a manner that was sensitive 
to established clinical interventions. These observations suggest that mesenteric blood flow is 
a sensitive indicator of syndrome progression, and that incorporation of this endpoint into all 
pre-clinical studies of intervention efficacy will improve research translatability. Importantly, 
the impact of interventions shown pre-clinically to improve mesenteric blood flow in sepsis 
may easily be monitored in the clinic, since both gut tonometry and sidestream dark field 
imaging are readily available monitoring tools.  
 Mechanisms underlying microvascular flow impairment in sepsis 7.3.1.2
A dramatic and time-dependent reduction in mesenteric flow was observed after the induction 
of sepsis by both LPS and CLP. Especially noteworthy was the observation that in both models, 
hypotension and alterations in cardiac output and heart rate stabilised between 6 h and 24 h 
after the induction of sepsis, whereas mesenteric blood flow continued to decline significantly 
over the 24-h time course in both models. This suggests that systemic stabilisation may be 
preserved at the expense of the microcirculation, as proposed previously (Spronk et al., 2004). 
The ability of SNP to improve mesenteric blood flow in septic mice gives credence to the 
254  |  G E N E R A L  D I S C U S S I O N  
‘shunting theory of sepsis’(Ince and Sinaasappel, 1999), which proposes active shut-down of 
compliant vascular beds in order to preserve global haemodynamics; while initially an adaptive 
response to hypovolaemia, prolonged shut-down of the mesenteric bed, in particular, is likely 
to become mal-adaptive. 
This is supported by the observation that in both models of sepsis, mesenteric perfusion, but 
not haemodynamic performance, was found to decline in line with the development of both 
acidosis and organ dysfunction. Moreover, administration of noradrenaline – known to raise 
arterial pressure – substantially diminished mesenteric perfusion in septic mice. These data 
suggest that prolonged vasopressor use may accelerate organ failure in septic patients; careful 
monitoring of microcirculatory perfusion is certainly advisable in patients receiving 
vasopressor therapy, and timing of intervention should be carefully considered. Furthermore, 
results indicate that treatment strategies targeted at global haemodynamics may have limited 
efficacy, as demonstrated previously (Gattinoni et al., 1995), and that stabilisation at a 
marginally hypotensive state may be better tolerated than excessively high target pressures.   
While disseminated intravascular coagulation, vessel remodelling, and oedema formation can 
all influence microvascular function, our results indicate that active peripheral constriction 
may be a potentially large contributing factor in the observed ‘oxygen extraction deficit’. This 
would certainly account for the measurements of normal mixed venous SO2 levels despite 
severe local tissue dysoxia, as observed both in this study and in septic patients (Ince and 
Sinaasappel, 1999), as well as the significant increase in blood flow elicited by SNP. While we 
did not observe substantial organ oedema in septic mice, or any beneficial impact of heparin 
therapy, the contribution of coagulation and plasma extravasation to the microcirculatory flow 
impairment recorded remains unknown; it is possible that more sensitive monitoring 
techniques or alternative anti-coagulant therapy would have uncovered a role for these 
processes. Irrespective of the mechanisms involved, however, the observations recorded in 
this thesis highlight the importance of measuring loco-regional perfusion directly, rather than 
using global surrogates. Numerous studies have demonstrated that restoration of global 
oxygen delivery does not necessarily enhance regional perfusion (Gattinoni et al., 1995, 
LeDoux et al., 2000, Bourgoin et al., 2005, Jhanji et al., 2009, Dubin et al., 2009), and we 
conclude that microvascular blood flow is a more sensitive and clinically relevant indicator of 
syndrome progression than haemodynamic indices alone.  
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 A technological advance 7.3.1.3
This thesis has described a novel approach to microvascular blood flow assessment in situ, that 
can be incorporated into a multi-parameter monitoring system, facilitating comprehensive 
evaluation of all levels of the cardiovascular system in a single mouse. Blood flow and core 
temperature were found to remain stable throughout the blood flow recording period, 
validating the use of this model for assessment of vasoactive responses to acute 
pharmacological intervention, and absolute values in both naïve and septic states were highly 
reproducible. The novel application of laser speckle contrast imaging technology described in 
this study enables real-time, in situ visualisation of blood flow across the entire mesenteric 
bed, with no dissection of perivascular tissue and minimal mechanical disruption to the 
vessels. This represents a significant advantage over traditional laser Doppler techniques that 
are usually limited to measurements in single vessels, often requiring extensive 
microdissection and probe-tissue contact, with significantly lower processing speeds. 
Additionally, this technique does not require the use of fluorescent dyes necessary for 
intravital microscopy. Furthermore, it allows quantification of flow within specified regions of 
interest, both at baseline and following topical or intravenous administration of a 
pharmacological agent. As such, the model represents a practical substitute to the sidestream 
dark field imaging technique that is used clinically, while circumventing the need for high-level 
operating expertise, as well as issues of inter-operator variability, user bias and probe-tissue 
contact artefacts. Furthermore, this microcirculatory blood flow model is not limited to sepsis 
research, but has wider applications for in situ investigation of thrombosis or acute 
vasoactivity; it can also be adapted to larger animals, in which the administration of greater 
fluid volumes facilitates hyperdynamic modelling.  
 Evaluation of TRPV ion channels as potential regulators of cardiovascular 7.3.1.4
function in sepsis 
7.3.1.4.1 TRPV1 
Based on numerous previous studies describing a protective role for TRPV1 in sepsis (Clark et 
al., 2007, Wang et al., 2008a, Fernandes et al., 2012, Wang and Wang, 2013), we aimed to 
determine the impact of TRPV1 deletion and activation on microcirculatory blood flow and 
blood biochemistry in the LPS model of sepsis.  
Our data demonstrate that TRPV1 gene ablation is associated with exaggerated microvascular 
impairment (and correspondingly with evidence of exaggerated organ dysfunction and 
metabolic acidosis), consistent with previous reports. Whether endogenous activation of 
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TRPV1 in sepsis contributes to local vasodilatation and the maintenance of regional perfusion 
is unclear, and warrants further investigation.  
Given that TRPV1 has reported to be expressed in endothelial cells, and to contribute directly 
to endothelium-dependent vasodilatation (Kark et al., 2008, Yang et al., 2010a), we decided to 
investigate whether TRPV1 may mediate vasculo-protective effects in sepsis via its expression 
in the vascular endothelium. We hypothesised that inflammation-induced 
upregulation/sensitisation of TRPV1 may contribute to the maintenance of regional perfusion. 
Despite finding robust evidence of TRPV1 mRNA in aortic lysates and endothelial cells, 
however, we have found no evidence of functional TRPV1 protein expression in either isolated 
endothelial or smooth muscle cells, or in bone marrow-derived macrophages, in either basal or 
inflammatory conditions. While these data do not preclude the possibility of induced 
endothelial TRPV1 expression under certain pathological conditions not tested in this study, or 
indeed of functional expression in specific subpopulations of endothelial cells (from the 
microvasculature, for example), our results suggest that in vivo observations of a protective 
role for TRPV1 in sepsis-associated vascular dysfunction are not due to direct activity in the 
vasculature itself.  
Importantly, a thorough investigation of widely used anti-TRPV1 antibodies revealed limited 
selectivity for the receptor. These data call into question the validity of numerous reports of 
TRPV1 expression that have not been validated using appropriate controls.  
7.3.1.4.2 TRPV4 
During our in vitro investigation of endothelial TRPV1 expression, we observed strong evidence 
of TRPV4 activity in a range of different endothelial cell lines. Based on observations of LPS-
induced sensitisation of endothelial TRPV4 activity, and in light of previous studies linking 
excessive TRPV4 activation with profound hypotension, endothelial failure, circulatory collapse 
(Willette et al., 2008) and hyperpermeability (Yin et al., 2008, Alvarez et al., 2006, Wu et al., 
2009, Hamanaka et al., 2010) , we hypothesised that TRPV4 may contribute to haemodynamic 
and vascular dysfunction during sepsis. Specifically, we expected blockade of TRPV4 activity to 
attenuate the circulatory dysfunction that underlies sepsis pathogenesis.  
We observed no dramatic effects on either haemodynamic or microcirculatory function in 
either antagonist-treated or TRPV4 KO mice. Surprisingly, given that TRPV4 has been 
implicated in both NO- and EDHF-mediated vasodilatory responses to physical and chemical 
stimuli in both conduit and resistance arteries (Kohler et al., 2006, Hartmannsgruber et al., 
2007, Loot et al., 2008, Zhang et al., 2009, Mendoza et al., 2010, Adapala et al., 2011, Rath et 
al., 2012, Sonkusare et al., 2012, Ma et al., 2013a), TRPV4 KO mice exhibited trends towards 
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basal hypotension, and, like antagonist-treated mice, exhibited a trend towards exaggerated 
LPS-induced hypotension. A possible explanation is that loss of TRPV4 leads to compensatory 
upregulation of alternative vasodilatory pathways during development. Previous reports have 
shown that blockade of the TRPV4-CYP450 epoxygenase axis only inhibits flow-induced 
vasodilatation in the presence of eNOS and prostacyclin antagonists (Loot et al., 2008), 
suggesting that blockade of one endothelium-dependent vasodilatory pathway can lead to 
acute upregulation of a compensatory pathway. Alternatively, since plasma osmolality is 
known to increase in sepsis (Jochberger et al., 2009), and hypertonicity inhibits TRPV4 activity 
(Strotmann et al., 2000), it is possible that under septic conditions, TRPV4 activity is inhibited 
such that gene deletion or pharmacological antagonism will produce no further effect. 
Importantly, while both antagonist-treated and TRPV4 KO mice exhibited exaggerated LPS-
induced hypotension relative to vehicle-treated controls, mesenteric perfusion was not worse 
in these mice; in fact, antagonist-treated mice exhibited trends towards improved 
microcirculatory blood flow after the induction of sepsis, and the development of metabolic 
acidosis appeared less severe in mice lacking TRPV4. These observations emphasise the low 
prognostic value of haemodynamic indices, which may be preserved at the expense of regional 
perfusion, and partially support the hypothesis that loss of TRPV4 signalling attenuates sepsis 
pathophysiology.  
 Study limitations and future directions 7.4
 Murine models of sepsis 7.4.1
Because murine models lend themselves well to genetic modification, they currently represent 
the only viable option for conducting mechanistic pre-clinical proof-of-concept research. 
Nonetheless, recent reports of divergent immune cell genomic responses to inflammation 
between mice and men (Seok et al., 2013) have called into question the validity of mouse 
models of inflammatory conditions, including sepsis. While it is clear that rodents do not 
necessarily recapitulate all the genomic responses to sepsis encountered in humans, they do 
exhibit highly similar pathophysiological sequelae (Osuchowski et al., 2014), most notably 
cardiovascular dysfunction, which is known to be a key feature of sepsis pathogenesis in 
humans (Parrillo, 1990). As such, the mouse represents a highly useful tool for early 
mechanistic studies in a mammalian system that largely mirrors the critical sepsis-induced 
pathophysiological changes that occur in human patients.  
Given the obvious limitations, it is essential that we optimise the systems available to us by 
limiting confounding influences and employing animal models to their full capacity, extracting 
as much information as possible from a single individual. With this in mind, we aimed to 
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establish a robust model for assessing microcirculatory perfusion in a septic mouse, and to 
incorporate this model into a multi-parameter monitoring system for direct comparison (in the 
same animal) of microvascular and global haemodynamic parameters. To our knowledge, this 
study represents the first comprehensive multi-parameter investigation of sepsis-associated 
cardiovascular derangements in a single animal. Results demonstrate that a number of 
biological measurements can be performed in a single mouse without compromising data 
quality or reproducibility, and without incurring undue suffering, which can lead to stress-
induced artefacts. While results, in sepsis research in particular, should always be interpreted 
with caution, and never over-extrapolated, proof-of-concept studies in well-designed mouse 
models with clinically relevant endpoints can provide valuable information on the likely impact 
of a particular intervention on a physiological system, and can inform the design of relevant 
clinical trials. This is particularly important in the later stages of sepsis, where mortality rates 
are unacceptably high, and where there is a strong requirement for adjunct therapies. 
A further limitation of the mouse model is its size, which precludes the administration of large 
volumes of fluid: it is consequently difficult to compare well resuscitated human patients with 
murine models of sepsis. The observed improvement in perfusion and organ function in 
response to fluid resuscitation, however, suggests that the model used here is clinically 
relevant and may be adapted to a comparatively hyperdynamic model of sepsis (Hollenberg et 
al., 2001). The extent to which a mouse can reflect the truly hyperdynamic state that occurs in 
continuously infused patients is undoubtedly limited. Murine models may be used effectively 
to understand the pathophysiological changes that occur when sepsis is allowed to progress 
unimpeded, however, and to establish the impact of pharmacological or genetic modification 
in the absence of other interventions. To mimic more closely the resuscitated clinical situation, 
larger species should be used, where administration of large volumes of fluid in addition to 
pharmacological agents is more feasible. Nonetheless, the data obtained emphasise the 
importance of using microcirculatory blood flow to assess a patient’s response to 
interventional treatment; use of this endpoint in pre-clinical models will help to determine 
more accurately the impact of a pharmacological intervention on overall health.  
 TRPV4 KO mice 7.4.2
Owing to breeding problems we unfortunately did not obtain sufficient numbers of TRPV4 KO 
mice to conduct a sufficiently well-powered study. An additional cohort of mice were included 
from the parent colony at the Wolfson Centre, King’s College London, though these were 
neither littermates nor age-matched, limiting the strength of comparison. It is unclear why 
these breeding issues arose in our animal unit, though sufficient numbers may be generated 
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for future work through homozygous crosses, as long as offspring are back-crossed every few 
generations to prevent genetic drift.  
 TRPV4 antagonism 7.4.3
Because the TRPV4 antagonist HC-067047 has not been well characterised in vivo, and has only 
been used for acute studies (Everaerts et al., 2010, Materazzi et al., 2012), its pharmacokinetic 
properties over the 24 h following a single i.p. injection are unknown. It is possible that the 
dose used in this study was insufficient to achieve complete and sustained TRPV4 blockade 
throughout the duration of the study, and that changes would have been detected at higher 
concentrations or with repeated dosing. Both options confer significant limitations: higher 
concentrations of HC-067047 are known to induce adverse effects, including piloerection and 
hunching (Everaerts et al., 2010) and the high percentage of DMSO that would be required to 
dissolve the compound may itself cause cytotoxicity; secondly, repeated handling and injection 
would certainly preclude meaningful haemodynamic recording, although this approach may be 
useful for further microcirculatory and biochemical studies. Alternatively, administration of 
orally available TRPV4 antagonists (Thorneloe et al., 2012) via supplementation of drinking 
water or a subcutaneous pump may represent a more attractive option, and could be used to 
elucidate further the role of TRPV4 in sepsis-associated vascular dysfunction.  
 Molecular investigation 7.4.4
Further biochemical investigation of TRPV1 and TRPV4 expression would be particularly 
informative. Identification of a more selective TRPV1 antibody could help to elucidate the 
exact localisation of the receptor; immunohistochemical analysis of mesenteric sections, for 
example, would be useful in determining whether TRPV1 is in fact expressed in mesenteric 
smooth muscle and/or endothelium, and whether its expression changes in these tissues and 
in perivascular nerves after the induction of sepsis, or whether it is simply channel activity that 
is altered.  
Investigation of the tissue localisation of TRPV4, and expression levels before and after the 
induction of sepsis, would be similarly informative, and would clarify whether LPS-induced 
changes in activity are due to sensitisation or upregulation. Further investigation of TRPV4 
expression and activity in macrophages, using fluorescence-associated cell sorting, would also 
shed light on the immunological function of this channel.     
Furthermore, it would be interesting to evaluate the extent of any vascular of cardiac 
remodelling in antagonist-treated or KO mice.  
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 Further applications of the microvascular blood flow model 7.4.5
Having established the prognostic sensitivity and clinical relevance of microvascular blood flow 
in sepsis, it would be interesting to use the model for assessment of alternative potential 
interventions. Since neither TRPV1 nor TRPV4 appear to be particularly attractive drug targets, 
owing to widespread expression and function, and the potential acute upregulation of 
compensatory pathways, assessment of more fruitful targets or interventions using this system 
could yield exciting results. Furthermore, simultaneous blood pressure recording (either 
through invasive catheterisation or through incorporation of telemetric receivers into the 
blood flow set-up) would help to elucidate further the relationship between alterations in 
global haemodynamics and regional perfusion. It would be interesting to measure blood flow 
in more critical microvascular beds, using transcranial Doppler probes, for example, or markers 
or cardiac perfusion, such as cardiac troponin, for further evaluation of the relative prognostic 
sensitivity of microvascular perfusion versus global haemodynamics.  
Use of alternative anti-coagulant drugs may also provide further mechanistic insight into the 
relative contributions of microthrombus formation and active vasoconstriction in sepsis-
associated microcirculatory impairment. It would also be interesting to apply the mesenteric 
model to in situ assessments of vasoactivity (since myographical methods are limited by the 
requirement for significant microdissection) and thrombus formation/resolution in more 
general studies. 
An additional limitation of this investigation is the restrictive 24-h time course, which prevents 
longer-term investigation of the impact of interventions on sepsis pathogensis. While 
extension of the study period is legally prohibited, a more comprehensive assessment of time-
dependent physiological changes within the 24-h window may be possible. Further validation 
of the ear blood flow model, or use of a non-invasive rectal Doppler probe, may facilitate 
continuous or repeated-measures evaluation of changes in microvascular blood flow over 
time.  
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 Concluding remarks 7.5
In summary, this thesis has demonstrated that microcirculatory perfusion correlates more 
closely with end organ damage and metabolic dysfunction than global haemodynamics, and 
that the latter should not be used as an indicator of outcome in isolation. Quantification of 
microcirculatory blood flow, as described in this thesis, provides a humane endpoint, whilst 
simultaneously improving the clinical translatability of pre-clinical sepsis studies. 
While in vitro data provided compelling evidence of a vasoregulatory role for TRPV4 in sepsis, 
our in vivo data did not support this hypothesis. Whether upregulation of alternative pathways 
can compensate for its loss, or whether TRPV4 is tonically inhibited during sepsis such that 
further inhibition is impossible, is not clear. Regardless, the channel does not appear to 
represent a viable target in the treatment of sepsis-associated vascular dysfunction. 
While TRPV1 did appear to play a protective role in the development of sepsis, its ubiquitous 
expression, not least in sensory nerves, limit the possibility of using channel activation as a 
potential therapeutic strategy. Further mechanistic investigation of downstream mediators of 
TRPV1 activation may be more fruitful.  
Overall, data obtained in this study have advanced understanding of the pathophysiological 
changes elicited in sepsis: we have demonstrated that mesenteric perfusion is substantially 
reduced after the onset of sepsis, in line with the development or organ dysfunction and 
metabolic acidosis, despite (or perhaps because of) systemic stabilisation. Using a novel 
approach to microcirculatory flow monitoring, we have demonstrated the prognostic value of 
mesenteric blood flow as an endpoint in sepsis, and suggest that pre-clinical models that 
incorporate this parameter will facilitate more clinically relevant studies. 
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